Astrana Health (ASTH) 10-K 15 Mar 21 2020 FY Annual report Financial data

Cover

Cover - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Mar. 08, 2021	Jun. 30, 2020
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2020
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-37392
Entity Registrant Name	Apollo Medical Holdings, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	95-4472349
Entity Address, Address Line One	1668 S. Garfield Avenue
Entity Address, Address Line Two	2nd Floor
Entity Address, City or Town	Alhambra
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91801
City Area Code	626
Local Phone Number	282-0288
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	AMEH
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 503.6
Entity Common Stock, Shares Outstanding (in shares)		54,585,258
Documents Incorporated by Reference	Portions of the registrant’s definitive Proxy Statement for the 2021 annual meeting of the stockholders of the registrant are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such Proxy Statement will be filed with the Securities and Exchange Commission (the “SEC”) within 120 days of the registrant’s fiscal year ended December 31, 2020.
Amendment Flag	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Central Index Key	0001083446

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands		Dec. 31, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents		$ 193,470	$ 103,189
Restricted cash		0	75
Investment in marketable securities		67,695	116,539
Receivables, net		7,058	11,004
Receivables, net – related parties		49,260	48,136
Other receivables		4,297	16,885
Prepaid expenses and other current assets		16,747	10,315
Loan receivable - short term		50	22,925
Total current assets		338,577	329,068
Noncurrent assets
Land, property and equipment, net		29,890	12,130
Intangible assets, net		86,985	103,012
Goodwill		239,053	238,505
Loans receivable		480	0
Loans receivable – related parties		4,145	0
Investments in other entities – equity method		43,292	28,427
Investments in privately held entities		37,075	896
Restricted cash		500	746
Operating lease right-of-use assets		18,574	14,248
Other assets		18,915	1,681
Total noncurrent assets		478,909	399,645
Total assets	[1]	817,486	728,713
Current liabilities
Accounts payable and accrued expenses		36,143	27,279
Fiduciary accounts payable		9,642	2,027
Medical liabilities		50,330	58,725
Income taxes payable		4,224	4,529
Dividend payable		485	271
Finance lease liabilities		102	102
Operating lease liabilities		3,177	2,991
Current portion of long-term debt		10,889	9,500
Total current liabilities		114,992	105,424
Noncurrent liabilities
Deferred tax liability		10,959	18,269
Finance lease liabilities, net of current portion		311	415
Operating lease liabilities, net of current portion		15,865	11,373
Long-term debt, net of current portion and deferred financing costs		230,211	232,172
Total noncurrent liabilities		257,346	262,229
Total liabilities	[1]	372,338	367,653
Commitments and Contingencies (Note 13)
Mezzanine equity
Noncontrolling interest in Allied Physicians of California, a Professional Medical Corporation ("APC")		114,237	168,725
Stockholders’ equity
Common stock, par value $0.001; 100,000,000 shares authorized, 42,249,137 and 35,908,057 shares outstanding, excluding 12,323,164 and 17,458,810 treasury shares, at December 31, 2020 and 2019, respectively		42	36
Additional paid-in capital		261,011	159,608
Retained earnings		69,771	31,905
Stockholders' equity attributable to parent		330,824	191,549
Noncontrolling interest		87	786
Total stockholders’ equity		330,911	192,335
Total liabilities, mezzanine equity and stockholders’ equity		817,486	728,713
Series A Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series B Preferred stock); 1,111,111 issued and zero outstanding
Stockholders’ equity
Preferred stock		0	0
Series B Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series A Preferred stock); 555,555 issued and zero outstanding
Stockholders’ equity
Preferred stock		$ 0	$ 0
[1]	The Company's consolidated balance sheets include the assets and liabilities of its consolidated variable interest entities ("VIEs"). The consolidated balance sheets include total assets that can be used only to settle obligations of the Company’s consolidated VIEs totaling $801.3 million and $849.3 million as of December 31, 2020 and December 31, 2019, respectively, and total liabilities of the Company’s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $111.3 million and $114.5 million as of December 31, 2020 and December 31, 2019, respectively. See Note 18 – Variable Interest Entities (VIEs) for further detail.

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands		Dec. 31, 2020	Dec. 31, 2019
Common stock, par value (in dollars per share)		$ 0.001	$ 0.001
Common stock, shares authorized (in shares)		100,000,000	100,000,000
Treasury stock, common, shares (in shares)		12,323,164	17,458,810
Assets	[1]	$ 817,486	$ 728,713
Liabilities	[1]	$ 372,338	$ 367,653
Common Stock
Common stock, shares outstanding (in shares)		42,249,137	35,908,057
Variable Interest Entity, Primary Beneficiary
Assets		$ 801,288	$ 849,291
Liabilities		$ 111,318	$ 114,499
Series A Preferred Stock
Preferred stock, par value (in dollars per share)		$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)		5,000,000	5,000,000
Preferred stock, shares issued (in shares)		1,111,111	1,111,111
Preferred stock, shares outstanding (in shares)		0	0
Series B Preferred Stock
Preferred stock, par value (in dollars per share)		$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)		5,000,000	5,000,000
Preferred stock, shares issued (in shares)		555,555	555,555
Preferred stock, shares outstanding (in shares)		0	0
[1]	The Company's consolidated balance sheets include the assets and liabilities of its consolidated variable interest entities ("VIEs"). The consolidated balance sheets include total assets that can be used only to settle obligations of the Company’s consolidated VIEs totaling $801.3 million and $849.3 million as of December 31, 2020 and December 31, 2019, respectively, and total liabilities of the Company’s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $111.3 million and $114.5 million as of December 31, 2020 and December 31, 2019, respectively. See Note 18 – Variable Interest Entities (VIEs) for further detail.

CONSOLIDATED STATEMENTS OF INCO

CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Revenue
Total revenue	$ 687,180	$ 560,618	$ 519,908
Operating expenses
Cost of services, excluding depreciation and amortization	539,211	467,805	361,132
General and administrative expenses	49,116	41,482	43,354
Depreciation and amortization	18,350	18,280	19,303
Provision for doubtful accounts	0	(1,363)	3,888
Impairment of goodwill and intangible assets	0	1,994	3,799
Total expenses	606,677	528,198	431,476
Income from operations	80,503	32,420	88,432
Other (expense) income
Income (loss) from equity method investments	3,694	(6,901)	(8,125)
Interest expense	(9,499)	(4,733)	(561)
Interest income	2,813	2,024	1,259
Gain on sale of equity method investment	99,839	0	0
Other income	1,077	3,030	1,622
Total other income (expense), net	97,924	(6,580)	(5,805)
Income before provision for income taxes	178,427	25,840	82,627
Provision for income taxes	56,107	8,167	22,360
Net income	122,320	17,673	60,267
Net income attributable to noncontrolling interests	84,454	3,557	49,432
Net income attributable to Apollo Medical Holdings, Inc.	$ 37,866	$ 14,116	$ 10,835
Earnings per share – basic (in dollars per share)	$ 1.04	$ 0.41	$ 0.33
Earnings per share – diluted (in dollars per share)	$ 1.01	$ 0.39	$ 0.29
Weighted average shares of common stock outstanding – basic (in shares)	36,527,672	34,708,429	32,893,940
Weighted average shares of common stock outstanding - diluted (in shares)	37,448,430	36,403,279	37,914,886
Capitation, net
Revenue
Total revenue	$ 557,326	$ 454,168	$ 344,307
Risk pool settlements and incentives
Revenue
Total revenue	77,367	51,098	100,928
Management fee income
Revenue
Total revenue	34,850	34,668	49,743
Fee-for-service, net
Revenue
Total revenue	12,683	15,475	19,704
Other income
Revenue
Total revenue	$ 4,954	$ 5,209	$ 5,226

CONSOLIDATED STATEMENTS OF MEZZ

CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY - USD ($)	Total	Cumulative Effect, Period of Adoption, Adjustment	Common Stock Outstanding	Additional Paid-in Capital	Retained Earnings (Accumulated Deficit)	Retained Earnings (Accumulated Deficit)Cumulative Effect, Period of Adoption, Adjustment	Noncontrolling Interest	Mezzanine Equity – Noncontrolling Interest in APCNoncontrolling Interest	Mezzanine Equity – Noncontrolling Interest in APCNoncontrolling InterestCumulative Effect, Period of Adoption, Adjustment
Balance at beginning at Dec. 31, 2017	$ 164,183,000	$ 1,002,000	$ 32,000	$ 158,181,000	$ 1,735,000	$ 1,002,000	$ 4,235,000	$ 172,130,000	$ 7,351,000
Balance at beginning (in shares) at Dec. 31, 2017			32,304,876
Increase (Decrease) in Stockholders' Equity
Accounting Standards Update [Extensible List]	us-gaap:AccountingStandardsUpdate201409Member
Net income	$ 12,378,000				10,835,000		1,543,000	47,890,000
Purchase price adjustment from Merger	868,000			868,000
Repurchase of treasury shares	432,000			(3,784,000)	4,216,000			(1,264,000)
Repurchase of treasury shares (in shares)			(168,493)
Shares issued for exercise of options and warrants	3,997,000		$ 1,000	3,996,000				200,000
Shares issued for exercise of options and warrants (in shares)			884,259
Share-based compensation	632,000			632,000				810,000
Share-based compensation (in shares)			37,593
Noncontrolling interest capital change	28,000						28,000
Dividends	(1,975,000)						(1,975,000)	(2,000,000)
Acquisition of additional shares in consolidated entity	0			2,832,000			(2,832,000)
Release of 50% holdback shares (in shares)			1,519,805
Release of 50% holdback shares	0		$ 2,000	(2,000)
Balance at ending at Dec. 31, 2018	181,545,000		$ 35,000	162,723,000	17,788,000		999,000	225,117,000
Balance at ending (in shares) at Dec. 31, 2018			34,578,040
Increase (Decrease) in Stockholders' Equity
Net income	15,866,000				14,117,000		1,749,000	1,808,000
Repurchase of treasury shares	(7,287,000)		$ (1,000)	(7,286,000)				(283,000)
Repurchase of treasury shares (in shares)			(601,581)
Shares issued for exercise of options and warrants	3,233,000			3,233,000
Shares issued for exercise of options and warrants (in shares)			418,619
Share-based compensation	940,000			940,000				607,000
Share-based compensation (in shares)			1,599
Noncontrolling interest capital change	28,000						28,000
Dividends	(1,990,000)						(1,990,000)	(60,000,000)
Reclassification of options liability to equity	0							1,185,000
Release of 50% holdback shares (in shares)			1,511,380
Release of 50% holdback shares	0		$ 2,000	(2,000)
Stock subscription	0							754,000
Shares issued in connection with business acquisition	0							414,000
Cost of equity issuance of preferred shares	0							(878,000)
Balance at ending at Dec. 31, 2019	192,335,000		$ 36,000	159,608,000	31,905,000		786,000	168,724,000
Balance at ending (in shares) at Dec. 31, 2019			35,908,057
Increase (Decrease) in Stockholders' Equity
Net income	38,699,000				37,866,000		833,000	83,621,000
Repurchase of treasury shares	(301,000)			(301,000)
Repurchase of treasury shares (in shares)			(16,897)
Distribution to noncontrolling interest								(1,037,000)
Shares issued for exercise of options and warrants	11,492,000		$ 1,000	11,491,000
Shares issued for exercise of options and warrants (in shares)			1,240,622
Share-based compensation	3,383,000			3,383,000
Shares issued for vesting of restricted stock awards (in shares)			66,788
Shares issued for cashless exercise of warrants (in shares)			66,517
Cancellation of restricted stock awards	(236,000)			(236,000)
Dividends (in shares)			4,984,050
Dividends	85,539,000		$ 5,000	87,066,000			(1,532,000)	(137,071,000)
Balance at ending at Dec. 31, 2020	$ 330,911,000		$ 42,000	$ 261,011,000	$ 69,771,000		$ 87,000	$ 114,237,000
Balance at ending (in shares) at Dec. 31, 2020			42,249,137

CONSOLIDATED STATEMENTS OF ME_2

CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY (Parenthetical)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Holdback shares
Vesting percentage	50.00%	50.00%

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities
Net income	$ 122,320	$ 17,673	$ 60,267
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	18,350	18,280	19,303
Amortization of debt issuance cost	1,347	473	0
Loss on disposal of property and equipment	91	0	42
Impairment of goodwill and intangible assets	0	1,994	3,799
Provision for doubtful accounts	0	(1,363)	3,888
Share-based compensation	3,383	1,547	1,441
Gain on sale of equity method investment	(99,839)	0	0
Gain on loan assumption	0	(2,250)	0
Unrealized loss (gain) from investment in equity securities	11	(9)	25
(Income) loss from equity method investments	(3,694)	6,901	8,125
Deferred tax	(6,620)	(6,801)	(8,345)
Changes in operating assets and liabilities, net of acquisition amounts:
Receivables, net	4,134	10,714	(263)
Receivables, net – related parties	(1,123)	(1,435)	(28,363)
Other receivables	12,589	(15,079)	0
Prepaid expenses and other current assets	(6,432)	(2,756)	(2,814)
Right-of-use assets	3,325	2,480	0
Other assets	(5,530)	(572)	2
Accounts payable and accrued expenses	8,204	(4,883)	(22,669)
Fiduciary accounts payable	7,615	488	0
Capitation incentives payable	0	0	(21,500)
Medical liabilities	(8,691)	(2,392)	4,134
Income taxes payable	(304)	(7,093)	8,424
Operating lease liabilities	(2,973)	(2,244)	0
Net cash provided by operating activities	46,163	13,673	25,496
Cash flows from investing activities
Purchases of marketable securities	(1,793)	(115,402)	(9)
Proceeds from sale of marketable securities	50,625	0	0
Proceeds from repayment of loans receivable - related parties	16,500	0	0
Advances on loans receivable	(145)	(11,425)	(7,500)
Dividends received from equity method investments	0	240	607
Proceeds from sale of fixed assets	50	0	0
Payments for business acquisitions, net of cash acquired	(11,354)	(49,403)	0
Purchases of investments in privately held entities	0	(491)	(405)
Proceeds from sale of equity method investment	52,743	0	0
Purchases of investments – equity method	(9,969)	(3,108)	(16,706)
Purchases of property and equipment	(1,164)	(1,042)	(1,170)
Net cash provided by (used in) investing activities	95,493	(180,631)	(25,183)
Cash flows from financing activities
Dividends paid	(51,319)	(61,717)	(17,759)
Repayments of debt	0	(2,375)	0
Change in noncontrolling interest capital	0	28	27
Borrowings on long-term debt	0	250,000	8,000
Borrowings on line of credit	0	39,600	0
Repayments on bank loan and lines of credit	0	(52,640)	(495)
Payment of capital lease obligations	(105)	(102)	(99)
Proceeds from exercise of stock options and warrants	10,802	3,123	3,997
Proceeds from common stock offering	0	755	200
Repurchase of common shares	(537)	(7,570)	(5,047)
Distribution to noncontrolling interest	(1,037)	0	0
Cost of debt and equity issuances	0	(5,771)	0
Net cash (used in) provided by financing activities	(51,696)	163,331	(11,176)
Net increase (decrease) in cash, cash equivalents and restricted cash	89,960	(3,627)	(10,863)
Cash, cash equivalents and restricted cash, beginning of year	104,010	107,637	118,500
Cash, cash equivalents and restricted cash, end of year	193,970	104,010	107,637
Supplemental disclosures of cash flow information
Cash paid for income taxes	62,002	20,200	23,643
Cash paid for interest	8,510	4,258	462
Supplemental disclosures of non-cash investing and financing activities
Cashless exercise of warrants	599	0	0
Deferred tax liability adjusted to goodwill	0	6,334	1,110
Reclassification of liability for equity shares	0	1,185	0
Purchase price adjustment for acceleration of vested stock options	0	0	868
Conversion of loan receivable to investment in Accountable Health Care, IPA	0	0	5,000
Reclassification of dividends related to share repurchase	0	0	4,216
Reclassification of APS noncontrolling interest to equity related to purchase of additional shares	0	0	2,832
Deferred tax liability adjustment related to warrant exercises	690	0	0
Preferred shares received from sale of equity method investment	36,179	0	0
Beneficial interest acquired from sale of equity method investment	15,723	0	0
Reconciliation of cash, cash equivalents, and restricted cash
Cash and cash equivalents	193,470	103,189	106,892
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	193,970	107,637	118,500
Affiliated Entity | APC
Supplemental disclosures of non-cash investing and financing activities
APC stock issued in exchange for AMG	0	414	0
Term Loan
Cash flows from financing activities
Repayments of debt	$ (9,500)	$ 0	$ 0

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Description of Business Apollo Medical Holdings, Inc. ("ApolloMed") is a leading physician-centric, technology-powered, risk-bearing healthcare management company. Leveraging its proprietary population health management and healthcare delivery platform, ApolloMed operates an integrated, value-based healthcare model, which aims to empower the providers in its network to deliver the highest quality of care to its patients in a cost-effective manner. ApolloMed was formed via its merger with Network Medical Management ("NMM") on December 8, 2017 ("2017 Merger"). As a result of the merger, NMM became a wholly-owned subsidiary of ApolloMed, and the former NMM shareholders own a majority of the issued and outstanding common stock of ApolloMed and maintain control of the board of directors of ApolloMed. Headquartered in Alhambra, California, ApolloMed's subsidiaries include management services organizations ("MSOs"), affiliated independent practice associations ("IPAs") and a Next Generation Accountable Care Organization ("NGACO"). Network Medical Management, Inc. ("NMM") and Apollo Medical Management, Inc. ("AMM") are the administrative and managerial services companies for the professional corporations that contract with independent physicians to deliver medical services in-office and virtually. Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA ("APC"), Alpha Care Medical Group, Inc. and Accountable Health Care IPA are the affiliated IPA groups that provide medical services. These affiliated IPAs are supported by ApolloMed Hospitalists, a Medical Corporation ("AMH") and Southern California Heart Centers, a Medical Corporation ("SCHC"). The Company's NGACO operates under the APA ACO, Inc. ("APAACO") brand and participates in the Centers for Medicare & Medicaid Services program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participation in the program's attribution-based risk sharing model. The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups and health plans. The Company’s physician network consists of primary care physicians, specialist physicians, and hospitalists. NMM was formed in 1994 as an MSO for the purposes of providing management services to medical companies and IPAs. The management services primarily include billing, collection, accounting, administration, quality assurance, marketing, compliance, and education. Following a business combination, NMM became a wholly-owned subsidiary of ApolloMed in December 2017. APC was incorporated in 1992 for the purpose of arranging healthcare services as an IPA. APC has contracts with various health maintenance organizations (“HMOs”) and other licensed healthcare service plans as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (“PMPM”) that is to be paid to APC. In return, APC arranges for the delivery of healthcare services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering healthcare services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is also minimized by stop-loss provisions in contracts with HMOs. In July 1999, APC entered into an amended and restated management and administrative services agreement with NMM (amending an initial management services agreement that was entered into in 1997) for an initial fixed term of 30 years. In accordance with relevant accounting guidance, APC is determined to be a variable interest entity (“VIE”) of the Company as NMM is the primary beneficiary with the ability to direct the activities (excluding clinical decisions) that most significantly affect APC’s economic performance through its majority representation on the APC Joint Planning Board; therefore APC is consolidated by NMM. AP-AMH Medical Corporation (“AP-AMH”) was formed in May 2019, as a designated shareholder professional corporation. Dr. Thomas Lam, a shareholder, and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is the sole shareholder of AP-AMH. ApolloMed makes all the decisions on behalf of AP-AMH and funds and receives all the distributions from its operations. ApolloMed has the right to receive benefits from the operations of AP-AMH and has the option, but not the obligation, to cover its losses. AP-AMH's sole function and only activity is to act as the nominee shareholder for ApolloMed's investments in APC. Therefore, AP-AMH is controlled by and consolidated by ApolloMed as the primary beneficiary of this VIE. In September 2019, ApolloMed completed the following series of transactions with its affiliates, AP-AMH and APC: 1. ApolloMed loaned AP-AMH $545.0 million pursuant to a ten-year secured loan agreement (the “AP-AMH Loan”). The loan bears interest at a rate of 10% per annum simple interest, is not prepayable (except in certain limited circumstances), requires quarterly payments of interest only in arrears, and is secured by a first priority security interest in all of AP-AMH's assets, including the shares of APC Series A Preferred Stock to be purchased by AP-AMH. To the extent that AP-AMH is unable to make any interest payment when due because it has received dividends on the APC Series A Preferred Stock insufficient to pay in full such interest payment, then the outstanding principal amount of the loan will be increased by the amount of any such accrued but unpaid interest, and any such increased principal amounts will bear interest at the rate of 10.75% per annum simple interest. 2. AP-AMH purchased 1,000,000 shares of APC Series A Preferred Stock for aggregate consideration of $545.0 million in a private placement. Under the terms of the APC Certificate of Determination of Preferences of Series A Preferred Stock (the "Certificate of Determination"), AP-AMH is entitled to receive preferential, cumulative dividends that accrue on a daily basis and that are equal to the sum of (i) APC's net income from Healthcare Services (as defined in the Certificate of Determination), plus (ii) any dividends received by APC from certain of APC's affiliated entities, less (iii) any Retained Amounts (as defined in the Certificate of Determination). During the year ended December 31, 2020 and 2019, APC distributed $30.4 million and $8.9 million, respectively, as preferred returns. 3. APC purchased 15,015,015 shares of the Company's common stock for total consideration of $300.0 million in private placement. In connection therewith, the Company granted APC certain registration rights with respect to the Company's common stock that APC purchased, and APC agreed that APC votes in excess of 9.99% of the Company's then outstanding shares will be voted by proxy given to the Company's management, and that those proxy holders will cast the excess votes in the same proportion as all other votes cast on any specific proposal coming before the Company's stockholders. During the year ended December 31, 2020, APC distributed approximately 5.0 million shares of the Company's common stock to APC shareholders. 4. ApolloMed licensed to AP-AMH the right to use certain tradenames for certain specified purposes for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The license fee is payable out of any Series A Preferred Stock dividends received by AP-AMH from APC. 5. Through its subsidiary, NMM, the Company agreed to provide certain administrative services to AP-AMH for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The administrative fee also is payable out of any APC Series A Preferred Stock dividends received by AP-AMH from APC. As part of the series of transactions, in September 2019, APC and AP-AMH entered into a Second Amendment to the Series A Preferred Stock Purchase Agreement clarifying the term excluded assets ("Excluded Assets"). Excluded Assets means (i) assets received from the sale of shares of the Series A Preferred equal to the Series A Purchase Price, (ii) the assets of the Company that are not Healthcare Services Assets, including the Company’s equity interests in Universal Care, Inc., Apollo Medical Holdings, Inc., and any entity that is primarily engaged in the business of owning, leasing, developing or otherwise operating real estate, (iii) any assets acquired with the proceeds of the sale, assignment or other disposition of any of the assets described in clauses (i) or (ii), and (iv) any proceeds of the assets described in clauses (i), (ii) and (iii). APC's ownership in ApolloMed was 22.58% and 32.50% as of December 31, 2020 and December 31, 2019, respectively. Concourse Diagnostic Surgery Center, LLC (“CDSC”) was formed in March 2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California, is organized by a group of highly qualified physicians, and the surgical center utilizes some of the most advanced equipment in Eastern Los Angeles County and San Gabriel Valley. The facility is Medicare Certified and accredited by the Accreditation Association for Ambulatory Healthcare, Inc. As of December 31, 2020, APC owned 45.01% of CDSC's capital stock. CDSC is determined to be a VIE and APC is determined to be the primary beneficiary. APC has the ability to direct the activities that most significantly affect CDSC’s economic performance and receives the most economic benefits; therefore CDSC is consolidated by APC. APC-LSMA Designated Shareholder Medical Corporation (“APC-LSMA”) was formed in October 2012 as a designated shareholder professional corporation. Dr. Thomas Lam, a shareholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is a nominee shareholder of APC-LSMA. APC makes all investment decisions on behalf of APC-LSMA, funds all investments and receives all distributions from the investments. APC has the obligation to absorb losses and the right to receive benefits from all investments made by APC-LSMA. APC-LSMA’s sole function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC as the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, including the IPA lines of business of LaSalle Medical Associates (“LMA”), Pacific Medical Imaging and Oncology Center, Inc. (“PMIOC”), Diagnostic Medical Group (“DMG”) and AHMC International Cancer Center, a Medical Corporation (“ICC”). APC-LSMA also holds a 100% ownership interest in Maverick Medical Group, Inc. (“MMG”), Alpha Care Medical Group, Inc. (“Alpha Care”), Accountable Health Care IPA, a Professional Medical Corporation ("Accountable Health Care"), and AMG, a Professional Medical Corporation ("AMG"). Alpha Care, an IPA, was acquired by APC-LSMA in May 2019 for an aggregate purchase price of $45.1 million in cash, has been operating in California since 1993 and is a risk bearing organization engaged in providing professional services under capitation arrangements with its contracted health plans through a provider network consisting of primary care and specialty care physicians. Alpha Care specializes in delivering high-quality healthcare to over 180,000 enrollees, as of December 31, 2020, and focuses on Medi-Cal/Medicaid, Commercial, Medicare and Dual Eligible members in the Riverside and San Bernardino counties of Southern California (see Note 3). Accountable Health Care is a California based IPA that has served the local community in the greater Los Angeles County area through a network of physicians and health care providers for more than 20 years. As of December 31, 2020, Accountable Health Care had a network of over 336 primary care physicians and 559 specialty care physicians and is affiliated with a community hospital and regional medical center that provide quality health care services to more than 73,000 members of three federally qualified health plans and multiple product lines, including Medi-Cal, Commercial, Medicare and the California Healthy Families program. In August 2019, APC and APC-LSMA acquired the remaining outstanding shares of capital stock they did not already own (comprising 75%) for $7.3 million in cash (see Note 3 and Note 6). AMG is a network of family practice clinics operating in three main locations in Southern California. AMG provides professional and post-acute care services to Medicare, Medi-Cal/Medicaid, and Commercial patients through its networks of doctors and nurse practitioners. On September 10, 2019, APC-LSMA acquired 100% of the aggregate issued and outstanding shares of capital stock of AMG for $1.2 million in cash and $0.4 million of APC common stock (see Note 3). Universal Care Acquisition Partners, LLC (“UCAP”), a 100% owned subsidiary of APC, was formed in June 2014 for the purpose of holding the investment in Universal Care, Inc. (“UCI”). On April 30, 2020, UCAP completed the sale of its 48.9% ownership interest in UCI to Bright Health Company of California, Inc. ("Bright") for approximately $69.2 million in cash proceeds (including $16.5 million as repayment of indebtedness owed to APC), plus non-cash consideration consisting of shares of Bright Health, Inc.'s preferred stock having an estimated fair value of approximately $36.2 million on the date of sale. In addition, pursuant to the terms of the stock purchase agreement, APC has a beneficial interest in the equity method investment sold. The estimated fair value of such interest on April 30, 2020 was $15.7 million (see Note 6). As set forth in the Company’s definitive proxy statement filed with the SEC on July 31, 2019 (the “2019 Proxy Statement”), the 48.9% interest in UCI is included in Excluded Assets that remain solely for the benefit of APC and its shareholders. As such, any proceeds or gain on the sale of APC’s indirect ownership interest in UCI has no impact on the Series A Dividend payable by APC to AP-AMH Medical Corporation as described in the 2019 Proxy Statement and consequently the sale did not affect net income attributable to ApolloMed. On December 31, 2020, APC paid $12.2 million for 100% interest in three limited liability companies that own office buildings leased to tenants (see Note 4). As a result, Medical Property Partners LLC ("MPP"), AMG Properties LLC ("AMG Properties"), and ZLL Partners LLC ("ZLL") are 100% owned subsidiaries of APC and are included in the consolidated financial statements. APAACO, jointly owned by NMM and AMM, began participating in the Next Generation Accountable Care Organization (“NGACO") Model of the Centers for Medicare & Medicaid Services (“CMS”) in January 2017. The NGACO Model is a CMS program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk sharing model. AMM, a wholly-owned subsidiary of ApolloMed, manages affiliated medical groups, consisting of ApolloMed Hospitalists (“AMH”), a hospitalist company and Southern California Heart Centers (“SCHC”). AMH provides hospitalist, intensivist and physician advisor services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Basis of Presentation and Summary of Significant Accounting PoliciesBasis of Presentation The accompanying consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Principles of Consolidation The consolidated balance sheets as of December 31, 2020 and 2019 and consolidated statements of income for the years ended December 31, 2020, 2019 and 2018 include the accounts of ApolloMed; its consolidated subsidiaries, NMM, AMM, and APAACO; its consolidated VIE, AP-AMH; AMM’s consolidated VIE, SCHC; NMM’s consolidated subsidiaries, APCN-ACO and AP-ACO; NMM’s consolidated VIE, APC; APC’s consolidated subsidiaries, UCAP, MPP, AMG Properties and ZLL, APC’s consolidated VIEs, CDSC, APC-LSMA and ICC; and APC-LSMA’s consolidated subsidiaries, Alpha Care and Accountable Health Care. Use of Estimates The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred but not reported (“IBNR”) claims), determination of full-risk and shared-risk revenue and receivables (including constraints, completion factors and historical margins), income tax valuation allowance, share-based compensation, and right-of-use ("ROU") assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions. Variable Interest Entities On an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly owned by it in accordance with the consolidation guidance. The evaluation considers all of the Company’s variable interests, including equity ownership, as well as management services agreements (“MSA”). To fall within the scope of the consolidation guidance, an entity must meet both of the following criteria: • The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity can be in the form of a partnership, limited liability company, or corporation, among others; and • The Company has a variable interest in the legal entity – i.e., variable interests that are contractual, such as equity ownership, or other financial interests that change with changes in the fair value of the entity’s net assets. If an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting. If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs. A legal entity is determined to be a VIE if it has any of the following three characteristics: • The entity does not have sufficient equity to finance its activities without additional subordinated financial support; • The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s) of voting rights); or • The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they lack any of the following: • The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entity’s economic performance, as evidenced by: • Substantive participating rights in day-to-day management of the entity’s activities; or • Substantive kick-out rights over the party responsible for significant decisions; • The obligation to absorb the entity’s expected losses; or • The right to receive the entity’s expected residual returns. If the Company concludes that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and evaluate it for consolidation under the variable interest model. Variable interest model If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company – that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE’s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer Note 18 – “Variable Interest Entities (VIEs)” to the consolidated financial statements for information on the Company’s consolidated VIE. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting, refer to Note 6 – “Investments in Other Entities” for entities that qualify as VIEs but the Company is not the primary beneficiary. Business Combinations The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition related costs separately from the business combination. Reportable Segments The Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative healthcare models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in one reportable segment. Reclassifications Certain 2019 amounts disclosed in prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications were made between depreciation and amortization and amortization of debt issuance cost on the consolidated statements of cash flows. They had no material effect on net income, earnings per share, retained earnings, cash flows or total assets. Cash and Cash Equivalents The Company's cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within ninety days from their date of purchase to be cash equivalents. The Company maintains its cash in deposit accounts with several banks, which at times may exceed the insured limits of the Federal Deposit Insurance Corporation (“FDIC”). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents and restricted cash. As of December 31, 2020 and 2019, the Company’s deposit accounts with banks exceeded the FDIC’s insured limit by approximately $294.9 million and $226.5 million, respectively. The Company has not experienced any losses to date and performs ongoing evaluations of these financial institutions to limit the Company’s concentration of risk exposure. Restricted Cash Restricted cash consists of cash held as collateral to secure standby letters of credits as required by certain contracts. The restricted cash of $0.1 million held as of December 31, 2019 was released in 2020. As of December 31, 2020 and 2019, there was $0 and $0.1 million, respectively, included in short-term restricted cash in the accompanying consolidated balance sheets. Investments in Marketable Securities The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date. As of December 31, 2020 and 2019, investments in marketable securities in the amount of approximately $67.7 million and $116.5 million, respectively, consisted of equity securities and certificates of deposit with various financial institutions, reported at fair value, with maturity dates from four months to twenty-four months (see fair value measurements of financial instruments below). Investments in certificates of deposits are classified as Level 1 investments in the fair value hierarchy. Receivables, Receivables – Related Parties, Loan Receivables and Loan Receivables - Related Parties The Company’s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements, management fee income, incentive receivables, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected. The Company's loan receivables and loan receivables - related party consist of promissory notes from payees that are expected to be collected between 2-4 years and accrue interest per annum. Capitation and claims receivable relate to each health plan’s capitation and is received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company’s full risk pool receivable that is recorded quarterly based on reports received from the Company's hospital partners and management’s estimate of the Company’s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consists of recoverable claims paid related to the 2019 APAACO performance year to be administered following instructions from CMS, fee-for-services (“FFS”) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop loss insurance premium reimbursements. The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis. Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses ("CECL") model. Concentrations of Risks The Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The consolidated statements of income present disaggregated revenue by service type. The following table presents disaggregated revenue generated by each payor type (in thousands): Years Ended December 31, 2020 2019 2018 Commercial $ 108,851 $ 107,340 $ 113,000 Medicare 271,596 226,002 226,353 Medicaid 269,079 192,596 134,904 Other third parties 37,654 34,680 45,651 Revenue $ 687,180 $ 560,618 $ 519,908 The Company had major payors that contributed the following percentages of net revenue: Years Ended December 31, 2020 2019 2018 Payor A 12.5 % 13.6 % 14.6 % Payor B 10.9 % 13.4 % 18.7 % Payor C *% *% 14.1 % Payor D 13.1 % 11.7 % 14.1 % Payor E 16.9 % 12.9 % *% * Less than 10% of total net revenues The Company had major payors that contributed to the following percentages of net receivables and receivables - related parties : As of December 31, 2020 2019 Payor F 43.9 % 30.4 % Payor G 36.5 % 36.0 % Land, Property and Equipment, Net Land is carried at cost and is not depreciated as it is considered to have an indefinite useful life. Property and equipment, including leasehold improvements, are carried at cost less accumulated depreciation and amortization. Depreciation is provided principally on the straight-line method over the estimated useful lives of the assets ranging from three Maintenance and repairs are charged to expense as incurred. Upon sale or retirement, the asset cost and related accumulated depreciation and amortization is removed from the accounts, and any related gain or loss is included in the determination of consolidated net income. Fair Value Measurements of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality. Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurement (“ASC 820”), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosures about fair value measurements. ASC 820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows: Level 1 —Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date. Level 2 —Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). Level 3 —Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company’s own data. The carrying amounts and fair values of the Company’s financial instruments as of December 31, 2020 are presented below (in thousands): Fair Value Measurements Level 1 Level 2 Level 3 Total Assets Money market accounts* $ 115,769 $ — $ — $ 115,769 Marketable securities – certificates of deposit 67,637 — — 67,637 Marketable securities – equity securities 58 — — 58 Total $ 183,464 $ — $ — $ 183,464 The carrying amounts and fair values of the Company’s financial instruments as of December 31, 2019 are presented below (in thousands): Fair Value Measurements Level 1 Level 2 Level 3 Total Assets Money market accounts* $ 50,731 $ — $ — $ 50,731 Marketable securities – certificates of deposit 116,469 — — 116,469 Marketable securities – equity securities 70 — — 70 Total $ 167,270 $ — $ — $ 167,270 * Included in cash and cash equivalents There have been no changes in Level 1, Level 2, or Level 3 classification and no changes in valuation techniques for these assets for the year ended December 31, 2020. Intangible Assets and Long-Lived Assets Intangible assets with finite lives include network-payor relationships, management contracts and member relationships and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate. Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method. Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques. The Company determined that there was no impairment of its finite-lived intangible or long-lived assets during the year ended December 31, 2020 and 2019. Goodwill and Indefinite-Lived Intangible Assets Under ASC 350, Intangibles – Goodwill and Other (“ASC 350”), goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment. At least annually, at the Company’s fiscal year end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company’s three reporting units (1) management services, (2) IPAs, and (3) ACOs. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit’s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill. An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances. At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances. For the year ended December 31, 2019, the Company wrote off indefinite-lived intangible assets of approximately $2.0 million related to Medicare licenses, acquired as part of the 2017 Merger between ApolloMed and NMM. The Company will no longer utilize the licenses and as such will not receive future economic benefits therefrom. For the year ended December 31, 2018, the Company wrote off approximately $3.8 million of goodwill related to MMG. The write-offs are included in impairment of goodwill and intangible assets in the accompanying consolidated statements of income. There was no impairment loss recorded related to goodwill and intangibles for the year ended December 31, 2020. Investments in Other Entities – Equity Method The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee’s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company’s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under “Income (loss) from equity method investments” and also is adjusted by contributions to and distributions from the investee. Equity method investments are subject to impairment evaluation. During the years ended December 31, 2019, the Company recognized an impairment loss of approximatel y $0.3 million rela ted to its investment in PASC as the Company does not believe it will recover its investment balance. Such impairment loss is included in loss from equity method investments in the accompanying consolidated statements of income. There was no impairment loss recorded related to equity method investments for the years ended December 31, 2020 and 2018. Investments in Privately Held Entities The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The investments in privately held entities that do not report NAV are subject to qualitative assessment for indicators of impairments. Medical Liabilities APC, Alpha Care, Accountable Health Care, and APAACO are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. APC, Alpha Care, Accountable Health Care, and APAACO provide integrated care to HMOs, Medicare and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services, excluding depreciation and amortization, expense in the accompanying consolidated statements of income. An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimated IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting accrual are periodically reviewed and updated. Many of the medical contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may not come to light until a substantial period of time has passed following the contract implementation. During the year ended December 31, 2017, as APAACO’s NGACO program was new and there was insufficient claims history, the medical liabilities for the NGACO program were estimated and recorded at 100% of the revenue less actual claims processed for or paid to in-network providers. The Company was notified by CMS that under the NGACO alternative payment arrangement the Company was paid an excess amount of approximately $34.5 million and $7.8 million related to the first performance year (January 1, 2017 through December 31, 2017) and second performance year (February 1, 2018 through December 31, 2018) with 18 month claims run outs, respectively. The excess amount for the first performance year was paid by the Company on December 4, 2018 and the excess for the second performance year was paid in February 2020. Revenue Recognition The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients. On January 1, 2018, the Company adopted the new revenue recognition standard Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606)”, using the modified retrospective method. Modified retrospective adoption requires entities to apply the standard retrospectively to the most current period presented in the financial statements, requiring the cumulative effect of the retrospective application as an adjustment to the opening balance of retained earnings and noncontrolling interests at the date of initial application. Revenue from substantially all of the Company’s contracts with customers continues to be recognized over time as services are rendered. The Company has elected to apply the modified retrospective method only to contracts not completed as of January 1, 2018. Under the new revenue standard, the Company recognizes incremental costs of obtaining a contract with amortization periods of one year or less as expense when incurred and records within general and administrative expenses, recognizes revenue in the amount of consideration to which the Company has a right to invoice the customer if that amount corresponds directly with the value to the customer of the Company’s services completed to date, and does not recognize an adjustment for the effects of a significant financing component as the period between the time of service and time of payment is typically one year or less. Nature of Services and Revenue Streams Revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO All-Inclusive Population-Based Payments (“AIPBP”), management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may vary by type of revenue and the customer. The following is a summary of the principal forms of the Company’s billing arrangements and how revenue is recognized for each. Capitation, Net Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months’ capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a “Risk Adjustment” model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company. PMPM managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk sharing. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company’s net PMPM transaction price relates specifically to the Company’s efforts to transfer the service for a distinct increment of the series (e.g. day or month) and is recognized as revenue in the month in which members are entitled to service. Risk Pool Settlements and Incentives APC enters into full risk capitation arrangements with certain health plans and local hospitals, which are administered by a third-party, where the hospital is responsible for providing, arranging and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a full risk pool sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital’s risk pools with HMOs after deductions for the affiliated hospitals costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company's risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. Assumptions based on factors including but not limited to historical margin, IBNR completion factors and constraint percentages were used by management in applying the most likely amount methodology. Under capitated arrangements with certain HMOs, APC participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent of any) risk sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished. The Company's risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and

Business Combinations and Goodw

Business Combinations and Goodwill	12 Months Ended
	Dec. 31, 2020
Business Combinations [Abstract]
Business Combinations and Goodwill	Business Combinations and Goodwill Alpha Care Medical Group, Inc. On May 31, 2019, APC and APC-LSMA completed their acquisition of 100% of the capital stock of Alpha Care from Dr. Kevin Tyson for an aggregate purchase price of approximately $45.1 million in cash, subject to post-closing adjustments. As part of the transaction the Company deposited $2.0 million into an escrow account for potential post-closing adjustments. As of December 31, 2020, no post-closing adjustment is expected to be paid to Dr. Tyson and the full amount of the escrow account is expected to be returned to the Company. As such, the escrow amount is presented within Other receivables in the accompanying consolidated balance sheet. The following table summarizes the fair values of the assets acquired and liabilities assumed, as of the acquisition date (in thousands): Assets acquired Cash and cash equivalents $ 3,569 Accounts receivable, net 10,336 Other current assets 4,675 Network relationship intangible assets 22,636 Goodwill 28,585 Accounts payable (2,795) Deferred tax liabilities (6,334) Medical liabilities (15,616) Net assets acquired $ 45,056 Cash paid $ 45,056 Accountable Health Care, IPA On August 30, 2019, APC and APC-LSMA, acquired the remaining outstanding shares of capital stock they did not already own (comprising 75%) in Accountable Health Care in exchange for $7.3 million in cash. In addition to the payment of $7.3 million APC assumed all assets and liabilities of Accountable Health Care, including loans payable to NMM and APC of $15.4 million, which has been eliminated upon consolidation. Including the 25% investment valued at $2.4 million already owned by APC the total purchase price was $25.1 million. The following table summarizes the fair values of the assets acquired and liabilities assumed, as of the acquisition date (in thousands): Assets acquired Cash and cash equivalents $ 582 Accounts receivable, net 5,150 Other current assets 198 Network relationship intangible assets 11,411 Goodwill 23,566 Accounts payable (3,759) Medical liabilities (12,154) Subordinated loan (15,327) Net assets acquired $ 9,667 Less: equity investment contributed 2,417 Cash paid $ 7,250 AMG, a Professional Medical Corporation The Company also completed one additional acquisition (AMG) on September 10, 2019 for total consideration of $1.6 million, of which $0.4 million was in the form of APC common stock. The business combination did not meet the quantitative thresholds to require separate disclosures based on the Company's consolidated net assets, investments and net income. Pro Forma Financial Information for All 2019 Acquisitions The following unaudited pro forma supplemental information is based on estimates and assumptions that ApolloMed believes are reasonable. However, this information is not necessarily indicative of the Company's consolidated results of income in future periods or the results that actually would have been realized if ApolloMed and the acquired businesses had been combined companies during the periods presented. These pro forma results exclude any savings or synergies that would have resulted from these business acquisitions had they occurred on January 1, 2018. This unaudited pro forma supplemental information includes incremental intangible asset amortization and other charges as a result of the acquisitions, net of the related tax effects. The supplemental information on an unaudited pro forma financial basis presents the combined results of ApolloMed and its 2019 acquisitions as if each acquisition had occurred on January 1, 2018 (in thousands except per share data): Year Ended Year Ended Revenue $ 658,011 $ 726,075 Net income 10,867 58,879 Net income attributable to Apollo Medical Holdings, Inc. 7,310 9,447 EPS - basic $ 0.21 $ 0.29 EPS - diluted $ 0.20 $ 0.25 The acquisitions were accounted for under the acquisition method of accounting. The fair value of the consideration for the acquired companies were allocated to acquired tangible and intangible assets and liabilities based upon their fair values. The excess of the purchase consideration over the fair value of the net tangible and identifiable intangible assets acquired were recorded as goodwill. The determination of the fair value of assets and liabilities acquired requires the Company to make estimates and use valuation techniques when market value is not readily available. The results of operations of the companies acquired have been included in the Company's financial statements from the respective dates of acquisition. Transaction costs associated with business acquisitions were expensed as incurred. At the time of acquisition, the Company estimates the amount of the identifiable intangible assets based on a valuation and the facts and circumstances available at the time. The Company determines the final value of the identifiable intangible assets as soon as information is available, but not more than 12 months from the date of acquisition. Goodwill is not deductible for tax purposes. The following is a summary of goodwill activity for the years ended December 31, 2020 and 2019 (in thousands): Amount Balance at January 1, 2019 $ 185,806 Acquisitions 52,699 Balance at December 31, 2019 238,505 Adjustments 548 Balance at December 31, 2020 $ 239,053

Land, Property and Equipment, N

Land, Property and Equipment, Net	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Land, Property and Equipment, Net	Land, Property and Equipment, Net Land, property and equipment, net consisted of (in thousands): Useful Life (Years) December 31, 2020 December 31, 2019 Land N/A $ 9,604 $ 3,300 Buildings 39 15,097 2,358 Computer software 3 - 5 3,104 3,088 Furniture and equipment 3 - 7 13,116 12,585 Construction in progress N/A 435 167 Leasehold improvements 3 - 39 6,722 6,655 48,078 28,153 Less accumulated depreciation and amortization (18,188) (16,023) Land, property and equipment, net $ 29,890 $ 12,130 As of December 31, 2020 and 2019, the Company had finance leases totaling $0.4 million a nd $0.5 million, respectively, included in Land, property and equipment, net in the accompanying consolidated balance sheets. Depreciation expense was $2.3 million, $2.0 million and $2.2 million for the years ended December 31, 2020, 2019, and 2018, respectively, which is included in depreciation and amortization in the accompanying consolidated statements of income. MPP, AMG Properties, and ZLL

Intangible Assets, Net

Intangible Assets, Net	12 Months Ended
	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, Net	Intangible Assets, NetAt December 31, 2020, intangible assets, net consisted of the following (in thousands): Useful Gross Additions Impairment/ Gross Accumulated Net Amortized intangible assets: Network relationships 11-15 143,930 — — 143,930 (73,169) 70,761 Management contracts 15 22,832 — — 22,832 (11,715) 11,117 Member relationships 12 6,696 — — 6,696 (3,234) 3,462 Patient management platform 5 2,060 — — 2,060 (1,270) 790 Tradename/trademarks 20 1,011 — — 1,011 (156) 855 $ 176,529 $ — $ — $ 176,529 $ (89,544) $ 86,985 At December 31, 2019, intangible assets, net consisted of the following (in thousands): Useful Gross Additions Impairment/ Gross Accumulated Net Indefinite lived assets: Medicare license N/A $ 1,994 $ — $ (1,994) $ — $ — $ — Amortized intangible assets: Network relationships 11-15 109,883 34,047 — 143,930 (60,525) 83,405 Management contracts 15 22,832 — — 22,832 (9,677) 13,155 Member relationships 12 6,696 — — 6,696 (2,352) 4,344 Patient management platform 5 2,060 — — 2,060 (858) 1,202 Tradename/trademarks 20 1,011 — — 1,011 (105) 906 $ 144,476 $ 34,047 $ (1,994) $ 176,529 $ (73,517) $ 103,012 Amortization expense was $16.0 million, $16.3 million and $17.1 million for the years ended December 31, 2020, 2019, and 2018, respectively, which is included in depreciation and amortization in the accompanying consolidated statements of income. During the year ended December 31, 2019, the Company wrote off indefinite-lived intangible assets of $2.0 million related to Medicare licenses it acquired as part of the Merger. The Company will no longer utilize these licenses and as such the Company will not receive future economic benefits. There was no impairment loss recorded related to intangibles for the year ended December 31, 2020. Future amortization expense is estimated to be as follows for the years ending December 31 (in thousands): Amount 2021 $ 14,524 2022 12,673 2023 10,842 2024 9,830 2025 8,758 Thereafter 30,358 $ 86,985

Investments in Other Entities

Investments in Other Entities	12 Months Ended
	Dec. 31, 2020
Equity Method Investments and Joint Ventures [Abstract]
Investments in Other Entities	Investments in Other Entities Equity Method Investments in other entities – equity method consisted of the following (in thousands): December 31, 2019 Allocation of Net Income (Loss) Additional/ Initial Investment Contribution Sale December 31, 2020 LaSalle Medical Associates – IPA Line of Business $ 6,396 $ 276 $ 6,375 $ — $ — $ 13,047 Pacific Medical Imaging & Oncology Center, Inc. 1,396 17 — — — 1,413 Universal Care, Inc. 1,438 3,560 — — (4,998) — Diagnostic Medical Group 2,334 279 — — — 2,613 531 W. College, LLC – related party 16,698 (448) — 950 — 17,200 MWN, LLC – related party 165 10 — — (175) — One MSO, LLC - related party — — 2,395 — — 2,395 Tag-6 Medical Investment Group, LLC - related party — — 4,516 — — 4,516 Tag-8 Medical Investment Group, LLC - related party — — 2,108 — — 2,108 $ 28,427 $ 3,694 $ 15,394 $ 950 $ (5,173) $ 43,292 LaSalle Medical Associates - IPA Line of Business LMA was founded by Dr. Albert Arteaga in 1996 and currently operates six neighborhood medical centers through its network of more than 2,300 PCP and Specialists providers, treating children, adults and seniors in San Bernardino County. LMA’s patients are primarily served by Medi-Cal and they also accept Blue Cross, Blue Shield, Molina, Care 1st, Health Net and Inland Empire Health Plan. LMA is also an IPA of independently contracted doctors, hospitals and clinics, delivering high quality care to patients in Fresno, Kings, Los Angeles, Madera, Riverside, San Bernardino and Tulare Counties. During 2012, APC-LSMA and LMA entered into a share purchase agreement whereby APC-LSMA invested $5.0 million for a 25% interest in LMA’s IPA line of business. NMM has a management services agreement with LMA. On December 18, 2020, the Company exercised its option to convert the promissory note totaling $6.4 million due from Dr. Arteaga into an additional 21.25% interest in LMA's IPA line of business. As a result, APC-LSMA's interest in LMA's IPA line of business as of December 31, 2020 was 46.25% (See Note 7). APC accounts for its investment in LMA under the equity method as APC has the ability to exercise significant influence, but not control over LMA’s operations. For the year ended December 31, 2020, APC recorded net income of $0.3 million from its investment in LMA as compared to a net loss of $2.8 million for the year ended December 31, 2019, in the accompanying consolidated statements of income. The investment balance was $13.0 million and $6.4 million at December 31, 2020 and 2019, respectively. LMA’s unaudited summarized balance sheets at December 31, 2020 and 2019 and unaudited summarized statements of operations for the years ended December 31, 2020 and 2019 are as follows (in thousands): Balance Sheets December 31, 2020 December 31, 2019 Assets Cash and cash equivalents $ 9,350 $ 6,345 Receivables, net 3,918 5,123 Other current assets 881 3,526 Loan receivable 2,250 2,250 Restricted cash 691 684 Total assets $ 17,090 $ 17,928 Liabilities and Stockholders’ Deficit Current liabilities $ 21,589 $ 23,530 Stockholders’ deficit (4,499) (5,602) Total liabilities and stockholders’ deficit $ 17,090 $ 17,928 Statements of Operations Year Ended Year Ended Revenues $ 186,964 $ 194,020 Expenses 185,724 205,153 Income (loss) from operations 1,240 (11,133) Other income 8 — Income (loss) before income tax benefit 1,248 (11,133) Income tax benefit — — Net income (loss) $ 1,248 $ (11,133) Pacific Medical Imaging and Oncology Center, Inc. PMIOC was incorporated in 2004 in the state of California. PMIOC provides comprehensive diagnostic imaging services using state-of-the-art technology. PMIOC offers high quality diagnostic services such as MRI/MRA, PET/CT, CT, nuclear medicine, ultrasound, digital x-rays, bone densitometry and digital mammography at their facilities. In July 2015, APC-LSMA and PMIOC entered into a share purchase agreement whereby APC-LSMA invested $1.2 million for a 40% ownership in PMIOC. APC and PMIOC have an Ancillary Service Contract together whereby PMIOC provides covered services on behalf of APC to enrollees of the plans of APC. Under the Ancillary Service Contract APC paid PMIOC fees of $2.2 million and $2.7 million for the years ended December 31, 2020 and 2019, respectively. APC accounts for its investment in PMIOC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over PMIOC’s operations. During the year ended December 31, 2020, APC recorded net income of $17,470 from its investment as compared to net loss of $36,384 for the year ended December 31, 2019 in the accompanying consolidated statements of income and has an investment balance of $1.4 million and $1.4 million at December 31, 2020 and 2019, respectively. Universal Care, Inc. UCI is a privately held health plan that has been in operation since 1985 in order to help its members through the complexities of the healthcare system. UCI holds a license under the California Knox-Keene Health Care Services Plan Act (Knox-Keene Act) to operate as a full-service health plan. UCI contracts with the CMS under the Medicare Advantage Prescription Drug Program. In August 2015, UCAP purchased 100,000 shares of UCI class A-2 voting common stock from UCI for $10.0 million, which shares comprise 48.9% of UCI’s total outstanding shares and 50% of UCI’s voting common stock. On April 30, 2020, UCAP completed the sale of its 48.9% ownership interest in UCI to Bright for approximately $69.2 million in cash proceeds (including $16.5 million as repayment of indebtedness owed to APC), plus non-cash consideration consisting of shares of Bright Health, Inc.’s preferred stock having an estimated fair value of approximately $36.2 million on the date of sale, included in investments in privately held entities. The fair value of the preferred shares was determined utilizing a market approach which includes significant unobservable inputs (Level 3) including forecasted revenue along with estimates of revenue multiples, volatility and time-to-liquidity. In addition, pursuant to the terms of the stock purchase agreement, APC has a beneficial interest in the equity method investment sold. The estimated fair value of such interest on April 30, 2020 was $15.7 million and is included in "Other assets" in the accompanying consolidated balance sheets. The beneficial interest is the result of a gross margin provision in the stock purchase agreement which entitles UCAP to potentially receive additional cash and preferred shares (currently held in an escrow account with cash of $15.6 million and preferred shares with an estimated fair value of $6.4 million, total estimated fair value of $22.0 million on the date of sale) based on the gross margin of UCI for calendar year 2020 as measured against a target. The amount to be received varies dependent upon the gross margin as compared to the target but cannot exceed the amounts that are in the escrow account. Additionally, the stock purchase agreement includes a tangible net equity provision that may result in the receipt or payment of additional amounts based on a comparison of final tangible net equity of UCI on the date of sale (determined with the benefit of one year of hindsight) as compared to the estimated tangible net equity at the time of sale. It is expected that settlement of the beneficial interest will begin in the second half of 2021. The Company determined the fair value of the beneficial interest using an income approach which includes significant unobservable inputs (Level 3). Specifically, the Company utilized a probability weighted discounted cash flow model using a risk-free treasury rate to estimate fair value which considered various scenarios of gross margin adjustment and the impact of each adjustment to the expected proceeds from the escrow account and assigned probabilities to each such scenario in determining fair value. The gross margin adjustment is defined as three times any deficit in actual gross margin of UCI for the year ended December 31, 2020 below a target gross margin unless such deficit is within a specific collar amount. The gain on sale of equity method investment recognized in connection with this transaction was determined as follows (in thousands): Amount Cash proceeds (excludes proceeds to settle indebtedness owed to APC from UCI) $ 52,743 Preferred shares in Bright Health, Inc. 36,179 Beneficial interest in UCI 15,723 Less: Carrying value of equity method investment on date of sale (4,998) Gain on sale of equity method investment $ 99,647 During the years ended December 31, 2020 and 2019, APC recorded income from this investment of $3.6 million and loss of $1.2 million, respectively, in the accompanying consolidated statements of income. As a result of the sale, there was no investment balance as of December 31, 2020 as compared to an investment balance of $1.4 million as of December 31, 2019. UCI’s unaudited balance sheet at December 31, 2019 and unaudited statements of operations for the four months ended April 30, 2020 and twelve months ended December 31, 2019 are as follows (in thousands): Balance Sheet December 31, 2019 Assets Cash $ 33,890 Receivables, net 63,843 Other current assets 38,280 Other assets 882 Property and equipment, net 4,021 Total assets $ 140,916 Liabilities and stockholders’ deficit Current liabilities $ 128,330 Other liabilities 33,133 Stockholders’ deficit (20,547) Total liabilities and stockholders’ deficit $ 140,916 Statements of Operations Four Months Ended April 30, 2020 Year Ended Revenues $ 195,308 $ 500,375 Expenses 189,028 502,567 Income (loss) before income tax provision 6,280 (2,192) Income tax provision — 258 Net income (loss) $ 6,280 $ (2,450) Diagnostic Medical Group APC accounts for its 40% investment in DMG, under the equity method of accounting as APC-LSMA, a designated shareholder professional corporation, has the ability to exercise significant influence, but not control over DMG’s operations. APC recorded income from this investment of $0.3 million and $0.3 million in 2020 and 2019, respectively, in the accompanying consolidated statements of income. During the years ended December 31, 2020 and 2019, APC received dividends of $0 and $0.2 million, respectively, from DMG. The investment balance was $2.6 million and $2.3 million as of December 31, 2020 and 2019, respectively. Accountable Health Care, IPA Accountable Health Care is a California professional medical corporation that has served the local community in the greater Los Angeles County area through a network of physicians and health care providers for more than 20 years. Accountable Health Care currently has a network of over 336 primary and 559 specialty care physicians, and is affiliated with one community regional hospital medical center that provides quality health care services to more than 73,000 members of three federally qualified health plans and multiple product lines, including Medi-Cal, Commercial, Medicare and Healthy Families. On September 21, 2018, APC and NMM each exercised their option to convert their respective $5.0 million loans into shares of Accountable Health Care capital stock. As a result, APC’s $5.0 million loan was converted into a 25% equity interest with the remaining $5.0 million loan held by NMM to be converted into an equity interest that will be determined based on a third-party valuation of Accountable Health Care’s current enterprise value. On August 30, 2019, APC and APC-LSMA entered into separate agreements with Dr. Jayatilaka to acquire the remaining outstanding shares of capital stock (comprising 75%) of Accountable Health Care in exchange for $7.3 million in cash. In addition to the payment of $7.3 million, APC assumed all liabilities and assets of Accountable Health Care. The Company recognized a gain of approximately $1.8 million as a result of the transaction, which represented the difference between the fair value of the 25% ownership held and the Company's basis at the time of acquisition. Such gain is included in loss from equity method investment in the accompanying consolidated statements of income for the year ended December 31, 2019. Effective September 1, 2019, Accountable Health Care's financial results are included in the consolidated balance sheets and the consolidated statements of income for the year ended December 31, 2019 and going forward. 531 W. College LLC In June 2018, College Street Investment LP, a California limited partnership (“CSI”), a related party, APC and NMM, entered into an operating agreement to govern the limited liability company, 531 W. College, LLC and the conduct of its business, and to specify their relative rights and obligations. CSI, APC and NMM, each owns 50%, 25% and 25%, respectively, of member units based on initial capital contributions of $16.7 million, $8.3 million, and $8.3 million, respectively. On June 29, 2018, 531 W. College, LLC closed its purchase of a non-operational hospital located in Los Angeles from Societe Francaise De Bienfaisance Mutuelle De Los Angeles, a California nonprofit corporation, for a total purchase price of $33.3 million. In June 2018, APC, NMM and AHMC Healthcare, Inc. ("AHMC") on behalf of CSI, wired $8.3 million, $8.3 million and $16.7 million, respectively into an escrow account for the benefit of 531 W. College, LLC to purchase the hospital pursuant to the Purchase Agreement. The transaction closed on June 28, 2018. On April 23, 2019, NMM and APC entered into an agreement whereby NMM assigned and APC assumed NMM's 25% membership interest in 531 W. College, LLC for approximately $8.3 million. Subsequently, APC has a 50% ownership in 531 W. College LLC with a total investment balance of approximately $16.1 million. APC accounts for its investment in 531 W. College, LLC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over the operations of this joint venture. APC’s investment is presented as an investment of equity method in the accompanying consolidated balance sheets as of December 31, 2020 and 2019. During the years ended December 31, 2020 and 2019, NMM and APC recorded losses from its investment in 531 W. College LLC of $0.4 million and $0.2 million, respectively, in the accompanying consolidated statements of income. During the years ended December 31, 2020 and 2019, APC contributed $1.0 million and $0.7 million, respectively to 531 W. College, LLC as part of its 50% interest. The accompanying consolidated balance sheet includes the related investment balance of $17.2 million and $16.7 million, respectively, related to APC's investment at December 31, 2020 and 2019. 531 W. College LLC’s unaudited balance sheets at December 31, 2020 and 2019 and unaudited statements of operations for the years ended December 31, 2020 and 2019 are as follows (in thousands): Balance Sheets December 31, 2020 December 31, 2019 Assets Cash $ 648 $ 139 Other current assets 17 17 Other assets 70 70 Property and equipment, net 33,697 33,581 Total assets $ 34,432 $ 33,807 Liabilities and Stockholders’ Equity Current liabilities $ 32 $ 1,061 Stockholders’ equity 34,400 32,746 Total liabilities and stockholders’ equity $ 34,432 $ 33,807 Statements of Operations Year Ended Year Ended Revenues $ — $ — Expenses 1,053 1,010 Loss from operations (1,053) (1,010) Other income 64 475 Provision for Income Taxes 3 — Net loss $ (992) $ (535) MWN LLC On December 18, 2018, NMM along with 6 Founders LLC, a California limited liability company doing business as Pacific6 Enterprises (“Pacific6”), and Health Source MSO Inc., a California corporation (“HSMSO”) entered into an operating agreement to govern MWN Community Hospital, LLC ("MWN") and the conduct of its business and to specify their relative rights and obligations. NMM, Pacific6, and HSMSO each owns 33.3% of membership shares based on each member’s initial capital contributions of $3,000 and working capital contributions of $30,000. NMM invested an additional $0.3 million, as part of its 33.3% interest, for working capital purpose. On October 30, 2020 NMM sold its shares in MWN to Pacific6 for $0.5 million in the form of a promissory note (see Note 7) and as a result of the sale, NMM recognized a gain of $0.2 million. One MSO LLC On December 31, 2020, APC purchased a 50% membership interest in One MSO LLC ("One MSO") for $2.4 million. One MSO owns an office building in Monterey Park, California that is currently being leased to tenants including NMM. Tag-6 Medical Investment Group, LLC and Tag-8 Medical Investment Group, LLC On December 31, 2020, APC purchased a 50% member interest in Tag-6 Medical Investment Group, LLC ("Tag 6") for $4.5 million. On December 31, 2020, APC purchased 50% member interest in Tag-8 Medical Investment Group, LLC ("Tag 8") for $2.1 million. Tag 6 and Tag 8 both own vacant land in Alhambra, California with plans to develop medical offices in the future. Both Tag 6 and Tag 8 shares common ownership with certain board members of APC and as such are considered related parties. Investment in privately held entities MediPortal, LLC In May 2018, APC purchased 270,000 membership interests of MediPortal LLC, a New York limited liability company, for $0.4 million or $1.50 per membership interest, which represented approximately 2.8% ownership. APC also received a 5-year warrant to purchase 270,000 membership interests. A 5-year option to purchase an additional 380,000 membership interests and a 5-year warrant to purchase 480,000 membership interests were contingent upon the portal completion date, however the Company did not exercise the option after completion of the portal. As APC does not have the ability to exercise significant influence, and lacks control, over the investee, this investment is accounted for using a measurement alternative which allows the investment to be measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. During the year ended December 31, 2020, there were no observable price changes to APC's investment. AchievaMed On July 1, 2019, NMM and AchievaMed, Inc., a California corporation ("AchievaMed"), entered into an agreement in which NMM would purchase up to 50% of the aggregate shares of capital stock of AchievaMed over a period of time not to exceed five years. As a result of this transaction, NMM invested $0.5 million for a 10% interest. The related investment balance of $0.5 million is included in "Investment in a privately held entities" in the accompanying consolidated balance sheet as of December 31, 2020. As NMM does not have the ability to exercise significant influence, and lacks control, over the investee, this investment is accounted for using a measurement alternative which allows the investment to be measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. During the year ended December 31, 2020, there were no observable price changes to NMM's investment. Bright Health, Inc. In April 2020, UCAP completed the sale of its 48.9% ownership interest in UCI to Bright for approximately $69.2 million in cash proceeds (including $16.5 million as repayment of indebtedness owed to APC), plus non-cash consideration consisting of shares of Bright Health, Inc.’s preferred stock having an estimated fair value on the transaction date of approximately $36.2 million. The related investment balance of $36.2 million is included in “Investment in privately held entities” in the accompanying consolidated balance sheet as of December 31, 2020. During the year ended December 31, 2020, there were no observable price changes to the Company's investment and no indicators of impairment.

Loans Receivable and Loans Rece

Loans Receivable and Loans Receivable - Related Parties	12 Months Ended
	Dec. 31, 2020
Loan Receivable [Abstract]
Loans Receivable and Loans Receivable – Related Parties	Loans Receivable and Loans Receivable – Related Parties Loans Receivable Dr. Albert Arteaga On June 28, 2019, APC entered into a convertible secured promissory note with Dr. Albert H. Arteaga, M.D. ("Dr. Arteaga"), Chief Executive Officer of LMA, to loan $6.4 million to Dr. Arteaga. Interest on the loan accrues at a rate that is equal to the prime rate plus 1% (4.25% as of December 31, 2020) and payable in monthly installments of interest only on the first day of each month until the maturity date of December 31, 2020, at which time, all outstanding principal and accrued interest thereon shall be due and payable in full. The note is secured by certain shares of LMA common stock held by Dr. Arteaga. At any time on or before December 31, 2020 and upon written notice by APC to Dr. Arteaga, APC has the right, but not the obligation, to convert the entire outstanding principal amount of this note into shares of LMA common stock which equal 21.25% of the aggregate then-issued and outstanding shares of LMA common stock to be held by APC's designee, which may include APC-LSMA. If converted, APC-LSMA and APC's designee will collectively own 46.25% of the equity of LMA with the remaining 53.75% to be owned by Dr. Arteaga. In December 2020 APC elected to convert the promissory note which resulted in an increase of 21.25% in its investment in LMA. The additional interest was reclassified as additional equity investment totaling $6.4 million. We further noted that there was no observable price movement and no indication of impairment as of and for the year ended December 31, 2020. On February 28, 2020, the Company entered into an agreement to advance Dr. Arteaga $2.2 million in the ordinary course of business. As of December 31, 2020, the $2.2 million was fully repaid. Pacific6 On October 30, 2020, NMM received a promissory note from Pacific6 totaling $0.5 million as a result of the sale of the Company's interest in MWN. Interest accrues at a rate of 5% per annum and is payable monthly through the maturity date of December 1, 2023. Loan Receivable - Related Parties AHMC In October 2020, APC entered into a promissory note with AHMC, a related party of the Company, (the “AHMC Note”) for a principal sum of $4.0 million with a maturity date of two years from the date of the agreement. The contractual interest rate on the AHMC Note is 3.75% per annum. The AHMC Note was entered into using cash strictly related to the Excluded Assets that were generated from the series of transactions with AP-AMH. As of December 31, 2020, the total principal of $4.0 million remains outstanding.

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	12 Months Ended
	Dec. 31, 2020
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses	Accounts Payable and Accrued Expenses Accounts payable and accrued expenses consisted of the following (in thousands): December 31, 2020 December 31, 2019 Accounts payable and other accruals $ 9,554 $ 6,914 Capitation payable 3,541 2,813 Subcontractor IPA payable 1,662 3,360 Professional fees 1,378 1,837 Due to related parties 50 225 Contract liabilities 12,988 8,892 Accrued compensation 6,970 3,238 Total accounts payable and accrued expenses $ 36,143 $ 27,279

Medical Liabilities

Medical Liabilities	12 Months Ended
	Dec. 31, 2020
Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]
Medical Liabilities	Medical LiabilitiesThe Company's medical liabilities consisted of the following (in thousands): December 31, 2020 December 31, 2019 Medical liabilities, beginning of year $ 58,725 $ 33,642 Acquired (see Note 3) — 27,474 Components of medical care costs related to claims incurred: Current period 309,848 271,987 Prior periods (3,258) 2,684 Total medical care costs 306,590 274,671 Payments for medical care costs related to claims incurred: Current period (261,062) (218,564) Prior periods (54,056) (58,633) Total paid (315,118) (277,197) Adjustments 133 135 Medical liabilities, end of year $ 50,330 $ 58,725

Credit Facility, Bank Loans and

Credit Facility, Bank Loans and Lines of Credit	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Credit Facility, Bank Loans and Lines of Credit	Credit Facility, Bank Loans and Lines of Credit Credit Facility The Company's credit facility consisted of the following (in thousands): December 31, 2020 December 31, 2019 Term Loan $ 178,125 $ 187,625 Revolver Loan 60,000 60,000 Real Estate Loans 7,580 — Total Debt 245,705 247,625 Less: current portion of debt (10,889) (9,500) Less: unamortized financing cost (4,605) (5,953) Long-term debt $ 230,211 $ 232,172 The following table presents scheduled maturities of the Company's credit facility as of December 31, 2020: Amount 2021 $ 10,889 2022 14,459 2023 15,653 2024 197,972 2025 and thereafter 6,732 Total $ 245,705 Credit Agreement In September 2019, the Company entered into a secured credit agreement (the “Credit Agreement,” and the credit facility thereunder, the “Credit Facility”) with Truist Bank (formerly known as SunTrust Bank), in its capacity as administrative agent for the lenders (in such capacity, the “Agent”), as a lender, an issuer of letters of credit and as swingline lender, and Preferred Bank, which is affiliated with one of the Company's board members, JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Royal Bank of Canada, Fifth Third Bank and City National Bank, as lenders (the “Lenders”). In connection with the closing of the Credit Agreement, the Company, its subsidiary, NMM, and the Agent entered into a Guaranty and Security Agreement (the “Guaranty and Security Agreement”), pursuant to which, among other things, NMM guaranteed the obligations of the Company under the Credit Agreement. The Credit Agreement provides for a five-year revolving credit facility to the Company of $100.0 million (“Revolver Loan”), which includes a letter of credit subfacility of up to $25.0 million. The Credit Agreement also provides for a term loan of $190.0 million, (“Term Loan A”). The unpaid principal amount of the term loan is payable in quarterly installments on the last day of each fiscal quarter commencing on December 31, 2019. The principal payment for each of the first eight fiscal quarters is $2.4 million, for the following eight fiscal quarters thereafter is $3.6 million and for the following three fiscal quarters thereafter is $4.8 million. The remaining principal payment on the term loan is due on September 11, 2024. The proceeds of the term loan and up to $60.0 million of the revolving credit facility may be used to (i) finance a portion of the $545.0 million loan made by the Company to AP-AMH Medical Corporation, a California professional medical corporation (“AP-AMH”), concurrently with the closing of the Credit Agreement (the “AP-AMH Loan”) as described in the May 13, 2019, Current Report and the August 29, 2019, Current Report, (ii) refinance certain indebtedness of the Company and its subsidiaries and, indirectly, APC, (iii) pay transaction costs and expenses arising in connection with the Credit Agreement, the AP-AMH Loan and certain other related transactions and (iv) provide for working capital, capital expenditures and other general corporate purposes. The remainder of the revolving credit facility will be used to finance future acquisitions and investments and to provide for working capital needs, capital expenditures and other general corporate purposes. The Company is required to pay an annual facility fee of 0.20% to 0.35% on the available commitments under the Credit Agreement, regardless of usage, with the applicable fee determined on a quarterly basis based on the Company’s leverage ratio. The Company is also required to pay customary fees as specified in a separate fee agreement between the Company and Truist Securities, Inc. (formerly SunTrust Robinson Humphrey, Inc.), the lead arranger of the Credit Agreement. Amounts borrowed under the Credit Agreement will bear interest at an annual rate equal to either, at the Company’s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on Reuters Screen LIBOR01 Page (“LIBOR”), adjusted for any reserve requirement in effect, plus a spread of from 2.00% to 3.00%, as determined on a quarterly basis based on the Company’s leverage ratio, or (b) a base rate, plus a spread of 1.00% to 2.00%, as determined on a quarterly basis based on the Company’s leverage ratio. As of December 31, 2020, the interest rate on the Credit Agreement was 2.27%. The base rate is defined in a manner such that it will not be less than LIBOR. The Company will pay fees for standby letters of credit at an annual rate equal to 2.00% to 3.00%, as determined on a quarterly basis based on the Company’s leverage ratio, plus facing fees and standard fees payable to the issuing bank on the respective letter of credit. Loans outstanding under the Credit Agreement may be prepaid at any time without penalty, except for LIBOR breakage costs and expenses. If LIBOR ceases to be reported, the Credit Agreement requires the Company and the Agent to endeavor to establish a commercially reasonable alternative rate of interest and until they are able to do so, all borrowings must be at the base rate. The Credit Agreement requires the Company and its subsidiaries to comply with various affirmative covenants, including, without limitation, furnishing updated financial and other information, preserving existence and entitlements, maintaining properties and insurance, complying with laws, maintaining books and records, requiring any new domestic subsidiary meeting a materiality threshold specified in the Credit Agreement to become a guarantor thereunder and paying obligations. The Credit Agreement requires the Company and its subsidiaries to comply with, and to use commercially reasonable efforts to the extent permitted by law to cause certain material associated practices of the Company, including APC, to comply with, restrictions on liens, indebtedness and investments (including restrictions on acquisitions by the Company), subject to specified exceptions. The Credit Agreement also contains various other negative covenants binding the Company and its subsidiaries, including, without limitation, restrictions on fundamental changes, dividends and distributions, sales and leasebacks, transactions with affiliates, burdensome agreements, use of proceeds, maintenance of business, amendments of organizational documents, accounting changes and prepayments and modifications of subordinated debt. The Credit Agreement requires the Company to comply with two key financial ratios, each calculated on a consolidated basis. The Company must maintain a maximum consolidated leverage ratio of not greater than 3.75 to 1.00 as of the last day of each fiscal quarter. The maximum consolidated leverage ratio decreases by 0.25 each year, until it is reduced to 3.00 to 1.00 for each fiscal quarter ending after September 30, 2022. In accordance with the Credit Agreement, the Company must maintain a maximum consolidated leverage ratio of not greater than 3.50 to 1.00 as of December 31, 2020. The Company must maintain a minimum consolidated interest coverage ratio of not less than 3.25 to 1.00 as of the last day of each fiscal quarter. As of December 31, 2020, the Company was in compliance with the covenants relating to its credit facility. Pursuant to the Guaranty and Security Agreement, the Company and NMM have granted the Lenders a security interest in all of their assets, including, without limitation, all stock and other equity issued by their subsidiaries (including NMM) and all rights with respect to the AP-AMH Loan. The Guaranty and Security Agreement requires the Company and NMM to comply with various affirmative and negative covenants, including, without limitation, covenants relating to maintaining perfected security interests, providing information and documentation to the Agent, complying with contractual obligations relating to the collateral, restricting the sale and issuance of securities by their respective subsidiaries and providing the Agent access to the collateral. The Credit Agreement contains events of default, including, without limitation, failure to make a payment when due, default on various covenants in the Credit Agreement, breach of representations or warranties, cross-default on other material indebtedness, bankruptcy or insolvency, occurrence of certain judgments and certain events under the Employee Retirement Income Security Act of 1974 aggregating more than $10.0 million, invalidity of the loan documents, any lien under the Guaranty and Security Agreement ceasing to be valid and perfected, any change in control, as defined in the Credit Agreement, an event of default under the AP-AMH Loan, failure by APC to pay dividends in cash for any period of two consecutive fiscal quarters, failure by AP-AMH to pay cash interest to the Company, or if any modification is made to the Certificate of Determination or the Special Purpose Shareholder Agreement that directly or indirectly restricts, conditions, impairs, reduces or otherwise limits the payment of the Series A Preferred dividend by APC to AP-AMH. In addition, it will constitute an event of default under the Credit Agreement if APC uses all or any portion of the consideration received by APC from AP-AMH on account of AP-AMH’s purchase of Series A Preferred Stock for any purpose other than certain specific approved uses described in the following sentence, unless not less than 50.01% of all holders of common stock of APC at such time approve such use; provided that APC may use up to $50.0 million in the aggregate of such consideration for any purpose without any requirement to obtain such approval of the holders of common stock of APC. The approved uses include (i) any permitted investment, (ii) any dividend or distribution to the holders of the common stock of APC, (iii) any repurchase of common stock of APC, (iv) paying taxes relating to or arising from certain assets and transactions, or (v) funding losses, deficits or working capital support on account of certain non-healthcare assets in an amount not to exceed $125.0 million. If any event of default occurs and is continuing under the Credit Agreement, the Lenders may terminate their commitments, and may require the Company and its guarantors to repay outstanding debt and/or to provide a cash deposit as additional security for outstanding letters of credit. In addition, the Agent, on behalf of the Lenders, may pursue remedies under the Guaranty and Security Agreement, including, without limitation, transferring pledged securities of the Company’s subsidiaries in the name of the Agent and exercising all rights with respect thereto (including the right to vote and to receive dividends), collect on pledged accounts, instruments and other receivables (including the AP-AMH Loan), and all other rights provided by law or under the loan documents and the AP-AMH Loan. In the ordinary course of business, certain of the Lenders under the Credit Agreement and their affiliates have provided to the Company and its subsidiaries and the associated practices, and may in the future provide, (i) investment banking, commercial banking (including pursuant to certain existing business loan and credit agreements being terminated in connection with entering into the Credit Agreement), cash management, foreign exchange or other financial services, and (ii) services as a bond trustee and other trust and fiduciary services, for which they have received compensation and may receive compensation in the future. Deferred Financing Costs The Company recorded deferred financing costs of $6.5 million related to the issuance of the Credit Facility. This amount was recorded as a direct reduction of the carrying amount of the related debt liability. The deferred financing costs related to the term loan will be amortized over the life of the Credit Facility using the effective interest rate method. The deferred financing costs related to the Revolver Loan will be amortized using the straight line method over the term of the revolver. Effective Interest Rate The Company’s average effective interest rate on its total debt during the years ended December 31, 2020, 2019 and 2018 was 3.48%, 3.39%, and 4.72%, respectively. Interest expense in the consolidated statements of income included amortization of deferred debt issuance costs for the years ended December 31, 2020 and 2019 of $1.4 million and, $0.5 million, respectively. Real Estate Loans On December 31, 2020, the Company purchased 100% of MPP, AMG Properties, and ZLL (refer to Note 4). As a result of this purchase, the Company assumed the existing loans held by MPP, AMG Properties, and ZLL. MPP On July 3, 2020, MPP entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December 31, 2020, the principal on the loan is $6.4 million with a variable interest rate of 0.50% less than the independent index which is the daily Wall Street Journal "Prime Rate." If the index is not available, East West Bank may designate a substitute index after notifying MPP. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. MPP must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt plus interest expense) of not less than 1.25 to 1. AMG On August 5, 2020, AMG Properties entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December 31, 2020, the principal on the loan is $0.7 million with a variable interest rate of 0.30% less than the independent index which is the daily Wall Street Journal "Prime Rate." If the index is not available, East West Bank may designate a substitute index after notifying AMG Properties. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. AMG Properties must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt plus interest expense) of not less than 1.25 to 1. ZLL On July 27, 2020, ZLL entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December 31, 2020, the principal on the loan is $0.7 million with a variable interest rate of 0.50% less than the independent index which is the daily Wall Street Journal "prime rate." If the index is not available, East West Bank may designate a substitute index after notifying AMG Properties. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. ZLL must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt plus interest expense) of not less than 1.25 to 1. Lines of Credit – Related Party NMM Business Loan On June 14, 2018, NMM amended its promissory note agreement with Preferred Bank (“NMM Business Loan Agreement”). Preferred Bank is affiliated with one of the Company’s board members who serves as the Chairman and CEO of Preferred Bank. The NMM Business Loan Agreement provides for loan availability of up to $20.0 million with a maturity date of June 22, 2020. The NMM Business Loan Agreement was subsequently amended to temporarily increase the loan availability to $27.0 million for the period from September 1, 2018 to October 31, 2019 to facilitate the issuance of an additional standby letter of credit for the benefit of CMS. The amounts outstanding as of June 30, 2019 of $5.0 million were fully repaid on September 11, 2019. On September 5, 2018, NMM entered into a non-revolving line of credit agreement with Preferred Bank (“NMM Line of Credit Agreement”) which provides for loan availability of up to $20.0 million with a maturity date of September 5, 2019. This credit facility was subsequently amended in 2019 to reduce the loan availability to $2.2 million. The interest rate is based on the Wall Street Journal “Prime Rate” plus 0.125%, or 3.375%, as of December 31, 2020. Each drawdown from the line of credit is converted into a five-year term loan with monthly principal payments plus interest based on a five-year amortization schedule. On September 11, 2019, the NMM Business Loan Agreement, dated as of June 14, 2018, between NMM and Preferred Bank, as amended, and the Line of Credit Agreement, dated as of September 5, 2018, between NMM and Preferred Bank, as amended, were terminated in connection with the closing of the credit facility. APC Business Loan On June 14, 2018, APC entered its promissory note agreement with Preferred Bank, which is affiliated with one of the Company’s board members, (“APC Business Loan Agreement”) which provides for loan availability of up to $10.0 million with a maturity date of June 22, 2020. APC Business Loan Agreement was subsequently amended on April 17, 2019 and June 11, 2019 to decrease the loan availability from $10.0 million to $4.1 million and extend the maturity date through December 31, 2020. On August 1, 2019 and September 10, 2019, APC Business Loan Agreement was further amended to increase loan availability from $40.0 million to $43.8 million, and decrease loan availability from $43.8 million to $4.1 million, respectively. This decrease further limited the purpose of the indebtedness under APC Business Loan Agreement to the issuance of standby letters of credit, and added as a permitted lien the security interest in all of its assets granted by APC in favor of NMM under a Security Agreement dated on or about September 11, 2019 securing APC’s obligations to NMM under, and as required pursuant to, that certain Management Services Agreement dated as of July 1, 1999, as amended. The interest rate is based on the Wall Street Journal “Prime Rate” plus 0.125%, or 3.375% and 4.875%, as of December 31, 2020 and December 31, 2019, respectively. As of December 31, 2020 and 2019, there is no additional availability under this line of credit. Standby Letters of Credit In September 2019, NMM held certain letters of credit issued by Preferred Bank that were terminated and reissued under the Credit Agreement. As of December 31, 2020, there was no outstanding letters of credit and the Company has $25.0 million available under the letter of credit subfacility. APAACO established an irrevocable standby letter of credit with Preferred Bank, which is affiliated with one of the Company’s board members, (through the NMM Business Loan Agreement) and was amended in 2019 to the amount of $14.8 million for the benefit of CMS. The letter of credit is automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution to terminate prior to 90 days from any expiration date. APAACO may continue to draw from the letter of credit for one year following the bank’s notification of non-renewal. In September 2019, these letters were terminated with Preferred Bank and reissued under the Credit Agreement. In August 2020, $14.8 million of the irrevocable standby letters of credit were released by CMS and no amounts remain outstanding as of December 31, 2020. APC established irrevocable standby letters of credit with a financial institution for a total of $0.3 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated. Alpha Care established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $3.8 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Provision for income taxes consisted of the following (in thousands): Years ended December 31, 2020 2019 2018 Current Federal $ 43,572 $ 9,035 $ 21,059 State 19,155 5,925 9,646 62,727 14,960 30,705 Deferred Federal (4,963) (3,508) (5,954) State (1,657) (3,285) (2,391) (6,620) (6,793) (8,345) Total provision for income taxes $ 56,107 $ 8,167 $ 22,360 The Company uses the liability method of accounting for income taxes as set forth in ASC 740. Under the liability method, deferred taxes are determined based on differences between the financial statement and tax bases of assets and liabilities using enacted tax rates. As of December 31, 2020, the Company had Federal and California net operating loss carryforwards of approximately $69.1 million and $89.4 million, respectively. The Federal and California net operating loss carryforwards will expire at various dates from 2027 through 2040; however, $49.8 million of the Federal operating loss does not expire and will be carried forward indefinitely. Pursuant to Internal Revenue Code Sections 382 and 383, use of the Company's net operating loss and credit carryforwards may be limited if a cumulative change in ownership of more than 50% occurs within any three years' period since the last ownership change. Significant components of the Company's deferred tax assets (liabilities) as of December 31, 2020 and December 31, 2019 are shown below (in thousands). A valuation allowance of $15.5 million and $8.2 million as of December 31, 2020 and December 31, 2019, respectively, has been established against the Company's deferred tax assets related to loss entities the Company cannot consolidate under the Federal consolidation rules, as realization of these assets is uncertain. Valuation allowance increased by $7.3 million in 2020. 2020 2019 Deferred tax assets State taxes $ 3,932 $ 1,111 Stock options 461 1,293 Accrued expenses 3,905 2,334 Allowance for bad debts 351 544 Investment in other entities 702 2,977 Net operating loss carryforward 20,758 13,850 Lease liability 4,979 3,568 Other 665 — Deferred tax assets before valuation allowance 35,753 25,677 Valuation allowance (15,517) (8,192) Net deferred tax assets 20,236 17,485 Deferred tax liabilities Property and equipment (661) (927) Acquired intangible assets (24,661) (29,195) Right-of-use assets (4,888) (3,544) 481(a) adjustment (985) (1,623) Other — (465) Deferred tax liabilities (31,195) (35,754) Net deferred liabilities $ (10,959) $ (18,269) The provision for income taxes differs from the amount computed by applying the federal income tax rate as follows for the years ended December 31: Years ended December 31, 2020 2019 2018 Tax provision at U.S. Federal statutory rates 21.0 % 21.0 % 21.0 % State income taxes net of federal benefit 7.7 8.1 6.7 Non-deductible permanent items 0.3 3.3 1.3 Non-taxable entities (0.2) (2.7) (0.7) Stock-based compensation 0.3 (1.5) (1.8) Change in valuation allowance 3.2 3.2 — Other (1.0) 0.2 0.6 Effective income tax rate 31.3 % 31.6 % 27.1 % The Company's effective tax rate is different from the federal statutory rate of 21% due primarily to state taxes, change in valuation allowance, and permanent adjustments. On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (“CARES”) Act was enacted and signed into law. The CARES Act, among other things, permits NOL carryovers and carrybacks and modifications on the limitation of business interests. As of December 31, 2020, the Company does not expect the CARES Act to result in any material impact on the Company’s effective tax rate.

Mezzanine and Stockholders' Equ

Mezzanine and Stockholders' Equity	12 Months Ended
	Dec. 31, 2020
Stockholders' Equity Note [Abstract]
Mezzanine and Stockholders’ Equity	Mezzanine and Stockholders’ Equity APC As the redemption feature (see Note 2) of APC's shares of common stock is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as noncontrolling interests in mezzanine or temporary equity. APC’s shares were not redeemable and it was not probable that the shares would become redeemable as of December 31, 2020, 2019 and 2018. On September 10, 2019, APC-LSMA, a holding company of APC, acquired 100% of the aggregate issued and outstanding shares of capital stock of AMG for $1.2 million in cash and $0.4 million of APC common stock. On September 11, 2019, AP-AMH purchased 1,000,000 shares of APC Series A Preferred Stock for aggregate consideration of $545.0 million in a private placement. This investment was eliminated in consolidation. In relation to the issuance of APC Series A Preferred Stock, APC incurred $0.9 million in cost (see Note 1). Stockholders’ Equity Preferred Stock – Series A In October 2015, ApolloMed entered into an agreement with NMM pursuant to which ApolloMed sold to NMM, and NMM purchased from ApolloMed, in a private offering of securities, 1,111,111 units, each unit consisting of one share of ApolloMed’s Series A Preferred Stock and a common stock warrant to purchase one share of ApolloMed’s common stock at an exercise price of $9.00 per share. NMM paid ApolloMed an aggregate of $10.0 million for the units. Preferred Stock – Series B In March 2016, ApolloMed entered into an agreement with NMM pursuant to which ApolloMed sold to NMM, and NMM purchased from ApolloMed, in a private offering of securities, 555,555 units, each unit consisting of one share of ApolloMed’s Series B Preferred Stock and a common stock warrant to purchase one share of ApolloMed’s common stock at an exercise price of $10.00 per share. NMM paid ApolloMed an aggregate $5.0 million for the units. 2017 Share Issuances and Repurchases In December 2017, ApolloMed completed its business combination with NMM following the satisfaction or waiver of the conditions set forth in the Merger Agreement, pursuant to which Merger Subsidiary merged with and into NMM, with NMM surviving as a wholly owned subsidiary of ApolloMed. In connection with the 2017 Merger and as of the effective time of the Merger (the “Effective Time”): • each issued and outstanding share of NMM common stock was converted into the right to receive such number of shares of common stock of ApolloMed that results in the former NMM shareholders who did not dissent from the 2017 Merger (“former NMM Shareholders”) having a right to receive an aggregate of 30,397,489 shares of common stock of ApolloMed, subject to the 10% holdback pursuant to the Merger Agreement; • ApolloMed issued to former NMM Shareholders each former NMM Shareholder’s pro rata portion of (i) warrants to purchase an aggregate of 850,000 shares of common stock of ApolloMed, exercisable at $11.00 per share, and (ii) warrants to purchase an aggregate of 900,000 shares of common stock of ApolloMed, exercisable at $10.00 per share; and • ApolloMed held back an aggregate of 3,039,749 shares of common stock issuable to former NMM Shareholders, representing 10% of the total number of shares of ApolloMed common stock issuable to former NMM Shareholders, to secure indemnification rights of AMEH and its affiliates under the Merger Agreement (the “Holdback Shares”). The Holdback Shares were issued and outstanding as of December 31, 2020. The first tranche of 1,519,805 shares were issued in December 2018 and the remaining 1,511,380 were issued in December 2019, net of shares repurchase. The shares of common stock issuable to former NMM shareholders in the exchange were 25,675,630 (net of 10% holdback and Treasury Shares). The 10% holdback shares will be released to all the former NMM shareholders based on their respective pro rata ownership interest in NMM at the Effective Time without regard to whether the former NMM shareholders are providing any services to the Company at the time of this distribution. This holdback accommodation was made as indemnification protection to the accounting acquiree (ApolloMed), and as such, is not considered compensatory. At the time when these holdback shares were issued to the former NMM shareholders, the Company recorded the stock issuance with a reduction to additional paid-in capital to properly reflect the shares outstanding. Upon consummation of the 2017 Merger, the Company issued 520,081 shares of its common stock with a fair value of approximately $5.4 million from the conversion of a convertible promissory note issued by the Company in 2017. Common Stock As of December 31, 2020, 276,038 holdback shares have not been issued to certain former NMM shareholders who were NMM shareholders at the time of closing of the Merger, as they have yet to submit properly completed letters of transmittal to ApolloMed in order to receive their pro rata portion of ApolloMed common stock and warrants as contemplated under the merger agreement. Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the Merger. The consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares in connection with the Merger. Warrants Common stock warrants, to purchase 1,111,111 shares of ApolloMed common stock, issued to NMM in connection with the Series A Preferred Stock investment in ApolloMed may be exercised at any time after issuance and through March 30, 2021, for $9.00 per share, subject to adjustment in the event of stock dividends and stock splits. As part of the Merger between NMM and ApolloMed, such warrants were distributed to former NMM shareholders on a pro-rata basis utilizing the percentage of shares of NMM held by each shareholder prior to the merger date. Common stock warrants, to purchase 555,555 shares of ApolloMed common stock, issued to NMM in connection with the Series B Preferred Stock investment in ApolloMed may be exercised at any time after issuance and through March 30, 2021, for $10.00 per share, subject to adjustment in the event of stock dividends and stock splits. As part of the Merger between NMM and ApolloMed, such warrants were distributed to former NMM shareholders on a pro-rata basis utilizing the percentage of shares of NMM held by each shareholder prior to the Merger date. The Company’s outstanding warrants consisted of the following: Shares Weighted Weighted Aggregate Warrants outstanding at January 1, 2018 3,648,541 $ 9.75 3.74 $ 52.0 Warrants exercised (286,357) 7.84 3.0 Warrants forfeited (30,189) 4.50 — Warrants outstanding at December 31, 2018 3,331,995 $ 9.93 2.97 33.1 Warrants granted — — — — Warrants exercised (177,405) 9.32 — 1.6 Warrants forfeited — — — Warrants outstanding at December 31, 2019 3,154,590 $ 9.96 2.01 26.7 Warrants granted — — — — Warrants exercised (1,247,644) 9.33 — 9.8 Warrants forfeited (28,820) 9.00 — — Warrants outstanding at December 31, 2020 1,878,126 $ 10.39 1.63 $ 14.8 Exercise Price Per Warrants Weighted Warrants Weighted $ 9.00 10,810 0.24 10,810 $ 9.00 10.00 1,115,342 1.44 1,115,342 10.00 11.00 751,974 1.93 751,974 11.00 $9.00 – $11.00 1,878,126 1.63 1,878,126 $ 10.39 During the years ended December 31, 2020 and 2019, common stock warrants were exercised for 1,247,644 and 177,405 shares of the Company’s common stock, respectively which resulted in proceeds of approximately $10.5 million and $1.7 million, respectively. The exercise price ranged from $9.00 to $11.00 per share during year ended December 31, 2020 and December 31, 2019. Dividends During the years ended December 31, 2020, 2019 and 2018, NMM paid dividends of $0, $0 and $13.8 million, respectively. The dividends paid in the year ended December 31, 2019 were declared in December 2018 as part of the merger between ApolloMed and NMM and was classified as restricted cash (see Note 3). During the years ended December 31, 2020, 2019 and 2018, APC paid dividends of $136.6 million, $60.0 million and $2.0 million, respectively. During the years ended December 31, 2020, 2019 and 2018, CDSC paid distributions of $2.1 million, $2.6 million and $2.0 million, respectively. Treasury Stock APC owned 12,323,164 shares of ApolloMed's common stock as of December 31, 2020, and 17,290,317 shares of ApolloMed’s common stock as of December 31, 2019, respectively, which are legally issued and outstanding but excluded from shares of common stock outstanding in the consolidated financial statements, as such shares are treated as treasury shares for accounting purposes (see Note 1).

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Regulatory Matters Laws and regulations governing the Medicare program and healthcare generally are complex and subject to interpretation. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While no regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation as well as significant regulatory action including fines, penalties, and exclusion from the Medicare and Medi-Cal programs. As a risk-bearing organization, the Company is required to follow regulations of the Department of Managed Health Care ("DMHC"). The Company must comply with a minimum working capital requirement, tangible net equity (“TNE”) requirement, cash-to-claims ratio and claims payment requirements prescribed by the DMHC. TNE is defined as net assets less intangibles, less non-allowable assets (which include amounts due from affiliates), plus subordinated obligations. At December 31, 2020 and 2019, APC, Alpha Care and Accountable Health Care were in compliance with these regulations. Many of the Company’s payor and provider contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services. Such differing interpretations may not come to light until a substantial period of time has passed following contract implementation. Liabilities for claims disputes are recorded when the loss is probable and can be estimated. Any adjustments to reserves are reflected in current operations. Standby Letters of Credit As part of the APAACO participation with CMS, the Company must provide a financial guarantee to CMS, the guarantee generally must be in an amount of 2% of the Company's benchmark Medicare Part A and Part B expenditures. In August 2020, $14.8 million of the irrevocable standby letters of credit were released by CMS and $0 remain outstanding as of December 31, 2020. APC and Alpha Care established irrevocable standby letters of credit with a Preferred Bank for a total of $0.3 million and $3.8 million, respectively, for the benefit of certain health plans (see Note 10). Litigation From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of its business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company’s financial condition, cash flows or results of operations. Liability Insurance The Company believes that its insurance coverage is appropriate based upon the Company’s claims experience and the nature and risks of the Company’s business. In addition to the known incidents that have resulted in the assertion of claims, the Company cannot be certain that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against the Company, the Company’s affiliated professional organizations or the Company’s affiliated hospitalists in the future where the outcomes of such claims are unfavorable. The Company believes that the ultimate resolution of all pending claims, including liabilities in excess of the Company’s insurance coverage, will not have a material adverse effect on the Company’s financial position, results of operations or cash flows; however, there can be no assurance that future claims will not have such a material adverse effect on the Company’s business. Contracted physicians are required to obtain their own insurance coverage. Although the Company currently maintains liability insurance policies on a claims-made basis, which are intended to cover malpractice liability and certain other claims, the coverage must be renewed annually, and may not continue to be available to the Company in future years at acceptable costs, and on favorable terms.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions During the years ended December 31, 2020, 2019, and 2018, NMM earned approximately $16.9 million, $17.3 million, and $21.6 million, respectively, in management fees, of which $2.3 million and $2.0 million, remained outstanding, at December 31, 2020 and 2019 respectively, from LMA, which is accounted for under the equity method based on 25% equity ownership interest held by APC (see Note 6). During the years ended December 31, 2020, 2019, and 2018, APC paid approximately $2.2 million, $2.7 million, and $2.5 million, respectively, to PMIOC for provider services, which is accounted for under the equity method based on 40% equity ownership interest held by APC (see Note 6). During the years ended December 31, 2020, 2019, and 2018, APC paid approximately $6.0 million, $7.8 million, and $7.0 million, respectively, to DMG for provider services, which is accounted for under the equity method based on 40% equity ownership interest held by APC (see Note 6). During the years ended December 31, 2020, 2019, and 2018, APC paid approximately $0.5 million, $0.4 million, $0.3 million, respectively, to Advance Diagnostic Surgery Center for services as a provider. Advance Diagnostic Surgery Center shares common ownership with certain board members of APC. During the years ended December 31, 2020, 2019, and 2018, APC paid approximately $0.1 million, $0.1 million, and $0.1 million respectively, to Fresenius and their subsidiaries for services as a provider. During the year ended December 31, 2020 and 2019, APAACO paid approximately $0.7 million and $0, respectively, to Fresenius and their subsidiaries for services as a provider. One of the Company's board members is an officer of Fresenius and their subsidiaries. During the years ended December 31, 2020 and 2019, APC paid approximately $0.3 million and $0, respectively, to Fulgent Genetics, Inc. for services as a provider. Fulgent Genetics, Inc. shares common a board member with the Company starting in 2019. During the years ended December 31, 2020, 2019, and 2018, NMM paid approximately $1.0 million and $1.1 million, and $1.0 million to Medical Property Partners (“MPP”) for an office lease. MPP shares common ownership with certain board members of NMM (see Note 19). During the years ended December 31, 2020 and 2019, NMM paid approximately $1.4 million and $0.2 million, respectively, to One MSO, Inc. (“One MSO”) for an office lease. One MSO was indirectly 50% owned by Drs. Sim and Lam in 2019, but as of December 31, 2020, Drs. Sim and Lam has sold their ownership to APC for $2.4 million. During the years ended December 31, 2020, 2019, and 2018, the Company paid approximately $0.3 million, $0.5 million, and $0.4 million respectively, to Critical Quality Management Corp (“CQMC”) for an office lease. CQMC shares common ownership with certain board members of APC (see Note 19). During the years ended December 31, 2020, 2019, and 2018, SCHC paid approximately $0.4 million, $0.4 million, and $0.5 million respectively, to Numen, LLC (“Numen”) for an office lease. Numen is owned by a shareholder of APC (see Note 19). The Company has agreements with HSMSO, Aurion Corporation (“Aurion”), and AHMC for services provided to the Company. One of the Company’s board members is an officer of AHMC, HSMSO and Aurion. Aurion is also partially owned by one of the Company’s board members. The following table sets forth fees incurred and income received related to AHMC, HSMSO and Aurion Corporation (in thousands): Years ended December 31, 2020 2019 AHMC – Risk pool earnings net claims payment $ 28,767 $ 40,000 HSMSO – Management fees, net (949) (1,700) Aurion – Management fees (303) (300) Receipts, net $ 27,515 $ 38,000 The Company and AHMC has a risk sharing agreement with certain AHMC hospitals to share the surplus and deficits of each of the hospital pools. During the years ended December 31, 2020, 2019, and 2018, the Company has recognized risk pool revenue under this agreement of $42.6 million, $49.3 million, and $68.2 million, respectively, of which $45.3 million and $40.4 million, remain outstanding as of December 31, 2020 and 2019, respectively. During the years ended December 31, 2020, 2019, and 2018, APC paid an aggregate of approximately $33.1 million, $30.8 million, and $35.2 million, respectively, to shareholders of APC for provider services, which included approximately $9.0 million, $8.8 million, and $13.5 million, respectively, to shareholders who are also officers of APC. During the years ended December 31, 2020 and 2019, NMM paid approximately $0.1 million and $0.2 million to an Apollo board member, Matthew Mazdyasni, for consulting services. In addition, affiliates wholly-owned by the Company’s officers, including Dr. Thomas Lam, ApolloMed's Co-CEO and President, are reported in the accompanying consolidated statements of income on a consolidated basis, together with the Company’s subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company’s subsidiaries as related party transactions. For equity method investments, loans receivable and line of credits from related parties, see Notes 6, 7 and 10, respectively.

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2020
Retirement Benefits [Abstract]
Employee Benefit Plan	Employee Benefit PlanNMM has a qualified 401(k) plan that covers substantially all employees who have completed at least six months of service and meet minimum age requirements. Participants may contribute a portion of their compensation to the plan, up to the maximum amount permitted under Section 401(k) of the Internal Revenue Code. Participants become fully vested after six years of service. NMM matches a portion of the participants’ contributions. NMM’s matching contributions for the years ended December 31, 2020 and 2019 were approximately $0.4 million and $0.2 million.

Stock Based Compensation

Stock Based Compensation	12 Months Ended
	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Stock Based Compensation	Stock-Based Compensation Equity Incentive Plans In connection with the Merger, the Company assumed ApolloMed’s 2013 Equity Incentive Plan (the “2013 Plan”), pursuant to which 500,000 shares of the Company’s common stock were reserved for issuance thereunder. The Company issues new shares to satisfy stock option and warrant exercises under the 2013 Plan. As of December 31, 2020, there were no shares available for future grants under the 2013 Plan. In connection with the Merger, the Company assumed ApolloMed’s 2015 Equity Incentive Plan (the “2015 Plan”), pursuant to which 1,500,000 shares of the Company’s common stock were reserved for issuance thereunder. In addition, shares that are subject to outstanding grants under the Company’s 2013 Plan but that ordinarily would have been restored to such plans reserve due to award forfeitures and terminations were rolled into and become available for awards under the 2015 Plan. The 2015 Plan provides for awards, including incentive stock options, non-qualified options, restricted common stock, and stock appreciation rights. The 2015 Plan was approved by ApolloMed’s stockholders at ApolloMed’s 2016 annual meeting of stockholders that was held in September 2016. As of December 31, 2020, 2019 and 2018, there were approximately 0.1 million, 0.5 million and 0.9 million shares available for future grants under the 2015 Plan, respectively. The following table summarizes the stock-based compensation expense recognized under all of the Company's stock plans in 2020, 2019, and 2018 and associated with the issuance of restricted shares of common stock and vesting of stock options which are included in General and administrative expenses in the accompanying consolidated statement of income recognized (in thousands): Years ended December 31, 2020 2019 2018 Stock options $ 1,763 $ 688 $ — Restricted stock awards 1,620 252 632 APC stock options — 607 810 Total share-based compensation expense $ 3,383 $ 1,547 $ 1,442 Options The Company’s outstanding stock options consisted of the following: Shares Weighted Weighted Aggregate Options outstanding at January 1, 2020 607,346 $ 9.22 3.42 $ 5.6 Options granted 250,746 18.11 — — Options exercised (120,000) 2.58 — 1.8 Options canceled, forfeited or expired (12,228) 17.57 — — Options outstanding at December 31, 2020 725,864 $ 13.25 3.75 $ 3.4 Options exercisable at December 31, 2020 449,464 $ 6.33 1.94 $ 3.6 During the years ended December 31, 2020 and 2019, stock options were exercised for 120,000 and 241,214 shares, respectively, of the Company’s common stock, which resulted in proceeds of approximately $0.3 million and $1.5 million, respectively. The exercise prices ranged from $2.10 to $5.00 per share for the exercises during the year ended December 31, 2020 and ranged from $1.50 to $10.00 per share for the exercises during the year ended December 31, 2019. During the year ended December 31, 2020, no stock options were exercised pursuant the cashless exercise provision. During the year ended December 31, 2020, the Company granted 191,742 and 59,004 five-year stock options to certain ApolloMed board members and executives, respectively, with exercise price ranging from $18.20-$18.41 and $17.78, respectively, which were recognized at fair value, as determined using the Black-Scholes option pricing model as follows: December 31, 2020 Board Members Executives Expected Term 3.0 years 3.5 years Expected volatility 85.44% - 90.01% 80.95 % Risk-free interest rate 0.23% - 1.43% 0.23 % Market value of common stock $18.20 - $18.41 $ 17.78 Annual dividend yield 0 % 0 % Forfeiture rate 0 % 0 % Restricted Stock Awards The Company grants restricted stock awards to employees and executives which are earned based on service conditions. The grant date fair value of the restricted stock awards is that day’s closing market price of the Company’s common stock. During the year ended December 31, 2020, the Company granted restricted stock awards for employees totaling 97,447 shares with a weighted average grant date fair value of $17.58 and for executives totaling 130,484 shares with the grant date fair value of $17.78. The grant date fair value of the restricted stock for employees was $1.6 million and will be recognized on a straight-line basis over the awards’ vesting period of three years, of which 7,394 shares of restricted stock with grant date fair value of $0.1 million were forfeited during the year ended December 31, 2020. The grant date fair value of restricted stock for executives was $2.3 million and will be recognized on a straight-line basis over the awards' vesting period of three years. The Company recorded approximately $1.6 million of share-based compensation expense associated with the issuance of restricted shares of common stock and vesting of stock options which are included in general and administrative expenses in the accompanying consolidated statements of income for the year ended December 31, 2020. Unrecognized compensation expense related to total share-based payments outstanding as of December 31, 2020 was $7.1 million. APC Stock Options Issued Under Primary Care Physician Agreements On October 1, 2014, NMM and APC entered into an Exclusivity Amendment Agreement as part of the Primary Care Physician Agreement to issue stock options to purchase shares of NMM and APC common stock. The medical providers agreed to exclusivity to APC for health enrollees in consideration per provider of an exclusivity incentive in the amount of $25,000 (or $15,000 if already a preferred provider). The stock options were granted from the date of agreement through May 1, 2015 and are treated as issuances to non-employees. The exercise price of the stock options was $2.44 (for NMM pre-merger) and $0.17 (for APC) per share and providers were able to exercise anytime between August 1, 2015 and October 1, 2019, as long as the providers continue to provide services pursuant to the terms of the agreement through October 1, 2019. If the agreement is terminated by the provider with or without cause, the exclusivity incentive and any capitation payment above standard rates made in accordance with the terms of the agreement shall be fully repaid to APC by the terminating medical provider. In addition, any unexercised share options held by the terminating medical provider will be forfeited on effective date of termination, and any share options that have been exercised will be bought back by NMM and APC at the original purchase price. As all outstanding options, and the contingency to repurchase these options, expired on October 1, 2019, there is no expense recognized in connection with the Exclusivity Amendment Agreements during the year ended December 31, 2020.

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2020
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Basic net income per share is calculated by dividing net income by the weighted average number of shares of the Company’s common stock issued and outstanding during a certain period. Diluted net income per share is calculated using the weighted average number of common and potentially dilutive common shares outstanding during the period, using the as-if converted method for preferred stock and the treasury stock method for options and common stock warrants. Pursuant to the Merger Agreement, ApolloMed held back 10% of the shares of its common stock that were issuable to NMM shareholders (“Holdback Shares”) to secure indemnification of ApolloMed and its affiliates under the Merger Agreement. The Holdback Shares will be held for a period of up to 24 months, with 50% issued on the first anniversary of the merger and the remaining 50% issued on the second anniversary, after the closing of the Merger (to be distributed on a pro-rata basis to former NMM shareholders), during which ApolloMed may seek indemnification for any breach of, or noncompliance with, any provision of the Merger Agreement, by NMM. The Holdback Shares are excluded from the computation of basic earnings per share but included in diluted earnings per share. As of December 31, 2020, 2019 and 2018, APC held 12,323,164, 17,290,317 and 1,682,110 shares, respectively, of ApolloMed's common stock, which are treated as treasury shares for accounting purposes and not included in the number of shares of common stock outstanding used to calculate earnings per share (see Note 12). The noncontrolling interests in APC are allocated their share of ApolloMed’s income from APC’s ownership of ApolloMed common stock and this is included in the net income attributable to noncontrolling interests on the consolidated statements of income. Therefore, none of the shares of ApolloMed held by APC are considered outstanding for the purposes of basic or diluted earnings per share computation. Below is a summary of the earnings per share computations: Years ended December 31, 2020 2019 2018 Earnings per share – basic $ 1.04 $ 0.41 $ 0.33 Earnings per share – diluted $ 1.01 $ 0.39 $ 0.29 Weighted average shares of common stock outstanding – basic 36,527,672 34,708,429 32,893,940 Weighted average shares of common stock outstanding – diluted 37,448,430 36,403,279 37,914,886 Below is a summary of the shares included in the diluted earnings per share computations: Years ended December 31, 2020 2019 2018 Weighted average shares of common stock outstanding – basic 36,527,672 34,708,429 32,893,940 10% shares held back pursuant to indemnification clause — — 2,935,512 Stock options 182,999 295,672 459,440 Warrants 717,029 1,384,078 1,625,994 Management restricted stock awards (dilutive) 7,242 15,100 — Executive restricted stock awards (dilutive) 13,488 — — Weighted average shares of common stock outstanding – diluted 37,448,430 36,403,279 37,914,886

Variable Interest Entities (VIE

Variable Interest Entities (VIEs)	12 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable Interest Entities (VIEs)	Variable Interest Entities (VIEs) A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity’s economic performance and the obligation to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE. The Company follows guidance on the consolidation of VIEs that requires companies to utilize a qualitative approach to determine whether it is the primary beneficiary of a VIE. See Note 2 to the accompanying consolidated financial statements for information on how the Company determines VIEs and its treatment. The following table includes assets that can only be used to settle the liabilities of APC and the creditors of APC have no recourse to the Company. These assets and liabilities, with the exception of the investment in a privately held entity and amounts due to affiliate, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands). December 31, 2020 2019 Assets Current assets Cash and cash equivalents $ 126,158 $ 87,110 Restricted cash – short-term — 75 Investment in marketable securities 67,637 123,948 Receivables, net 5,155 9,300 Receivables, net – related party 46,718 42,976 Other receivables 1,084 744 Prepaid expenses and other current assets 14,813 7,403 Loans receivable 50 6,425 Loans receivable - related parties — 16,500 Total current assets 261,615 294,481 Noncurrent assets Land, property and equipment, net 27,599 9,547 Intangible assets, net 69,250 81,439 Goodwill 109,460 108,913 Loans receivable – related parties 4,145 — Investment in affiliates* 225,144 318,315 Investments in other entities – equity method 43,516 28,427 Investment in privately held entities 36,584 1,615 Restricted cash – long-term 500 746 Operating lease right-of-use assets 6,298 4,751 Other assets 17,177 1,057 Total noncurrent assets 539,673 554,810 Total assets $ 801,288 $ 849,291 Current liabilities Accounts payable and accrued expenses $ 12,963 $ 11,187 Fiduciary accounts payable 9,642 2,027 Medical liabilities 37,684 49,019 Income taxes payable 4,225 4,530 Dividend payable 485 271 Amount due to affiliate 22,698 28,058 Current portion of long-term debt 201 — Finance lease liabilities 102 102 Operating lease liabilities 1,242 1,088 Total current liabilities 89,242 96,282 Noncurrent liabilities Long-term debt, net of current portion 7,379 — Deferred tax liability 9,144 14,059 Liability for unissued equity shares — — Finance lease liabilities, net of current portion 311 416 Operating lease liabilities, net of current portion 5,242 3,742 Total noncurrent liabilities 22,076 18,217 Total liabilities $ 111,318 $ 114,499 *Investment in affiliates include APC’s investment in ApolloMed which is reflected as treasury shares and eliminated upon consolidation. As a result this balance is not reflected on ApolloMed’s consolidated balance sheets as of December 31, 2020 and 2019.

Leases

Leases	12 Months Ended
	Dec. 31, 2020
Leases [Abstract]
Leases	Leases The Company has operating and finance leases for corporate offices, physicians’ offices, and certain equipment. These leases have remaining lease terms ranging from 1 month to 5 years, some of which may include options to extend the leases for up to 10 years, and some of which may include options to terminate the leases within one year. As of December 31, 2020 and December 31, 2019, assets recorded under finance leases were $0.4 million and $0.5 million, respectively, and accumulated depreciation associated with finance leases was $0.4 million and $0.3 million, respectively. Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The components of lease expense were as follows (in thousands): December 31, 2020 December 31, 2019 Operating lease cost $ 6,589 $ 5,437 Finance lease cost Amortization of lease expense 105 102 Interest on lease liabilities 14 17 Sublease income (784) (415) Total lease cost $ 5,924 $ 5,141 December 31, 2020 December 31, 2019 Supplemental Cash Flows Information Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 5,804 $ 5,254 Operating cash flows from finance leases 14 17 Financing cash flows from finance leases 105 102 Right-of-use assets obtained in exchange for lease liabilities: Operating leases 7,652 16,728 Finance leases — — December 31, 2020 December 31, 2019 Weighted Average Remaining Lease Term Operating leases 6.80 years 6.48 years Finance leases 3.67 years 4.67 years Weighted Average Discount Rate Operating leases 6.10 % 6.11 % Finance leases 3.00 % 3.00 % Years ending December 31, Operating Leases Finance Leases 2021 $ 4,297 $ 119 2022 3,529 119 2023 3,303 119 2024 2,940 79 2025 2,648 — Thereafter 6,818 — Total future minimum lease payments 23,535 436 Less: imputed interest 4,493 23 Total lease obligations 19,042 413 Less: current portion 3,177 102 Long-term lease obligations $ 15,865 $ 311 As of December 31, 2020, the Company does not have additional operating or finance leases that have not yet commenced.
Leases	Leases The Company has operating and finance leases for corporate offices, physicians’ offices, and certain equipment. These leases have remaining lease terms ranging from 1 month to 5 years, some of which may include options to extend the leases for up to 10 years, and some of which may include options to terminate the leases within one year. As of December 31, 2020 and December 31, 2019, assets recorded under finance leases were $0.4 million and $0.5 million, respectively, and accumulated depreciation associated with finance leases was $0.4 million and $0.3 million, respectively. Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The components of lease expense were as follows (in thousands): December 31, 2020 December 31, 2019 Operating lease cost $ 6,589 $ 5,437 Finance lease cost Amortization of lease expense 105 102 Interest on lease liabilities 14 17 Sublease income (784) (415) Total lease cost $ 5,924 $ 5,141 December 31, 2020 December 31, 2019 Supplemental Cash Flows Information Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 5,804 $ 5,254 Operating cash flows from finance leases 14 17 Financing cash flows from finance leases 105 102 Right-of-use assets obtained in exchange for lease liabilities: Operating leases 7,652 16,728 Finance leases — — December 31, 2020 December 31, 2019 Weighted Average Remaining Lease Term Operating leases 6.80 years 6.48 years Finance leases 3.67 years 4.67 years Weighted Average Discount Rate Operating leases 6.10 % 6.11 % Finance leases 3.00 % 3.00 % Years ending December 31, Operating Leases Finance Leases 2021 $ 4,297 $ 119 2022 3,529 119 2023 3,303 119 2024 2,940 79 2025 2,648 — Thereafter 6,818 — Total future minimum lease payments 23,535 436 Less: imputed interest 4,493 23 Total lease obligations 19,042 413 Less: current portion 3,177 102 Long-term lease obligations $ 15,865 $ 311 As of December 31, 2020, the Company does not have additional operating or finance leases that have not yet commenced.

Quarterly Financial Information

Quarterly Financial Information (Unaudited)	12 Months Ended
	Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information (Unaudited)	Quarterly Financial Information (Unaudited) The following tables represent our quarterly financial results (in thousands, except per share data): 2020 Calendar Quarter First Second 2 Third Fourth Annual Revenue $ 165,105 $ 165,169 $ 180,123 $ 176,783 $ 687,180 Income from operations 4,365 12,906 37,356 25,876 80,503 Net income 2,987 81,001 25,424 12,908 122,320 Net income attributable to ApolloMed 4,052 7,044 16,713 10,057 37,866 Earnings per share - basic attributable to common stock 1 $ 0.11 $ 0.20 $ 0.46 $ 0.27 $ 1.04 Earnings per share - diluted attributable to common stock 1 $ 0.11 $ 0.19 $ 0.45 $ 0.26 $ 1.01 1 Quarterly earnings per share impacts may not add to full-year earnings per share impacts due to the difference in weighted-average common shares for the quarters versus the weighted-average common shares for the year. 2 Includes a pre-tax gain of $99.6 million related to sale of UCI (Note 6). 2019 Calendar Quarter First Second Third Fourth Annual Revenue $ 95,757 $ 130,050 $ 156,060 $ 178,751 $ 560,618 (Loss) income from operations (3,307) 14,728 10,066 10,933 32,420 Net (loss) income (2,450) 10,664 10,739 (1,280) 17,673 Net income attributable to ApolloMed 140 3,545 3,704 6,727 14,116 Earnings per share - basic attributable to common stock 1 $ 0.00 $ 0.10 $ 0.11 $ 0.19 $ 0.41 Earnings per share - diluted attributable to common stock 1 $ 0.00 $ 0.09 $ 0.10 $ 0.18 $ 0.39

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	Subsequent EventsOn January 26, 2021, the Company entered into an agreement to purchase a 30% interest in CAIPA MSO. CAIPA MSO provides management, consulting, administrative, and other support services to professional healthcare service providers, including to Chinese American IPA d/b/a Coalition of Asian-American IPA ("CAIPA"), a leading independent practice association serving the greater New York City area. The transaction is subject to third-party consents and other customary closing conditions. ApolloMed will fund the transaction from cash on hand. The transaction is expected to close by the end of the second quarter of 2021.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of PresentationThe accompanying consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
Principles of Consolidation	Principles of Consolidation The consolidated balance sheets as of December 31, 2020 and 2019 and consolidated statements of income for the years ended December 31, 2020, 2019 and 2018 include the accounts of ApolloMed; its consolidated subsidiaries, NMM, AMM, and APAACO; its consolidated VIE, AP-AMH; AMM’s consolidated VIE, SCHC; NMM’s consolidated subsidiaries, APCN-ACO and AP-ACO; NMM’s consolidated VIE, APC; APC’s consolidated subsidiaries, UCAP, MPP, AMG Properties and ZLL, APC’s consolidated VIEs, CDSC, APC-LSMA and ICC; and APC-LSMA’s consolidated subsidiaries, Alpha Care and Accountable Health Care.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred but not reported (“IBNR”) claims), determination of full-risk and shared-risk revenue and receivables (including constraints, completion factors and historical margins), income tax valuation allowance, share-based compensation, and right-of-use ("ROU") assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.
Variable Interest Entities	Variable Interest Entities On an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly owned by it in accordance with the consolidation guidance. The evaluation considers all of the Company’s variable interests, including equity ownership, as well as management services agreements (“MSA”). To fall within the scope of the consolidation guidance, an entity must meet both of the following criteria: • The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity can be in the form of a partnership, limited liability company, or corporation, among others; and • The Company has a variable interest in the legal entity – i.e., variable interests that are contractual, such as equity ownership, or other financial interests that change with changes in the fair value of the entity’s net assets. If an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting. If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs. A legal entity is determined to be a VIE if it has any of the following three characteristics: • The entity does not have sufficient equity to finance its activities without additional subordinated financial support; • The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s) of voting rights); or • The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they lack any of the following: • The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entity’s economic performance, as evidenced by: • Substantive participating rights in day-to-day management of the entity’s activities; or • Substantive kick-out rights over the party responsible for significant decisions; • The obligation to absorb the entity’s expected losses; or • The right to receive the entity’s expected residual returns. If the Company concludes that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and evaluate it for consolidation under the variable interest model. Variable interest model If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company – that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE’s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer Note 18 – “Variable Interest Entities (VIEs)” to the consolidated financial statements for information on the Company’s consolidated VIE. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting, refer to Note 6 – “Investments in Other Entities” for entities that qualify as VIEs but the Company is not the primary beneficiary.
Business Combinations	Business Combinations The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition related costs separately from the business combination.
Reportable Segments	Reportable SegmentsThe Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative healthcare models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in one reportable segment.
Reclassifications	ReclassificationsCertain 2019 amounts disclosed in prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications were made between depreciation and amortization and amortization of debt issuance cost on the consolidated statements of cash flows. They had no material effect on net income, earnings per share, retained earnings, cash flows or total assets.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company's cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within ninety days from their date of purchase to be cash equivalents.
Restricted Cash	Restricted CashRestricted cash consists of cash held as collateral to secure standby letters of credits as required by certain contracts.
Investments in Marketable Securities	Investments in Marketable SecuritiesThe appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date. As of December 31, 2020 and 2019, investments in marketable securities in the amount of approximately $67.7 million and $116.5 million, respectively, consisted of equity securities and certificates of deposit with various financial institutions, reported at fair value, with maturity dates from four months to twenty-four months (see fair value measurements of financial instruments below). Investments in certificates of deposits are classified as Level 1 investments in the fair value hierarchy.
Receivables and Receivables – Related Parties, Loan Receivables and Loan Receivables - Related Parties	Receivables, Receivables – Related Parties, Loan Receivables and Loan Receivables - Related Parties The Company’s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements, management fee income, incentive receivables, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected. The Company's loan receivables and loan receivables - related party consist of promissory notes from payees that are expected to be collected between 2-4 years and accrue interest per annum. Capitation and claims receivable relate to each health plan’s capitation and is received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company’s full risk pool receivable that is recorded quarterly based on reports received from the Company's hospital partners and management’s estimate of the Company’s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consists of recoverable claims paid related to the 2019 APAACO performance year to be administered following instructions from CMS, fee-for-services (“FFS”) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop loss insurance premium reimbursements. The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.
Concentrations of Risks	Concentrations of RisksThe Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts.
Land, Property and Equipment, Net	Land, Property and Equipment, Net Land is carried at cost and is not depreciated as it is considered to have an indefinite useful life. Property and equipment, including leasehold improvements, are carried at cost less accumulated depreciation and amortization. Depreciation is provided principally on the straight-line method over the estimated useful lives of the assets ranging from three Maintenance and repairs are charged to expense as incurred. Upon sale or retirement, the asset cost and related accumulated depreciation and amortization is removed from the accounts, and any related gain or loss is included in the determination of consolidated net income.
Fair Value Measurements of Financial Instruments	Fair Value Measurements of Financial Instruments The Company’s financial instruments consist of cash and cash equivalents, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality. Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurement (“ASC 820”), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosures about fair value measurements. ASC 820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows: Level 1 —Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date. Level 2 —Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs). Level 3 —Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company’s own data.
Intangible Assets and Long-Lived Assets	Intangible Assets and Long-Lived Assets Intangible assets with finite lives include network-payor relationships, management contracts and member relationships and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate.
Goodwill and Indefinite-Lived Intangible Assets	Goodwill and Indefinite-Lived Intangible Assets Under ASC 350, Intangibles – Goodwill and Other (“ASC 350”), goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment. At least annually, at the Company’s fiscal year end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company’s three reporting units (1) management services, (2) IPAs, and (3) ACOs. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit’s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill. An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.
Investments in Other Entities - Equity Method	Investments in Other Entities – Equity Method The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee’s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company’s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under “Income (loss) from equity method investments” and also is adjusted by contributions to and distributions from the investee. Equity method investments are subject to impairment evaluation. During the years ended December 31, 2019, the Company recognized an impairment loss of approximatel y $0.3 million rela ted to its investment in PASC as the Company does not believe it will recover its investment balance. Such impairment loss is included in loss from equity method investments in the accompanying consolidated statements of income. There was no impairment loss recorded related to equity method investments for the years ended December 31, 2020 and 2018. Investments in Privately Held Entities
Medical Liabilities	Medical Liabilities APC, Alpha Care, Accountable Health Care, and APAACO are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. APC, Alpha Care, Accountable Health Care, and APAACO provide integrated care to HMOs, Medicare and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services, excluding depreciation and amortization, expense in the accompanying consolidated statements of income.
Revenue Recognition	Revenue Recognition The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients. On January 1, 2018, the Company adopted the new revenue recognition standard Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (Topic 606)”, using the modified retrospective method. Modified retrospective adoption requires entities to apply the standard retrospectively to the most current period presented in the financial statements, requiring the cumulative effect of the retrospective application as an adjustment to the opening balance of retained earnings and noncontrolling interests at the date of initial application. Revenue from substantially all of the Company’s contracts with customers continues to be recognized over time as services are rendered. The Company has elected to apply the modified retrospective method only to contracts not completed as of January 1, 2018. Under the new revenue standard, the Company recognizes incremental costs of obtaining a contract with amortization periods of one year or less as expense when incurred and records within general and administrative expenses, recognizes revenue in the amount of consideration to which the Company has a right to invoice the customer if that amount corresponds directly with the value to the customer of the Company’s services completed to date, and does not recognize an adjustment for the effects of a significant financing component as the period between the time of service and time of payment is typically one year or less. Nature of Services and Revenue Streams Revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO All-Inclusive Population-Based Payments (“AIPBP”), management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may vary by type of revenue and the customer. The following is a summary of the principal forms of the Company’s billing arrangements and how revenue is recognized for each. Capitation, Net Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months’ capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a “Risk Adjustment” model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company. PMPM managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk sharing. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company’s net PMPM transaction price relates specifically to the Company’s efforts to transfer the service for a distinct increment of the series (e.g. day or month) and is recognized as revenue in the month in which members are entitled to service. Risk Pool Settlements and Incentives APC enters into full risk capitation arrangements with certain health plans and local hospitals, which are administered by a third-party, where the hospital is responsible for providing, arranging and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a full risk pool sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital’s risk pools with HMOs after deductions for the affiliated hospitals costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company's risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. Assumptions based on factors including but not limited to historical margin, IBNR completion factors and constraint percentages were used by management in applying the most likely amount methodology. Under capitated arrangements with certain HMOs, APC participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent of any) risk sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished. The Company's risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans’ data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC’s risk share revenue is deemed to be fully constrained until APC is notified of the amount by the health plan. Risk pools for the prior contract years are generally final settled in the third or fourth quarter of the following year. In addition to risk-sharing revenues, the Company also receives incentives under “pay-for-performance” programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company's incentives under “pay-for-performance” programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received. Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day’s performance within the annual measurement period but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e. the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained. NGACO AIPBP Revenue APAACO and CMS entered into a NGACO Model Participation Agreement (the “Participation Agreement”) with an initial term of two two For each performance year, the Company must submit to CMS its selections for risk arrangement; the amount of the profit/loss cap; alternative payment mechanism; benefits enhancements, if any; and its decision regarding voluntary alignment under the NGACO Model. The Company must obtain CMS consent before voluntarily discontinuing any benefit enhancement during a performance year. Under the NGACO Model, CMS aligns beneficiaries to the Company to manage (direct care and pay providers) based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation from CMS on a monthly basis to pay claims from in-network providers. The Company records such capitation received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS and the Company’s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company’s risk share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company’s efficiency, in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company’s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO capitation revenues monthly. Excess over claims paid, plus an estimate for the related IBNR claims (see Note 9), are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there was any excess capitation paid for the performance year and the excess is refunded to CMS. For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company; the risk arrangement for which the Company has been approved by CMS; and as otherwise provided in the Participation Agreement. Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within 30 days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS shall assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company. The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO’s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients. As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit for the performance year and therefore this shared risk pool revenue is considered fully constrained. Pursuant to the Participation Agreement, the Company received $19.8 million and $0.9 million in risk pool savings, related to the 2019 and 2018 performance years, respectively, and has recognized such savings as revenue in risk pool settlements and incentives in the accompanying consolidated statements of income for the years ended December 31, 2020 and 2019, respectively. The Company will need to continue to comply with all terms and conditions in the Participation Agreement and various regulatory requirements to be eligible to participate in the AIPBP mechanism and/or NGACO Model. The Company continues to be eligible in receiving AIPBP under the NGACO Model for performance year 2020, with the effective date of the performance year beginning January 1, 2020. For performance year 2020, the Company receives monthly AIPBP payments at a rate of approximately $7.2 million per month from CMS. The monthly AIPBP received by the Company for performance year 2019 was approximately $8.3 million per month for the period from April 1, 2019 through August 30, 2019 and subsequently adjusted to approximately $3.7 million for the period starting September 1, 2019 based on CMS' updated estimate of total claims to be incurred. The Company has received approximately $85.9 million in total AIPBP for the year ended December 31, 2020 of which $75.1 million has been recognized as revenue. Management Fee Income Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of revenue or fee collections, or amounts fixed on a monthly, quarterly or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues as revenue in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement. The Company’s MSA revenue also includes revenue sharing payments from the Company’s partners based on their non-medical services. The Company provides a significant service of integrating the services selected by the Company’s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company’s performance obligation is to stand ready to provide services over the contractual period. Also, the Company’s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company’s performance obligation is satisfied as the Company completes each period’s obligations. Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company’s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company’s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled. The Company’s management contracts generally have long terms (e.g., ten years), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations. Fee-for-Service Revenue FFS revenue represents revenue earned under contracts in which the Company bills and collects the professional component of charges for medical services rendered by the Company’s contracted physicians and employed physicians. Under the FFS arrangements, the Company bills hospitals and third-party payors for the physician staffing and further bills patients or their third-party payors for patient care services provided and receives payment. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and is recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the consolidated financial statements. The recognition of net revenue (gross charges less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company’s billing center for medical coding and entering into the Company’s billing system and the verification of each patient’s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company’s billing systems as well as an estimate of the revenue associated with medical services. The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company’s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues. Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period. Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient's healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors. The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether and with whom the patients the Company provides services to in the period are insured and the Company's contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statement of income in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions and healthcare coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows. Contract Assets Revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company does not have any contract assets since all obligations have been performed when revenue was recognized. The Company's billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable aging and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly as revenues are recognized. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance. Contract Liabilities (Deferred Revenue )
Income Taxes	Income Taxes Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized. The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.
Share-Based Compensation	Share-Based Compensation The Company maintains a stock-based compensation program for employees, non-employees, directors and consultants. The value of share-based awards such as options is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for expected forfeitures. From time to time, the Company issues shares of its common stock to its employees, directors and consultants, which shares may be subject to the Company’s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules.
Basic and Diluted Earnings Per Share	Basic and Diluted Earnings Per Share Basic earnings per share (“EPS”) is computed by dividing net income attributable to the holders of the Company's common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding plus the effect of dilutive securities outstanding during the periods presented, using the treasury stock method. See Note 17 for a discussion of shares treated as treasury shares for accounting purposes.
Noncontrolling Interests	Noncontrolling Interests The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Noncontrolling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company’s consolidated entities. Net income attributable to noncontrolling interests is disclosed in the consolidated statements of income.
Mezzanine Equity	Mezzanine Equity Pursuant to APC's shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase its shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes
Leases	Leases The Company adopted ASC 842 effective January 1, 2019 on a modified retrospective basis using the following practical expedients as permitted under the transition guidance within the new standard; (i) not reassess whether any expired or existing contracts are or contain leases; not reassess the lease classification for any expired or existing leases; not reassess initial direct costs for existing leases; and (ii) use hindsight in determining the lease term and in assessing impairment of the entity’s right-of-use assets. The Company determines if an arrangement is a lease at its inception. The expected term of the lease used for computing the lease liability and right-of-use ("ROU") asset and determining the classification of the lease as operating or financing may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company elected practical expedients for ongoing accounting that is provided by the new standard comprised of the following: (1) the election for classes of underlying asset to not separate non-lease components from lease components, and (2) the election for short-term lease recognition exemption for all leases under 12 months term. The present value of the lease payments is calculated using a rate implicit in the lease, when readily determinable. However, as most of the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate to determine the present value of the lease payments for the majority of its leases.
Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted	Recently Adopted Accounting Pronouncements In June 2016, the FASB issued Accounting Standards Update ("ASU") No. 2016-13, “Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 became effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company adopted ASU 2016-13 on January 1, 2020. The adoption of ASU 2016-13 did not have a material impact on the consolidated financial statements. In January 2020, the FASB issued ASU No. 2020-01, "Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)" ("ASU 2020-01"). This ASU clarifies the interaction between accounting for equity securities, equity method investments and certain derivative instruments. This amendment in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. Early adoption is permitted, including early adoption in an interim period, for public business entities for periods for which financial statements have not yet been issued. The Company early adopted ASU 2020-01 on October 1, 2020 on a prospective basis which did not have a material impact on the Company’s consolidated financial statements or related disclosures. Recent Accounting Pronouncements Not Yet Adopted In December 2019, the FASB issued ASU No. 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes" ("ASU 2019-12"). This ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 Income Taxes related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently assessing the impact of that adoption of ASU 2019-12 will have on the Company's consolidated financial statements.

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Schedule of Disaggregated Revenue by Payor Type	The following table presents disaggregated revenue generated by each payor type (in thousands): Years Ended December 31, 2020 2019 2018 Commercial $ 108,851 $ 107,340 $ 113,000 Medicare 271,596 226,002 226,353 Medicaid 269,079 192,596 134,904 Other third parties 37,654 34,680 45,651 Revenue $ 687,180 $ 560,618 $ 519,908
Schedule of Contributions to Revenue and Receivables by Payor	The Company had major payors that contributed the following percentages of net revenue: Years Ended December 31, 2020 2019 2018 Payor A 12.5 % 13.6 % 14.6 % Payor B 10.9 % 13.4 % 18.7 % Payor C *% *% 14.1 % Payor D 13.1 % 11.7 % 14.1 % Payor E 16.9 % 12.9 % *% * Less than 10% of total net revenues The Company had major payors that contributed to the following percentages of net receivables and receivables - related parties : As of December 31, 2020 2019 Payor F 43.9 % 30.4 % Payor G 36.5 % 36.0 %
Schedule of Carrying Amounts and Fair Values of Financial Instruments	The carrying amounts and fair values of the Company’s financial instruments as of December 31, 2020 are presented below (in thousands): Fair Value Measurements Level 1 Level 2 Level 3 Total Assets Money market accounts* $ 115,769 $ — $ — $ 115,769 Marketable securities – certificates of deposit 67,637 — — 67,637 Marketable securities – equity securities 58 — — 58 Total $ 183,464 $ — $ — $ 183,464 The carrying amounts and fair values of the Company’s financial instruments as of December 31, 2019 are presented below (in thousands): Fair Value Measurements Level 1 Level 2 Level 3 Total Assets Money market accounts* $ 50,731 $ — $ — $ 50,731 Marketable securities – certificates of deposit 116,469 — — 116,469 Marketable securities – equity securities 70 — — 70 Total $ 167,270 $ — $ — $ 167,270 * Included in cash and cash equivalents

Business Combinations and Goo_2

Business Combinations and Goodwill (Tables)	12 Months Ended
	Dec. 31, 2020
Business Combinations [Abstract]
Summary of Estimated Fair Values of Assets Acquired and Liabilities Assumed	The following table summarizes the fair values of the assets acquired and liabilities assumed, as of the acquisition date (in thousands): Assets acquired Cash and cash equivalents $ 3,569 Accounts receivable, net 10,336 Other current assets 4,675 Network relationship intangible assets 22,636 Goodwill 28,585 Accounts payable (2,795) Deferred tax liabilities (6,334) Medical liabilities (15,616) Net assets acquired $ 45,056 Cash paid $ 45,056 The following table summarizes the fair values of the assets acquired and liabilities assumed, as of the acquisition date (in thousands): Assets acquired Cash and cash equivalents $ 582 Accounts receivable, net 5,150 Other current assets 198 Network relationship intangible assets 11,411 Goodwill 23,566 Accounts payable (3,759) Medical liabilities (12,154) Subordinated loan (15,327) Net assets acquired $ 9,667 Less: equity investment contributed 2,417 Cash paid $ 7,250
Summary of Pro Forma Information	The supplemental information on an unaudited pro forma financial basis presents the combined results of ApolloMed and its 2019 acquisitions as if each acquisition had occurred on January 1, 2018 (in thousands except per share data): Year Ended Year Ended Revenue $ 658,011 $ 726,075 Net income 10,867 58,879 Net income attributable to Apollo Medical Holdings, Inc. 7,310 9,447 EPS - basic $ 0.21 $ 0.29 EPS - diluted $ 0.20 $ 0.25
Summary of Goodwill Activity	The following is a summary of goodwill activity for the years ended December 31, 2020 and 2019 (in thousands): Amount Balance at January 1, 2019 $ 185,806 Acquisitions 52,699 Balance at December 31, 2019 238,505 Adjustments 548 Balance at December 31, 2020 $ 239,053

Land, Property and Equipment,_2

Land, Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Schedule of Land, Property and Equipment, Net	Land, property and equipment, net consisted of (in thousands): Useful Life (Years) December 31, 2020 December 31, 2019 Land N/A $ 9,604 $ 3,300 Buildings 39 15,097 2,358 Computer software 3 - 5 3,104 3,088 Furniture and equipment 3 - 7 13,116 12,585 Construction in progress N/A 435 167 Leasehold improvements 3 - 39 6,722 6,655 48,078 28,153 Less accumulated depreciation and amortization (18,188) (16,023) Land, property and equipment, net $ 29,890 $ 12,130

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Indefinite-Lived Intangible Assets, Net	At December 31, 2020, intangible assets, net consisted of the following (in thousands): Useful Gross Additions Impairment/ Gross Accumulated Net Amortized intangible assets: Network relationships 11-15 143,930 — — 143,930 (73,169) 70,761 Management contracts 15 22,832 — — 22,832 (11,715) 11,117 Member relationships 12 6,696 — — 6,696 (3,234) 3,462 Patient management platform 5 2,060 — — 2,060 (1,270) 790 Tradename/trademarks 20 1,011 — — 1,011 (156) 855 $ 176,529 $ — $ — $ 176,529 $ (89,544) $ 86,985 At December 31, 2019, intangible assets, net consisted of the following (in thousands): Useful Gross Additions Impairment/ Gross Accumulated Net Indefinite lived assets: Medicare license N/A $ 1,994 $ — $ (1,994) $ — $ — $ — Amortized intangible assets: Network relationships 11-15 109,883 34,047 — 143,930 (60,525) 83,405 Management contracts 15 22,832 — — 22,832 (9,677) 13,155 Member relationships 12 6,696 — — 6,696 (2,352) 4,344 Patient management platform 5 2,060 — — 2,060 (858) 1,202 Tradename/trademarks 20 1,011 — — 1,011 (105) 906 $ 144,476 $ 34,047 $ (1,994) $ 176,529 $ (73,517) $ 103,012
Schedule of Finite-Lived Intangible Assets, Net	At December 31, 2020, intangible assets, net consisted of the following (in thousands): Useful Gross Additions Impairment/ Gross Accumulated Net Amortized intangible assets: Network relationships 11-15 143,930 — — 143,930 (73,169) 70,761 Management contracts 15 22,832 — — 22,832 (11,715) 11,117 Member relationships 12 6,696 — — 6,696 (3,234) 3,462 Patient management platform 5 2,060 — — 2,060 (1,270) 790 Tradename/trademarks 20 1,011 — — 1,011 (156) 855 $ 176,529 $ — $ — $ 176,529 $ (89,544) $ 86,985 At December 31, 2019, intangible assets, net consisted of the following (in thousands): Useful Gross Additions Impairment/ Gross Accumulated Net Indefinite lived assets: Medicare license N/A $ 1,994 $ — $ (1,994) $ — $ — $ — Amortized intangible assets: Network relationships 11-15 109,883 34,047 — 143,930 (60,525) 83,405 Management contracts 15 22,832 — — 22,832 (9,677) 13,155 Member relationships 12 6,696 — — 6,696 (2,352) 4,344 Patient management platform 5 2,060 — — 2,060 (858) 1,202 Tradename/trademarks 20 1,011 — — 1,011 (105) 906 $ 144,476 $ 34,047 $ (1,994) $ 176,529 $ (73,517) $ 103,012
Schedule of Future Amortization Expense	Future amortization expense is estimated to be as follows for the years ending December 31 (in thousands): Amount 2021 $ 14,524 2022 12,673 2023 10,842 2024 9,830 2025 8,758 Thereafter 30,358 $ 86,985

Investments in Other Entities (

Investments in Other Entities (Tables)	12 Months Ended
	Dec. 31, 2020
Equity Method Investments and Joint Ventures [Abstract]
Schedule of Equity Method Investments, Financial Statement Information	Investments in other entities – equity method consisted of the following (in thousands): December 31, 2019 Allocation of Net Income (Loss) Additional/ Initial Investment Contribution Sale December 31, 2020 LaSalle Medical Associates – IPA Line of Business $ 6,396 $ 276 $ 6,375 $ — $ — $ 13,047 Pacific Medical Imaging & Oncology Center, Inc. 1,396 17 — — — 1,413 Universal Care, Inc. 1,438 3,560 — — (4,998) — Diagnostic Medical Group 2,334 279 — — — 2,613 531 W. College, LLC – related party 16,698 (448) — 950 — 17,200 MWN, LLC – related party 165 10 — — (175) — One MSO, LLC - related party — — 2,395 — — 2,395 Tag-6 Medical Investment Group, LLC - related party — — 4,516 — — 4,516 Tag-8 Medical Investment Group, LLC - related party — — 2,108 — — 2,108 $ 28,427 $ 3,694 $ 15,394 $ 950 $ (5,173) $ 43,292 LMA’s unaudited summarized balance sheets at December 31, 2020 and 2019 and unaudited summarized statements of operations for the years ended December 31, 2020 and 2019 are as follows (in thousands): Balance Sheets December 31, 2020 December 31, 2019 Assets Cash and cash equivalents $ 9,350 $ 6,345 Receivables, net 3,918 5,123 Other current assets 881 3,526 Loan receivable 2,250 2,250 Restricted cash 691 684 Total assets $ 17,090 $ 17,928 Liabilities and Stockholders’ Deficit Current liabilities $ 21,589 $ 23,530 Stockholders’ deficit (4,499) (5,602) Total liabilities and stockholders’ deficit $ 17,090 $ 17,928 Statements of Operations Year Ended Year Ended Revenues $ 186,964 $ 194,020 Expenses 185,724 205,153 Income (loss) from operations 1,240 (11,133) Other income 8 — Income (loss) before income tax benefit 1,248 (11,133) Income tax benefit — — Net income (loss) $ 1,248 $ (11,133) UCI’s unaudited balance sheet at December 31, 2019 and unaudited statements of operations for the four months ended April 30, 2020 and twelve months ended December 31, 2019 are as follows (in thousands): Balance Sheet December 31, 2019 Assets Cash $ 33,890 Receivables, net 63,843 Other current assets 38,280 Other assets 882 Property and equipment, net 4,021 Total assets $ 140,916 Liabilities and stockholders’ deficit Current liabilities $ 128,330 Other liabilities 33,133 Stockholders’ deficit (20,547) Total liabilities and stockholders’ deficit $ 140,916 Statements of Operations Four Months Ended April 30, 2020 Year Ended Revenues $ 195,308 $ 500,375 Expenses 189,028 502,567 Income (loss) before income tax provision 6,280 (2,192) Income tax provision — 258 Net income (loss) $ 6,280 $ (2,450) 531 W. College LLC’s unaudited balance sheets at December 31, 2020 and 2019 and unaudited statements of operations for the years ended December 31, 2020 and 2019 are as follows (in thousands): Balance Sheets December 31, 2020 December 31, 2019 Assets Cash $ 648 $ 139 Other current assets 17 17 Other assets 70 70 Property and equipment, net 33,697 33,581 Total assets $ 34,432 $ 33,807 Liabilities and Stockholders’ Equity Current liabilities $ 32 $ 1,061 Stockholders’ equity 34,400 32,746 Total liabilities and stockholders’ equity $ 34,432 $ 33,807 Statements of Operations Year Ended Year Ended Revenues $ — $ — Expenses 1,053 1,010 Loss from operations (1,053) (1,010) Other income 64 475 Provision for Income Taxes 3 — Net loss $ (992) $ (535)
Schedule of Equity Method Investment, Gain on Sale Information	The gain on sale of equity method investment recognized in connection with this transaction was determined as follows (in thousands): Amount Cash proceeds (excludes proceeds to settle indebtedness owed to APC from UCI) $ 52,743 Preferred shares in Bright Health, Inc. 36,179 Beneficial interest in UCI 15,723 Less: Carrying value of equity method investment on date of sale (4,998) Gain on sale of equity method investment $ 99,647

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2020
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses consisted of the following (in thousands): December 31, 2020 December 31, 2019 Accounts payable and other accruals $ 9,554 $ 6,914 Capitation payable 3,541 2,813 Subcontractor IPA payable 1,662 3,360 Professional fees 1,378 1,837 Due to related parties 50 225 Contract liabilities 12,988 8,892 Accrued compensation 6,970 3,238 Total accounts payable and accrued expenses $ 36,143 $ 27,279

Medical Liabilities (Tables)

Medical Liabilities (Tables)	12 Months Ended
	Dec. 31, 2020
Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]
Schedule of Medical Liabilities	The Company's medical liabilities consisted of the following (in thousands): December 31, 2020 December 31, 2019 Medical liabilities, beginning of year $ 58,725 $ 33,642 Acquired (see Note 3) — 27,474 Components of medical care costs related to claims incurred: Current period 309,848 271,987 Prior periods (3,258) 2,684 Total medical care costs 306,590 274,671 Payments for medical care costs related to claims incurred: Current period (261,062) (218,564) Prior periods (54,056) (58,633) Total paid (315,118) (277,197) Adjustments 133 135 Medical liabilities, end of year $ 50,330 $ 58,725

Credit Facility, Bank Loans a_2

Credit Facility, Bank Loans and Lines of Credit (Tables)	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Schedule of Credit Facility	The Company's credit facility consisted of the following (in thousands): December 31, 2020 December 31, 2019 Term Loan $ 178,125 $ 187,625 Revolver Loan 60,000 60,000 Real Estate Loans 7,580 — Total Debt 245,705 247,625 Less: current portion of debt (10,889) (9,500) Less: unamortized financing cost (4,605) (5,953) Long-term debt $ 230,211 $ 232,172
Schedule of Maturities of Credit Facility	The following table presents scheduled maturities of the Company's credit facility as of December 31, 2020: Amount 2021 $ 10,889 2022 14,459 2023 15,653 2024 197,972 2025 and thereafter 6,732 Total $ 245,705

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of Provision for Income Taxes	Provision for income taxes consisted of the following (in thousands): Years ended December 31, 2020 2019 2018 Current Federal $ 43,572 $ 9,035 $ 21,059 State 19,155 5,925 9,646 62,727 14,960 30,705 Deferred Federal (4,963) (3,508) (5,954) State (1,657) (3,285) (2,391) (6,620) (6,793) (8,345) Total provision for income taxes $ 56,107 $ 8,167 $ 22,360
Schedule of Components of Deferred Tax Assets (Liabilities)	Significant components of the Company's deferred tax assets (liabilities) as of December 31, 2020 and December 31, 2019 are shown below (in thousands). A valuation allowance of $15.5 million and $8.2 million as of December 31, 2020 and December 31, 2019, respectively, has been established against the Company's deferred tax assets related to loss entities the Company cannot consolidate under the Federal consolidation rules, as realization of these assets is uncertain. Valuation allowance increased by $7.3 million in 2020. 2020 2019 Deferred tax assets State taxes $ 3,932 $ 1,111 Stock options 461 1,293 Accrued expenses 3,905 2,334 Allowance for bad debts 351 544 Investment in other entities 702 2,977 Net operating loss carryforward 20,758 13,850 Lease liability 4,979 3,568 Other 665 — Deferred tax assets before valuation allowance 35,753 25,677 Valuation allowance (15,517) (8,192) Net deferred tax assets 20,236 17,485 Deferred tax liabilities Property and equipment (661) (927) Acquired intangible assets (24,661) (29,195) Right-of-use assets (4,888) (3,544) 481(a) adjustment (985) (1,623) Other — (465) Deferred tax liabilities (31,195) (35,754) Net deferred liabilities $ (10,959) $ (18,269)
Schedule of Effective Income Tax Rate Reconciliation for Provision for Income Taxes	The provision for income taxes differs from the amount computed by applying the federal income tax rate as follows for the years ended December 31: Years ended December 31, 2020 2019 2018 Tax provision at U.S. Federal statutory rates 21.0 % 21.0 % 21.0 % State income taxes net of federal benefit 7.7 8.1 6.7 Non-deductible permanent items 0.3 3.3 1.3 Non-taxable entities (0.2) (2.7) (0.7) Stock-based compensation 0.3 (1.5) (1.8) Change in valuation allowance 3.2 3.2 — Other (1.0) 0.2 0.6 Effective income tax rate 31.3 % 31.6 % 27.1 %

Mezzanine and Stockholders' E_2

Mezzanine and Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2020
Stockholders' Equity Note [Abstract]
Schedule of Warrants Outstanding	The Company’s outstanding warrants consisted of the following: Shares Weighted Weighted Aggregate Warrants outstanding at January 1, 2018 3,648,541 $ 9.75 3.74 $ 52.0 Warrants exercised (286,357) 7.84 3.0 Warrants forfeited (30,189) 4.50 — Warrants outstanding at December 31, 2018 3,331,995 $ 9.93 2.97 33.1 Warrants granted — — — — Warrants exercised (177,405) 9.32 — 1.6 Warrants forfeited — — — Warrants outstanding at December 31, 2019 3,154,590 $ 9.96 2.01 26.7 Warrants granted — — — — Warrants exercised (1,247,644) 9.33 — 9.8 Warrants forfeited (28,820) 9.00 — — Warrants outstanding at December 31, 2020 1,878,126 $ 10.39 1.63 $ 14.8 Exercise Price Per Warrants Weighted Warrants Weighted $ 9.00 10,810 0.24 10,810 $ 9.00 10.00 1,115,342 1.44 1,115,342 10.00 11.00 751,974 1.93 751,974 11.00 $9.00 – $11.00 1,878,126 1.63 1,878,126 $ 10.39

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
Schedule of Fees Incurred and Income Received Related to AHMC, HSMSO and Aurion Corporation	The following table sets forth fees incurred and income received related to AHMC, HSMSO and Aurion Corporation (in thousands): Years ended December 31, 2020 2019 AHMC – Risk pool earnings net claims payment $ 28,767 $ 40,000 HSMSO – Management fees, net (949) (1,700) Aurion – Management fees (303) (300) Receipts, net $ 27,515 $ 38,000

Stock Based Compensation (Table

Stock Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Schedule of Share-Based Compensation Expense	The following table summarizes the stock-based compensation expense recognized under all of the Company's stock plans in 2020, 2019, and 2018 and associated with the issuance of restricted shares of common stock and vesting of stock options which are included in General and administrative expenses in the accompanying consolidated statement of income recognized (in thousands): Years ended December 31, 2020 2019 2018 Stock options $ 1,763 $ 688 $ — Restricted stock awards 1,620 252 632 APC stock options — 607 810 Total share-based compensation expense $ 3,383 $ 1,547 $ 1,442
Schedule of Stock Option Transactions Under Stock Option Plans	The Company’s outstanding stock options consisted of the following: Shares Weighted Weighted Aggregate Options outstanding at January 1, 2020 607,346 $ 9.22 3.42 $ 5.6 Options granted 250,746 18.11 — — Options exercised (120,000) 2.58 — 1.8 Options canceled, forfeited or expired (12,228) 17.57 — — Options outstanding at December 31, 2020 725,864 $ 13.25 3.75 $ 3.4 Options exercisable at December 31, 2020 449,464 $ 6.33 1.94 $ 3.6
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	During the year ended December 31, 2020, the Company granted 191,742 and 59,004 five-year stock options to certain ApolloMed board members and executives, respectively, with exercise price ranging from $18.20-$18.41 and $17.78, respectively, which were recognized at fair value, as determined using the Black-Scholes option pricing model as follows: December 31, 2020 Board Members Executives Expected Term 3.0 years 3.5 years Expected volatility 85.44% - 90.01% 80.95 % Risk-free interest rate 0.23% - 1.43% 0.23 % Market value of common stock $18.20 - $18.41 $ 17.78 Annual dividend yield 0 % 0 % Forfeiture rate 0 % 0 %

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2020
Earnings Per Share [Abstract]
Schedule of Earnings Per Share Computations	Below is a summary of the earnings per share computations: Years ended December 31, 2020 2019 2018 Earnings per share – basic $ 1.04 $ 0.41 $ 0.33 Earnings per share – diluted $ 1.01 $ 0.39 $ 0.29 Weighted average shares of common stock outstanding – basic 36,527,672 34,708,429 32,893,940 Weighted average shares of common stock outstanding – diluted 37,448,430 36,403,279 37,914,886
Schedule of Shares Included in the Diluted Earnings Per Share Computations	Below is a summary of the shares included in the diluted earnings per share computations: Years ended December 31, 2020 2019 2018 Weighted average shares of common stock outstanding – basic 36,527,672 34,708,429 32,893,940 10% shares held back pursuant to indemnification clause — — 2,935,512 Stock options 182,999 295,672 459,440 Warrants 717,029 1,384,078 1,625,994 Management restricted stock awards (dilutive) 7,242 15,100 — Executive restricted stock awards (dilutive) 13,488 — — Weighted average shares of common stock outstanding – diluted 37,448,430 36,403,279 37,914,886

Variable Interest Entities (V_2

Variable Interest Entities (VIEs) (Tables)	12 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Variable Interest Entities	The following table includes assets that can only be used to settle the liabilities of APC and the creditors of APC have no recourse to the Company. These assets and liabilities, with the exception of the investment in a privately held entity and amounts due to affiliate, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands). December 31, 2020 2019 Assets Current assets Cash and cash equivalents $ 126,158 $ 87,110 Restricted cash – short-term — 75 Investment in marketable securities 67,637 123,948 Receivables, net 5,155 9,300 Receivables, net – related party 46,718 42,976 Other receivables 1,084 744 Prepaid expenses and other current assets 14,813 7,403 Loans receivable 50 6,425 Loans receivable - related parties — 16,500 Total current assets 261,615 294,481 Noncurrent assets Land, property and equipment, net 27,599 9,547 Intangible assets, net 69,250 81,439 Goodwill 109,460 108,913 Loans receivable – related parties 4,145 — Investment in affiliates* 225,144 318,315 Investments in other entities – equity method 43,516 28,427 Investment in privately held entities 36,584 1,615 Restricted cash – long-term 500 746 Operating lease right-of-use assets 6,298 4,751 Other assets 17,177 1,057 Total noncurrent assets 539,673 554,810 Total assets $ 801,288 $ 849,291 Current liabilities Accounts payable and accrued expenses $ 12,963 $ 11,187 Fiduciary accounts payable 9,642 2,027 Medical liabilities 37,684 49,019 Income taxes payable 4,225 4,530 Dividend payable 485 271 Amount due to affiliate 22,698 28,058 Current portion of long-term debt 201 — Finance lease liabilities 102 102 Operating lease liabilities 1,242 1,088 Total current liabilities 89,242 96,282 Noncurrent liabilities Long-term debt, net of current portion 7,379 — Deferred tax liability 9,144 14,059 Liability for unissued equity shares — — Finance lease liabilities, net of current portion 311 416 Operating lease liabilities, net of current portion 5,242 3,742 Total noncurrent liabilities 22,076 18,217 Total liabilities $ 111,318 $ 114,499 *Investment in affiliates include APC’s investment in ApolloMed which is reflected as treasury shares and eliminated upon consolidation. As a result this balance is not reflected on ApolloMed’s consolidated balance sheets as of December 31, 2020 and 2019.

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2020
Leases [Abstract]
Schedule of Lease Expense and Other Information Related to Lease Costs	The components of lease expense were as follows (in thousands): December 31, 2020 December 31, 2019 Operating lease cost $ 6,589 $ 5,437 Finance lease cost Amortization of lease expense 105 102 Interest on lease liabilities 14 17 Sublease income (784) (415) Total lease cost $ 5,924 $ 5,141 December 31, 2020 December 31, 2019 Supplemental Cash Flows Information Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 5,804 $ 5,254 Operating cash flows from finance leases 14 17 Financing cash flows from finance leases 105 102 Right-of-use assets obtained in exchange for lease liabilities: Operating leases 7,652 16,728 Finance leases — — December 31, 2020 December 31, 2019 Weighted Average Remaining Lease Term Operating leases 6.80 years 6.48 years Finance leases 3.67 years 4.67 years Weighted Average Discount Rate Operating leases 6.10 % 6.11 % Finance leases 3.00 % 3.00 %
Schedule of Operating Leases, Future Minimum Lease Payments After Adoption of 842	Years ending December 31, Operating Leases Finance Leases 2021 $ 4,297 $ 119 2022 3,529 119 2023 3,303 119 2024 2,940 79 2025 2,648 — Thereafter 6,818 — Total future minimum lease payments 23,535 436 Less: imputed interest 4,493 23 Total lease obligations 19,042 413 Less: current portion 3,177 102 Long-term lease obligations $ 15,865 $ 311
Schedule of Finance Lease, Future Minimum Lease Payments After Adoption of 842	Years ending December 31, Operating Leases Finance Leases 2021 $ 4,297 $ 119 2022 3,529 119 2023 3,303 119 2024 2,940 79 2025 2,648 — Thereafter 6,818 — Total future minimum lease payments 23,535 436 Less: imputed interest 4,493 23 Total lease obligations 19,042 413 Less: current portion 3,177 102 Long-term lease obligations $ 15,865 $ 311

Quarterly Financial Informati_2

Quarterly Financial Information (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information	The following tables represent our quarterly financial results (in thousands, except per share data): 2020 Calendar Quarter First Second 2 Third Fourth Annual Revenue $ 165,105 $ 165,169 $ 180,123 $ 176,783 $ 687,180 Income from operations 4,365 12,906 37,356 25,876 80,503 Net income 2,987 81,001 25,424 12,908 122,320 Net income attributable to ApolloMed 4,052 7,044 16,713 10,057 37,866 Earnings per share - basic attributable to common stock 1 $ 0.11 $ 0.20 $ 0.46 $ 0.27 $ 1.04 Earnings per share - diluted attributable to common stock 1 $ 0.11 $ 0.19 $ 0.45 $ 0.26 $ 1.01 1 Quarterly earnings per share impacts may not add to full-year earnings per share impacts due to the difference in weighted-average common shares for the quarters versus the weighted-average common shares for the year. 2 Includes a pre-tax gain of $99.6 million related to sale of UCI (Note 6). 2019 Calendar Quarter First Second Third Fourth Annual Revenue $ 95,757 $ 130,050 $ 156,060 $ 178,751 $ 560,618 (Loss) income from operations (3,307) 14,728 10,066 10,933 32,420 Net (loss) income (2,450) 10,664 10,739 (1,280) 17,673 Net income attributable to ApolloMed 140 3,545 3,704 6,727 14,116 Earnings per share - basic attributable to common stock 1 $ 0.00 $ 0.10 $ 0.11 $ 0.19 $ 0.41 Earnings per share - diluted attributable to common stock 1 $ 0.00 $ 0.09 $ 0.10 $ 0.18 $ 0.39

Description of Business - Addit

Description of Business - Additional Information (Details)

Apr. 30, 2020USD ($)

Sep. 11, 2019USD ($)shares

Sep. 10, 2019USD ($)

Aug. 30, 2019USD ($)

May 31, 2019USD ($)

Jul. 01, 1999

Dec. 31, 2020USD ($)

Dec. 31, 2019USD ($)

Dec. 31, 2018USD ($)

Dec. 31, 2020enrollee

Dec. 31, 2020primary_care_physician

Dec. 31, 2020specialty_care_physician

Dec. 31, 2020plan

Dec. 31, 2020clinic

Dec. 31, 2020company

Dec. 31, 2020medical_center

Dec. 31, 2020member

Sep. 30, 2019USD ($)

Description Of Business [Line Items]

Distributions of preferred returns

$ 1,990,000

$ 1,975,000

Stock issued during period new issues

0

Cash paid

$ 11,354,000

49,403,000

0

Proceeds from sale of equity method investment

52,743,000

$ 0

$ 0

Accountable Health Care IPA

Description Of Business [Line Items]

Consideration transferred

$ 25,100,000

AMG

Description Of Business [Line Items]

Consideration transferred

$ 1,600,000

Universal Care, Inc.

Description Of Business [Line Items]

Proceeds from sale of equity method investment

$ 52,743,000

Beneficial interest in UCI

$ 15,723,000

Dr. Jay | Accountable Health Care IPA

Description Of Business [Line Items]

Interest acquired

75.00%

Consideration transferred

$ 7,300,000

Affiliated Entity | AP-AMH

Description Of Business [Line Items]

Amount of loan

$ 545,000,000

$ 545,000,000

Term of receivable

10 years

Stated rate of note of loan receivable

10.00%

Interest rate in the event of default

10.75%

Affiliated Entity | APC

Description Of Business [Line Items]

Number of shares purchased by related party (in shares) | shares

15,015,015

Stock issued during period new issues

$ 300,000,000

Proxy votes

9.99%

APC

Description Of Business [Line Items]

Initial fixed term of amended and restated management and administrative services agreement

30 years

APC | MPP, AMG Properties, and ZLL Asset Acquisition

Description Of Business [Line Items]

Asset acquisition, purchase price

$ 12,200,000

Asset acquisition, percentage of shares acquired

100.00%

Asset acquisition, number of companies acquired | company

3

APC | Accountable Health Care IPA

Description Of Business [Line Items]

Interest acquired

25.00%

APC | AMG

Description Of Business [Line Items]

Interest acquired

100.00%

Payments to acquire business

$ 1,200,000

Value of shares transferred in acquisition

$ 400,000

APC | Universal Care Acquisition Partners, LLC

Description Of Business [Line Items]

Ownership interest

100.00%

APC | MPP, AMG Properties, and ZLL Asset Acquisition

Description Of Business [Line Items]

Ownership interest

100.00%

APC | ApolloMed

Description Of Business [Line Items]

Investment, ownership interest

22.58%

32.50%

APC | Concourse Diagnostic Surgery Center, LLC

Description Of Business [Line Items]

Investment, ownership interest

45.01%

APC | Universal Care, Inc.

Description Of Business [Line Items]

Ownership interest disposed

48.90%

Proceeds from sale of equity method investment

$ 69,200,000

Repayment of indebtedness received

16,500,000

Beneficial interest in UCI

15,700,000

APC | Bright | Preferred stock | Universal Care, Inc.

Description Of Business [Line Items]

Preferred shares received from sale of equity method investment

$ 36,200,000

APC | Affiliated Entity

Description Of Business [Line Items]

Distributions of preferred returns

$ 5,000,000

APC | Affiliated Entity | AP-AMH

Description Of Business [Line Items]

Distributions of preferred returns

$ 30,400,000

$ 8,900,000

APC | Affiliated Entity | AP-AMH | Series A Preferred Stock

Description Of Business [Line Items]

Number of shares purchased by related party (in shares) | shares

1,000,000

APC LSMA | Alpha Care

Description Of Business [Line Items]

Cash paid

$ 45,100,000

APC LSMA | Accountable Health Care IPA

Description Of Business [Line Items]

Interest acquired

75.00%

APC LSMA | AMG

Description Of Business [Line Items]

Interest acquired

100.00%

Payments to acquire business

$ 1,200,000

APC LSMA | Maverick Medical Group, Inc

Description Of Business [Line Items]

Ownership interest

100.00%

APC LSMA | Dr. Jay | Accountable Health Care IPA

Description Of Business [Line Items]

Consideration transferred

$ 7,300,000

Accountable Health Care IPA

Description Of Business [Line Items]

Number of employees (more than)

336

559

Number of medical centers | medical_center

1

Number of members of federally qualified health plans (more than) | member

73,000

Number federally qualified health plans | plan

3

AMG

Description Of Business [Line Items]

Number of family practice clinics | clinic

3

Alpha Care

Description Of Business [Line Items]

Number of healthcare enrollees | enrollee

180,000

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)	5 Months Ended	12 Months Ended
	Aug. 30, 2019USD ($)	Dec. 31, 2020USD ($)segmentunit	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Sep. 01, 2019USD ($)
Summary Of Significant Accounting Policies [Line Items]
Number of operating segments | segment		1
Number of reportable segments | segment		1
Amount deposit accounts exceeded FDIC insured limit		$ 294,900,000	$ 226,500,000
Restricted cash		0	100,000
Amount of short-term marketable securities		67,695,000	116,539,000
Impairment of finite-lived intangible assets		$ 0	0
Number of main reporting units | unit		3
Impairment of goodwill and intangible assets		$ 0	1,994,000	$ 3,799,000
Impairment of intangible assets		0	1,994,000
Impairment of goodwill		0
Billing in excess of costs				7,800,000	$ 34,500,000
Risk pool settlement			19,800,000	$ 900,000
Payment of revenue, monthly amount	$ 8,300,000	7,200,000
AIPBP payments						$ 3,700,000
Payment of revenue, revenue recognized		75,100,000
Contract liabilities		12,988,000	8,892,000
Contract liability repaid, capitation received and not earned		$ 8,500,000
Voting rights held (more than)		50.00%
Accounts Payable and Accrued Expenses
Summary Of Significant Accounting Policies [Line Items]
Payment of revenue		$ 85,900,000
Revenue recognized		$ 400,000
CMS
Summary Of Significant Accounting Policies [Line Items]
Expected period of payment upon termination of agreement		30 days
PMPM
Summary Of Significant Accounting Policies [Line Items]
Contract term		one year
Management contracts
Summary Of Significant Accounting Policies [Line Items]
Contract term		ten years
NGACO
Summary Of Significant Accounting Policies [Line Items]
Contract liabilities		$ 12,600,000	8,500,000
APAACO
Summary Of Significant Accounting Policies [Line Items]
Estimated revenue percentage					100.00%
PASC
Summary Of Significant Accounting Policies [Line Items]
Impairment of investments		$ 0	300,000
Medicare license
Summary Of Significant Accounting Policies [Line Items]
Indefinite-lived assets written off			2,000,000
Impairment of intangible assets			$ 1,994,000
Minimum
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, useful life		3 years
Maximum
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, useful life		39 years

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information, Performance Obligation (Details) - NGACO	Dec. 31, 2020	Dec. 31, 2019
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2018-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Term, performance obligation		2 years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Term, performance obligation	2 years

Basis of Presentation and Sum_6

Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Payor Type (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disaggregation of Revenue [Line Items]
Revenue	$ 176,783	$ 180,123	$ 165,169	$ 165,105	$ 178,751	$ 156,060	$ 130,050	$ 95,757	$ 687,180	$ 560,618	$ 519,908
Commercial
Disaggregation of Revenue [Line Items]
Revenue									108,851	107,340	113,000
Medicare
Disaggregation of Revenue [Line Items]
Revenue									271,596	226,002	226,353
Medicaid
Disaggregation of Revenue [Line Items]
Revenue									269,079	192,596	134,904
Other third parties
Disaggregation of Revenue [Line Items]
Revenue									$ 37,654	$ 34,680	$ 45,651

Basis of Presentation and Sum_7

Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Net revenue | Payor A
Concentration Risk [Line Items]
Concentration risk	12.50%	13.60%	14.60%
Net revenue | Payor B
Concentration Risk [Line Items]
Concentration risk	10.90%	13.40%	18.70%
Net revenue | Payor C
Concentration Risk [Line Items]
Concentration risk			14.10%
Net revenue | Payor D
Concentration Risk [Line Items]
Concentration risk	13.10%	11.70%	14.10%
Net revenue | Payor E
Concentration Risk [Line Items]
Concentration risk	16.90%	12.90%
Gross receivables | Payor F
Concentration Risk [Line Items]
Concentration risk	43.90%	30.40%
Gross receivables | Payor G
Concentration Risk [Line Items]
Concentration risk	36.50%	36.00%

Basis of Presentation and Sum_8

Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Company's Financial Instruments (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market accounts	$ 115,769	$ 50,731
Marketable securities – certificates of deposit	67,637	116,469
Marketable securities – equity securities	58	70
Total	183,464	167,270
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market accounts	115,769	50,731
Marketable securities – certificates of deposit	67,637	116,469
Marketable securities – equity securities	58	70
Total	183,464	167,270
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market accounts	0	0
Marketable securities – certificates of deposit	0	0
Marketable securities – equity securities	0	0
Total	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market accounts	0	0
Marketable securities – certificates of deposit	0	0
Marketable securities – equity securities	0	0
Total	$ 0	$ 0

Business Combinations and Goo_3

Business Combinations and Goodwill - Additional Information (Details) $ in Thousands	Sep. 10, 2019USD ($)acquisition	Aug. 30, 2019USD ($)	May 31, 2019USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Business Acquisition [Line Items]
Aggregate purchase price				$ 11,354	$ 49,403	$ 0
Acquisition of Alpha Care | APC and APC-LSMA
Business Acquisition [Line Items]
Interest acquired			100.00%
Aggregate purchase price			$ 45,056
Escrow deposit			$ 2,000
Accountable Health Care IPA
Business Acquisition [Line Items]
Consideration transferred		$ 25,100
Assets and liabilities assumed		$ 15,400
Accountable Health Care IPA | Dr. Jay
Business Acquisition [Line Items]
Interest acquired		75.00%
Consideration transferred		$ 7,300
Accountable Health Care IPA | APC and APC-LSMA | Dr. Jay
Business Acquisition [Line Items]
Interest acquired		75.00%
Aggregate purchase price		$ 7,250
Consideration transferred		$ 7,300
Accountable Health Care IPA | APC
Business Acquisition [Line Items]
Interest acquired		25.00%
Payments to acquire investments		$ 2,400
AMG
Business Acquisition [Line Items]
Consideration transferred	$ 1,600
Number of additional acquisitions completed | acquisition	1
AMG | APC
Business Acquisition [Line Items]
Interest acquired	100.00%
Value of shares transferred in acquisition	$ 400

Business Combinations and Goo_4

Business Combinations and Goodwill - Assumption of Identifiable Assets Acquired and Liabilities (Details) - USD ($) $ in Thousands	Aug. 30, 2019	May 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Assets acquired
Goodwill			$ 239,053	$ 238,505	$ 185,806
Liabilities assumed
Cash paid			$ 11,354	$ 49,403	$ 0
Dr. Jay | Accountable Health Care IPA
Assets acquired
Cash and cash equivalents	$ 582
Accounts receivable, net	5,150
Other current assets	198
Network relationship intangible assets	11,411
Goodwill	23,566
Liabilities assumed
Accounts payable	(3,759)
Medical liabilities	(12,154)
Subordinated loan	(15,327)
Net assets acquired	9,667
Less: equity investment contributed	2,417
APC and APC-LSMA | Acquisition of Alpha Care
Assets acquired
Cash and cash equivalents		$ 3,569
Accounts receivable, net		10,336
Other current assets		4,675
Network relationship intangible assets		22,636
Goodwill		28,585
Liabilities assumed
Accounts payable		(2,795)
Deferred tax liabilities		(6,334)
Medical liabilities		(15,616)
Net assets acquired		45,056
Cash paid		$ 45,056
APC and APC-LSMA | Dr. Jay | Accountable Health Care IPA
Liabilities assumed
Cash paid	$ 7,250

Business Combinations and Goo_5

Business Combinations and Goodwill - Pro Forma Financial Information All 2019 Acquisitions (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Business Combinations [Abstract]
Revenue	$ 658,011	$ 726,075
Net income	10,867	58,879
Net income attributable to Apollo Medical Holdings, Inc.	$ 7,310	$ 9,447
EPS - basic (in dollars per share)	$ 0.21	$ 0.29
EPS - diluted (in dollars per share)	$ 0.20	$ 0.25

Business Combinations and Goo_6

Business Combinations and Goodwill - Goodwill Roll Forward (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Goodwill
Beginning Balance	$ 238,505	$ 185,806
Acquisitions		52,699
Adjustments	548
Ending Balance	$ 239,053	$ 238,505

Land, Property and Equipment,_3

Land, Property and Equipment, Net - Schedule of Land, Property and Equipment, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Land, property and equipment, gross	$ 48,078	$ 28,153
Less accumulated depreciation and amortization	(18,188)	(16,023)
Land, property and equipment, net	$ 29,890	12,130
Minimum
Property, Plant and Equipment [Line Items]
Useful Life (Years)	3 years
Maximum
Property, Plant and Equipment [Line Items]
Useful Life (Years)	39 years
Land
Property, Plant and Equipment [Line Items]
Land, property and equipment, gross	$ 9,604	3,300
Buildings
Property, Plant and Equipment [Line Items]
Useful Life (Years)	39 years
Land, property and equipment, gross	$ 15,097	2,358
Computer software
Property, Plant and Equipment [Line Items]
Land, property and equipment, gross	$ 3,104	3,088
Computer software | Minimum
Property, Plant and Equipment [Line Items]
Useful Life (Years)	3 years
Computer software | Maximum
Property, Plant and Equipment [Line Items]
Useful Life (Years)	5 years
Furniture and equipment
Property, Plant and Equipment [Line Items]
Land, property and equipment, gross	$ 13,116	12,585
Furniture and equipment | Minimum
Property, Plant and Equipment [Line Items]
Useful Life (Years)	3 years
Furniture and equipment | Maximum
Property, Plant and Equipment [Line Items]
Useful Life (Years)	7 years
Construction in progress
Property, Plant and Equipment [Line Items]
Land, property and equipment, gross	$ 435	167
Leasehold improvements
Property, Plant and Equipment [Line Items]
Land, property and equipment, gross	$ 6,722	$ 6,655
Leasehold improvements | Minimum
Property, Plant and Equipment [Line Items]
Useful Life (Years)	3 years
Leasehold improvements | Maximum
Property, Plant and Equipment [Line Items]
Useful Life (Years)	39 years

Land, Property and Equipment,_4

Land, Property and Equipment, Net - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Assets recorded under finance leases	$ 0.4	$ 0.5
Depreciation expense	$ 2.3	$ 2	$ 2.2

Land, Property and Equipment,_5

Land, Property and Equipment, Net - Asset Acquisition Narrative (Details) $ in Millions	12 Months Ended
	Dec. 31, 2020USD ($)building
MPP | Land
Asset Acquisition [Line Items]
Acquired value	$ 3.7
MPP | Buildings
Asset Acquisition [Line Items]
Acquired value	10.8
AMG Properties | Land
Asset Acquisition [Line Items]
Acquired value	1.5
AMG Properties | Buildings
Asset Acquisition [Line Items]
Acquired value	0.4
ZLL | Land
Asset Acquisition [Line Items]
Acquired value	1.2
ZLL | Buildings
Asset Acquisition [Line Items]
Acquired value	$ 1.5
APC | MPP
Asset Acquisition [Line Items]
Asset acquisition, percentage of shares acquired	100.00%
Asset acquisition, purchase price	$ 9
APC | AMG Properties
Asset Acquisition [Line Items]
Asset acquisition, percentage of shares acquired	100.00%
Asset acquisition, purchase price	$ 1.2
APC | ZLL
Asset Acquisition [Line Items]
Asset acquisition, percentage of shares acquired	100.00%
Asset acquisition, purchase price	$ 2
APC | MPP, AMG Properties, and ZLL Asset Acquisition
Asset Acquisition [Line Items]
Asset acquisition, percentage of shares acquired	100.00%
Asset acquisition, purchase price	$ 12.2
Number of assets acquired | building	4

Intangible Assets, Net - Schedu

Intangible Assets, Net - Schedule of Intangible Assets (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Indefinite lived assets:
Impairment/ Disposal	$ 0	$ (1,994,000)
Amortized intangible assets:
Additions	0	34,047,000
Accumulated Amortization	(89,544,000)	(73,517,000)
Total	86,985,000
Intangible Assets, Gross	176,529,000	176,529,000	$ 144,476,000
Intangible Assets, Net	86,985,000	103,012,000
Network relationships
Amortized intangible assets:
Beginning Balance, Gross	143,930,000	109,883,000
Additions	0	34,047,000
Ending Balance, Gross	143,930,000	143,930,000
Accumulated Amortization	(73,169,000)	(60,525,000)
Total	$ 70,761,000	$ 83,405,000
Network relationships | Minimum
Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)	11 years	11 years
Network relationships | Maximum
Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)	15 years	15 years
Management contracts
Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)	15 years	15 years
Amortized intangible assets:
Beginning Balance, Gross	$ 22,832,000	$ 22,832,000
Additions	0	0
Ending Balance, Gross	22,832,000	22,832,000
Accumulated Amortization	(11,715,000)	(9,677,000)
Total	$ 11,117,000	$ 13,155,000
Member relationships
Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)	12 years	12 years
Amortized intangible assets:
Beginning Balance, Gross	$ 6,696,000	$ 6,696,000
Additions	0	0
Ending Balance, Gross	6,696,000	6,696,000
Accumulated Amortization	(3,234,000)	(2,352,000)
Total	$ 3,462,000	$ 4,344,000
Patient management platform
Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)	5 years	5 years
Amortized intangible assets:
Beginning Balance, Gross	$ 2,060,000	$ 2,060,000
Additions	0	0
Ending Balance, Gross	2,060,000	2,060,000
Accumulated Amortization	(1,270,000)	(858,000)
Total	$ 790,000	$ 1,202,000
Tradename/trademarks
Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)	20 years	20 years
Amortized intangible assets:
Beginning Balance, Gross	$ 1,011,000	$ 1,011,000
Additions	0	0
Ending Balance, Gross	1,011,000	1,011,000
Accumulated Amortization	(156,000)	(105,000)
Total	855,000	906,000
Medicare license
Indefinite lived assets:
Beginning Balance	$ 0	1,994,000
Additions		0
Impairment/ Disposal		(1,994,000)
Ending Balance		$ 0

Intangible Assets, Net - Additi

Intangible Assets, Net - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 16	$ 16.3	$ 17.1
Medicare license
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived assets written off		$ 2

Intangible Assets, Net - Sche_2

Intangible Assets, Net - Schedule of Future Amortization Expense (Details) $ in Thousands	Dec. 31, 2020USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2021	$ 14,524
2022	12,673
2023	10,842
2024	9,830
2025	8,758
Thereafter	30,358
Total	$ 86,985

Investments in Other Entities -

Investments in Other Entities - Equity Method (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Equity Method Investments [Roll Forward]
Beginning Balance	$ 28,427,000
Allocation of Net Income (Loss)	3,694,000	$ (6,901,000)	$ (8,125,000)
Additional/ Initial Investment	15,394,000
Contribution	950,000
Sale	(5,173,000)
Ending Balance	43,292,000	28,427,000
LaSalle Medical Associates – IPA Line of Business
Equity Method Investments [Roll Forward]
Beginning Balance	6,396,000
Allocation of Net Income (Loss)	276,000
Additional/ Initial Investment	6,375,000
Contribution	0
Ending Balance	13,047,000	6,396,000
Pacific Medical Imaging & Oncology Center, Inc.
Equity Method Investments [Roll Forward]
Beginning Balance	1,396,000
Allocation of Net Income (Loss)	17,000
Contribution	0
Ending Balance	1,413,000	1,396,000
Universal Care, Inc.
Equity Method Investments [Roll Forward]
Beginning Balance	1,438,000
Allocation of Net Income (Loss)	3,560,000
Contribution	0
Sale	(4,998,000)
Ending Balance	0	1,438,000
Diagnostic Medical Group
Equity Method Investments [Roll Forward]
Beginning Balance	2,334,000
Allocation of Net Income (Loss)	279,000
Contribution	0
Ending Balance	2,613,000	2,334,000
531 W. College, LLC – related party
Equity Method Investments [Roll Forward]
Beginning Balance	16,698,000
Allocation of Net Income (Loss)	(448,000)
Contribution	950,000
Ending Balance	17,200,000	16,698,000
MWN, LLC – related party
Equity Method Investments [Roll Forward]
Beginning Balance	165,000
Allocation of Net Income (Loss)	10,000
Contribution	0
Sale	(175,000)
Ending Balance	0	165,000
One MSO, LLC - related party
Equity Method Investments [Roll Forward]
Beginning Balance	0
Allocation of Net Income (Loss)	0
Additional/ Initial Investment	2,395,000
Contribution	0
Ending Balance	2,395,000	0
Tag-6 Medical Investment Group, LLC - related party
Equity Method Investments [Roll Forward]
Beginning Balance	0
Allocation of Net Income (Loss)	0
Additional/ Initial Investment	4,516,000
Contribution	0
Ending Balance	4,516,000	0
Tag-8 Medical Investment Group, LLC - related party
Equity Method Investments [Roll Forward]
Beginning Balance	0
Allocation of Net Income (Loss)	0
Additional/ Initial Investment	2,108,000
Contribution	0
Ending Balance	$ 2,108,000	$ 0

Investments in Other Entities_2

Investments in Other Entities - Additional Information (Details)

Oct. 30, 2020USD ($)

Apr. 30, 2020USD ($)

Aug. 30, 2019USD ($)

Jul. 01, 2019USD ($)

Jun. 29, 2018USD ($)

Jun. 30, 2018USD ($)

May 31, 2018USD ($)$ / sharesshares

Aug. 31, 2015USD ($)shares

Dec. 31, 2020USD ($)

Dec. 31, 2019USD ($)

Dec. 31, 2018USD ($)

Dec. 31, 2020

Dec. 31, 2020primary_care_physician

Dec. 31, 2020specialty_care_physician

Dec. 31, 2020plan

Dec. 31, 2020medical_center

Dec. 31, 2020provider

Dec. 31, 2020member

Dec. 18, 2020USD ($)

Dec. 16, 2020

Aug. 31, 2019USD ($)

Jun. 28, 2019USD ($)

Apr. 23, 2019USD ($)

Dec. 18, 2018USD ($)

Sep. 21, 2018USD ($)

Jul. 31, 2015USD ($)

Dec. 31, 2012USD ($)

Schedule of Equity Method Investments [Line Items]

Income (loss) from equity method investments

$ 3,694,000

$ (6,901,000)

$ (8,125,000)

Investments in other entities – equity method

43,292,000

28,427,000

Payments to acquire equity method investments

9,969,000

3,108,000

16,706,000

Proceeds from sale of equity method investment

52,743,000

0

0

Investments in privately held entities

37,075,000

896,000

Proceeds from equity method investment

0

240,000

607,000

Contribution

950,000

Gain on sale of equity method investment

99,839,000

0

$ 0

Accountable Health Care IPA

Schedule of Equity Method Investments [Line Items]

Consideration transferred

$ 25,100,000

Accountable Health Care IPA | Dr. Jay

Schedule of Equity Method Investments [Line Items]

Income (loss) from equity method investments

$ 1,800,000

Interest acquired

75.00%

Consideration transferred

$ 7,300,000

APC LSMA | Accountable Health Care IPA

Schedule of Equity Method Investments [Line Items]

Interest acquired

75.00%

APC LSMA | Accountable Health Care IPA | Dr. Jay

Schedule of Equity Method Investments [Line Items]

Consideration transferred

$ 7,300,000

APC and APC-LSMA | Accountable Health Care IPA | Dr. Jay

Schedule of Equity Method Investments [Line Items]

Interest acquired

75.00%

Consideration transferred

$ 7,300,000

APC | Notes Receivable | Dr. Arteaga

Schedule of Equity Method Investments [Line Items]

Amount of loan

$ 6,400,000

APC | Accountable Health Care IPA

Schedule of Equity Method Investments [Line Items]

Interest acquired

25.00%

APC | MediPortal LLC

Schedule of Equity Method Investments [Line Items]

Membership interests purchased (in shares) | shares

270,000

Payments to purchase membership interests

$ 400,000

Membership interests acquired (in dollars per share) | $ / shares

$ 1.50

Ownership percentage

2.80%

Term of warrant

5 years

Number of warrants (in shares) | shares

270,000

Term of option

5 years

Options to purchase additional membership interests (in shares) | shares

380,000

Number of warrants available to purchase, contingent upon the portal completion date (in shares) | shares

480,000

NMM | Notes Receivable | Pacific6

Schedule of Equity Method Investments [Line Items]

Amount of loan

$ 500,000

Gain on sale of equity method investment

$ 200,000

NMM | AchievaMed, Inc.

Schedule of Equity Method Investments [Line Items]

Ownership percentage

10.00%

Percentage of voting common stock, within five years

50.00%

Duration of investment

5 years

Investment amount

$ 500,000

500,000

Accountable Health Care IPA

Schedule of Equity Method Investments [Line Items]

Number of medical centers | medical_center

1

Number of employees (more than)

336

559

Number of members of federally qualified health plans (more than) | member

73,000

Number federally qualified health plans | plan

3

Pacific6

Schedule of Equity Method Investments [Line Items]

Ownership interest

33.30%

HSMSO

Schedule of Equity Method Investments [Line Items]

Ownership interest

33.30%

LaSalle Medical Associates – IPA Line of Business

Schedule of Equity Method Investments [Line Items]

Number of medical centers | medical_center

6

Number of employees (more than) | provider

2,300

Income (loss) from equity method investments

276,000

Investments in other entities – equity method

13,047,000

6,396,000

Contribution

0

LaSalle Medical Associates – IPA Line of Business | APC LSMA

Schedule of Equity Method Investments [Line Items]

Amount invested for interest

$ 5,000,000

Ownership interest

25.00%

LaSalle Medical Associates – IPA Line of Business | APC and APC-LSMA | Notes Receivable | Dr. Arteaga

Schedule of Equity Method Investments [Line Items]

Ownership upon conversion of finance receivable

46.25%

LaSalle Medical Associates – IPA Line of Business | APC

Schedule of Equity Method Investments [Line Items]

Income (loss) from equity method investments

300,000

(2,800,000)

Investments in other entities – equity method

6,400,000

LaSalle Medical Associates – IPA Line of Business | APC | Notes Receivable | Dr. Arteaga

Schedule of Equity Method Investments [Line Items]

Amount of loan

$ 6,400,000

Increase in ownership percentage, finance receivable converted

21.25%

21.25%

Pacific Medical Imaging & Oncology Center, Inc.

Schedule of Equity Method Investments [Line Items]

Income (loss) from equity method investments

17,000

Investments in other entities – equity method

1,413,000

1,396,000

Contribution

0

Pacific Medical Imaging & Oncology Center, Inc. | APC LSMA

Schedule of Equity Method Investments [Line Items]

Amount invested for interest

$ 1,200,000

Ownership interest

40.00%

Pacific Medical Imaging & Oncology Center, Inc. | APC

Schedule of Equity Method Investments [Line Items]

Income (loss) from equity method investments

17,470

(36,384)

Investments in other entities – equity method

1,400,000

1,400,000

Pacific Medical Imaging & Oncology Center, Inc. | APC | Ancillary Service Contract

Schedule of Equity Method Investments [Line Items]

Fees paid

2,200,000

2,700,000

Universal Care, Inc.

Schedule of Equity Method Investments [Line Items]

Income (loss) from equity method investments

3,560,000

Investments in other entities – equity method

$ 4,998,000

0

1,438,000

Proceeds from sale of equity method investment

52,743,000

Beneficial interest in UCI

15,723,000

Contribution

0

Gain on sale of equity method investment

99,647,000

Universal Care, Inc. | Bright | Preferred stock

Schedule of Equity Method Investments [Line Items]

Investments in privately held entities

$ 36,179,000

Universal Care, Inc. | APC

Schedule of Equity Method Investments [Line Items]

Income (loss) from equity method investments

3,600,000

(1,200,000)

Investments in other entities – equity method

1,400,000

Ownership interest disposed

48.90%

Proceeds from sale of equity method investment

$ 69,200,000

Repayment of indebtedness received

16,500,000

Beneficial interest in UCI

15,700,000

Universal Care, Inc. | APC | Bright | Preferred stock

Schedule of Equity Method Investments [Line Items]

Investments in privately held entities

36,200,000

36,200,000

Universal Care, Inc. | UCAP

Schedule of Equity Method Investments [Line Items]

Contingent consideration, cash held in escrow

15,600,000

Contingent consideration, preferred shares

6,400,000

Contingent consideration, fair value

$ 22,000,000

Universal Care, Inc. | UCAP | A-2 Voting Common Stock

Schedule of Equity Method Investments [Line Items]

Shares purchased (in shares) | shares

100,000

Payments to acquire equity method investments

$ 10,000,000

Percentage of voting common stock

50.00%

Universal Care, Inc. | UCAP | A-2 Voting Common Stock | Ancillary Service Contract

Schedule of Equity Method Investments [Line Items]

Ownership interest

48.90%

Universal Care, Inc. | UCAP | Bright

Schedule of Equity Method Investments [Line Items]

Ownership interest disposed

48.90%

Proceeds from sale of equity method investment

$ 69,200,000

Universal Care, Inc. | UCAP | APC

Schedule of Equity Method Investments [Line Items]

Repayment of indebtedness received

$ 16,500,000

Diagnostic Medical Group

Schedule of Equity Method Investments [Line Items]

Income (loss) from equity method investments

279,000

Investments in other entities – equity method

2,613,000

2,334,000

Contribution

0

Diagnostic Medical Group | APC

Schedule of Equity Method Investments [Line Items]

Ownership interest

40.00%

Income (loss) from equity method investments

300,000

300,000

Investments in other entities – equity method

2,600,000

2,300,000

Proceeds from equity method investment

0

200,000

Accountable Health Care IPA

Schedule of Equity Method Investments [Line Items]

Ownership interest

25.00%

Accountable Health Care IPA | NMM and APC | Convertible Debt

Schedule of Equity Method Investments [Line Items]

Loan balance converted

$ 5,000,000

Accountable Health Care IPA | APC

Schedule of Equity Method Investments [Line Items]

Ownership interest

25.00%

Accountable Health Care IPA | APC | Convertible Debt

Schedule of Equity Method Investments [Line Items]

Loan balance converted

$ 5,000,000

Accountable Health Care IPA | NMM

Schedule of Equity Method Investments [Line Items]

Investments in other entities – equity method

$ 5,000,000

531 W. College, LLC – related party

Schedule of Equity Method Investments [Line Items]

Income (loss) from equity method investments

(448,000)

Investments in other entities – equity method

17,200,000

16,698,000

Payments to acquire real estate

$ 33,300,000

Contribution

950,000

531 W. College, LLC – related party | NMM and APC

Schedule of Equity Method Investments [Line Items]

Income (loss) from equity method investments

(400,000)

(200,000)

531 W. College, LLC – related party | APC

Schedule of Equity Method Investments [Line Items]

Ownership interest

25.00%

50.00%

50.00%

Investments in other entities – equity method

17,200,000

16,700,000

$ 16,100,000

Initial capital contributions

$ 8,300,000

Payments to escrow deposit

$ 8,300,000

Contribution

1,000,000

700,000

531 W. College, LLC – related party | NMM

Schedule of Equity Method Investments [Line Items]

Amount invested for interest

$ 8,300,000

Ownership interest

25.00%

25.00%

Initial capital contributions

$ 8,300,000

Payments to escrow deposit

$ 8,300,000

531 W. College, LLC – related party | College Street Investment LP

Schedule of Equity Method Investments [Line Items]

Ownership interest

50.00%

Initial capital contributions

$ 16,700,000

531 W. College, LLC – related party | AHMC Healthcare Inc

Schedule of Equity Method Investments [Line Items]

Payments to escrow deposit

$ 16,700,000

MWN, LLC – related party

Schedule of Equity Method Investments [Line Items]

Income (loss) from equity method investments

10,000

Investments in other entities – equity method

0

165,000

Contribution

0

MWN, LLC – related party | NMM

Schedule of Equity Method Investments [Line Items]

Ownership interest

33.30%

33.30%

Initial capital contributions

$ 3,000

Working capital contribution

$ 300,000

30,000

MWN, LLC – related party | Pacific6

Schedule of Equity Method Investments [Line Items]

Initial capital contributions

3,000

Working capital contribution

30,000

MWN, LLC – related party | HSMSO

Schedule of Equity Method Investments [Line Items]

Initial capital contributions

3,000

Working capital contribution

$ 30,000

One MSO, LLC - related party

Schedule of Equity Method Investments [Line Items]

Income (loss) from equity method investments

0

Investments in other entities – equity method

2,395,000

0

Contribution

0

One MSO, LLC - related party | APC

Schedule of Equity Method Investments [Line Items]

Ownership interest

50.00%

Tag-6 Medical Investment Group, LLC - related party

Schedule of Equity Method Investments [Line Items]

Income (loss) from equity method investments

0

Investments in other entities – equity method

4,516,000

0

Contribution

0

Tag-6 Medical Investment Group, LLC - related party | APC

Schedule of Equity Method Investments [Line Items]

Ownership interest

50.00%

Tag-8 Medical Investment Group, LLC - related party

Schedule of Equity Method Investments [Line Items]

Income (loss) from equity method investments

0

Investments in other entities – equity method

2,108,000

$ 0

Contribution

$ 0

Tag-8 Medical Investment Group, LLC - related party | APC

Schedule of Equity Method Investments [Line Items]

Ownership interest

50.00%

Investments in Other Entities _

Investments in Other Entities — Summarized Balance Sheets and Statements of Income (Details) - USD ($) $ in Thousands		3 Months Ended								12 Months Ended
		Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Assets
Cash and cash equivalents		$ 193,470				$ 103,189				$ 193,470	$ 103,189	$ 106,892
Receivables, net		7,058				11,004				7,058	11,004
Loans receivable		50				22,925				50	22,925
Restricted cash		0				75				0	75
Property and equipment, net		29,890				12,130				29,890	12,130
Total assets	[1]	817,486				728,713				817,486	728,713
Liabilities and Stockholders’ Deficit
Current liabilities		114,992				105,424				114,992	105,424
Stockholders’ deficit		330,911				192,335				330,911	192,335	181,545	$ 164,183
Total liabilities and stockholders’ deficit		817,486				728,713				817,486	728,713
Statements of Operations
Revenues		176,783	$ 180,123	$ 165,169	$ 165,105	178,751	$ 156,060	$ 130,050	$ 95,757	687,180	560,618	519,908
Expenses										606,677	528,198	431,476
(Loss) income from operations		25,876	37,356	12,906	4,365	10,933	10,066	14,728	(3,307)	80,503	32,420	88,432
Other income										1,077	3,030	1,622
Income (loss) before income tax benefit										178,427	25,840	82,627
Income tax provision (benefit)										56,107	8,167	22,360
Net income		12,908	$ 25,424	$ 81,001	$ 2,987	(1,280)	$ 10,739	$ 10,664	$ (2,450)	122,320	17,673	$ 60,267
LaSalle Medical Associates
Assets
Cash and cash equivalents		9,350				6,345				9,350	6,345
Receivables, net		3,918				5,123				3,918	5,123
Other current assets		881				3,526				881	3,526
Loans receivable		2,250				2,250				2,250	2,250
Restricted cash		691				684				691	684
Total assets		17,090				17,928				17,090	17,928
Liabilities and Stockholders’ Deficit
Current liabilities		21,589				23,530				21,589	23,530
Stockholders’ deficit		(4,499)				(5,602)				(4,499)	(5,602)
Total liabilities and stockholders’ deficit		17,090				17,928				17,090	17,928
Statements of Operations
Revenues										186,964	194,020
Expenses										185,724	205,153
(Loss) income from operations										1,240	(11,133)
Other income										8	0
Income (loss) before income tax benefit										1,248	(11,133)
Income tax provision (benefit)										0	0
Net income										1,248	(11,133)
Universal Care, Inc.
Assets
Cash and cash equivalents						33,890					33,890
Receivables, net						63,843					63,843
Other current assets						38,280					38,280
Other Assets						882					882
Property and equipment, net						4,021					4,021
Total assets						140,916					140,916
Liabilities and Stockholders’ Deficit
Current liabilities						128,330					128,330
Other Liabilities						33,133					33,133
Stockholders’ deficit						(20,547)					(20,547)
Total liabilities and stockholders’ deficit						140,916					140,916
Statements of Operations
Revenues										195,308	500,375
Expenses										189,028	502,567
Income (loss) before income tax benefit										6,280	(2,192)
Income tax provision (benefit)										0	258
Net income										6,280	(2,450)
531 W. College, LLC – related party
Assets
Cash and cash equivalents		648				139				648	139
Other current assets		17				17				17	17
Other Assets		70				70				70	70
Property and equipment, net		33,697				33,581				33,697	33,581
Total assets		34,432				33,807				34,432	33,807
Liabilities and Stockholders’ Deficit
Current liabilities		32				1,061				32	1,061
Stockholders’ deficit		34,400				32,746				34,400	32,746
Total liabilities and stockholders’ deficit		$ 34,432				$ 33,807				34,432	33,807
Statements of Operations
Revenues										0	0
Expenses										1,053	1,010
(Loss) income from operations										(1,053)	(1,010)
Other income										64	475
Income tax provision (benefit)										3	0
Net income										$ (992)	$ (535)
[1]	The Company's consolidated balance sheets include the assets and liabilities of its consolidated variable interest entities ("VIEs"). The consolidated balance sheets include total assets that can be used only to settle obligations of the Company’s consolidated VIEs totaling $801.3 million and $849.3 million as of December 31, 2020 and December 31, 2019, respectively, and total liabilities of the Company’s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $111.3 million and $114.5 million as of December 31, 2020 and December 31, 2019, respectively. See Note 18 – Variable Interest Entities (VIEs) for further detail.

Investments in Other Entities_3

Investments in Other Entities — Gain on Sale (Details) - USD ($)	Apr. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Schedule of Equity Method Investments [Line Items]
Cash proceeds (excludes proceeds to settle indebtedness owed to APC from UCI)		$ 52,743,000	$ 0	$ 0
Preferred shares in Bright Health, Inc.		37,075,000	896,000
Less: Carrying value of equity method investment on date of sale		(43,292,000)	(28,427,000)
Gain on sale of equity method investment		99,839,000	0	$ 0
Universal Care, Inc.
Schedule of Equity Method Investments [Line Items]
Cash proceeds (excludes proceeds to settle indebtedness owed to APC from UCI)	$ 52,743,000
Beneficial interest in UCI	15,723,000
Less: Carrying value of equity method investment on date of sale	(4,998,000)	$ 0	$ (1,438,000)
Gain on sale of equity method investment	99,647,000
Universal Care, Inc. | Bright | Preferred stock
Schedule of Equity Method Investments [Line Items]
Preferred shares in Bright Health, Inc.	$ 36,179,000

Loans Receivable and Loans Re_2

Loans Receivable and Loans Receivable - Related Parties - Additional Information (Details) - USD ($)	1 Months Ended	10 Months Ended	12 Months Ended
	Oct. 31, 2020	Dec. 31, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 18, 2020	Oct. 30, 2020	Feb. 28, 2020	Jun. 28, 2019
Accounts, Notes, Loans and Financing Receivable [Line Items]
Investments in other entities – equity method		$ 43,292,000	$ 43,292,000	$ 28,427,000
Proceeds from repayment of loans receivable - related parties			16,500,000	0	$ 0
Loss recorded, loan receivable			0
Loss recorded, loan receivable - related parties			0
LaSalle Medical Associates – IPA Line of Business
Accounts, Notes, Loans and Financing Receivable [Line Items]
Investments in other entities – equity method		13,047,000	13,047,000	$ 6,396,000
APC | LaSalle Medical Associates – IPA Line of Business
Accounts, Notes, Loans and Financing Receivable [Line Items]
Investments in other entities – equity method		$ 6,400,000	$ 6,400,000
Notes Receivable | Dr. Arteaga | LaSalle Medical Associates – IPA Line of Business
Accounts, Notes, Loans and Financing Receivable [Line Items]
Ownership upon conversion of finance receivable									53.75%
Notes Receivable | Dr. Arteaga | APC and APC-LSMA | LaSalle Medical Associates – IPA Line of Business
Accounts, Notes, Loans and Financing Receivable [Line Items]
Ownership upon conversion of finance receivable						46.25%
Notes Receivable | Dr. Arteaga | APC
Accounts, Notes, Loans and Financing Receivable [Line Items]
Amount of loan									$ 6,400,000
Interest rate on loan receivable		4.25%	4.25%
Percentage of outstanding stock, upon conversion of finance receivable									21.25%
Notes Receivable | Dr. Arteaga | APC | LaSalle Medical Associates – IPA Line of Business
Accounts, Notes, Loans and Financing Receivable [Line Items]
Amount of loan						$ 6,400,000
Increase in ownership percentage, finance receivable converted		21.25%	21.25%			21.25%
Notes Receivable | Pacific6 | NMM
Accounts, Notes, Loans and Financing Receivable [Line Items]
Amount of loan							$ 500,000
Interest rate on loan receivable							5.00%
Notes Receivable | AHMC | APC
Accounts, Notes, Loans and Financing Receivable [Line Items]
Note receivable, amount	$ 4,000,000	$ 4,000,000	$ 4,000,000
Note receivable, maturity period	2 years
Note receivable, interest rate	3.75%
Notes Receivable | Prime Rate | Dr. Arteaga | APC
Accounts, Notes, Loans and Financing Receivable [Line Items]
Basis spread on variable rate			1.00%
Financing Receivable | Dr. Arteaga
Accounts, Notes, Loans and Financing Receivable [Line Items]
Amount of loan								$ 2,200,000
Proceeds from repayment of loans receivable - related parties		$ 2,200,000

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Accounts payable and other accruals	$ 9,554	$ 6,914
Capitation payable	3,541	2,813
Subcontractor IPA payable	1,662	3,360
Professional fees	1,378	1,837
Due to related parties	50	225
Contract liabilities	12,988	8,892
Accrued compensation	6,970	3,238
Total accounts payable and accrued expenses	$ 36,143	$ 27,279

Medical Liabilities - Schedule

Medical Liabilities - Schedule of Medical Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Medical Liabilities [Roll Forward]
Medical liabilities, beginning of year	$ 58,725	$ 33,642
Acquired (see Note 3)	0	27,474
Components of medical care costs related to claims incurred:
Current period	309,848	271,987
Prior periods	(3,258)	2,684
Total medical care costs	306,590	274,671
Payments for medical care costs related to claims incurred:
Current period	(261,062)	(218,564)
Prior periods	(54,056)	(58,633)
Total paid	(315,118)	(277,197)
Adjustments	133	135
Medical liabilities, end of year	$ 50,330	$ 58,725

Credit Facility, Bank Loans a_3

Credit Facility, Bank Loans and Lines of Credit - Schedule of Credit Facility Information (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Line of Credit Facility [Line Items]
Total Debt	$ 245,705	$ 247,625
Less: current portion of debt	(10,889)	(9,500)
Less: unamortized financing cost	(4,605)	(5,953)
Long-term debt	230,211	232,172
Real Estate Loans
Line of Credit Facility [Line Items]
Total Debt	7,580	0
Term Loan
Line of Credit Facility [Line Items]
Total Debt	178,125	187,625
Revolver Loan
Line of Credit Facility [Line Items]
Total Debt	$ 60,000	$ 60,000

Credit Facility, Bank Loans a_4

Credit Facility, Bank Loans and Lines of Credit - Schedule of Maturities (Details) $ in Thousands	Dec. 31, 2020USD ($)
Debt Disclosure [Abstract]
2021	$ 10,889
2022	14,459
2023	15,653
2024	197,972
2025 and thereafter	6,732
Total	$ 245,705

Credit Facility, Bank Loans a_5

Credit Facility, Bank Loans and Lines of Credit - Additional Information (Detail)	Sep. 05, 2018USD ($)	Sep. 30, 2019USD ($)financial_ratio	Dec. 31, 2020USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Jul. 31, 2020USD ($)	Sep. 11, 2019USD ($)	Sep. 10, 2019USD ($)	Aug. 01, 2019USD ($)	Jul. 29, 2019USD ($)	Jun. 30, 2019USD ($)	Jun. 11, 2019USD ($)	Sep. 01, 2018USD ($)	Jun. 14, 2018USD ($)
Debt Instrument [Line Items]
Interest expense						$ 9,499,000	$ 4,733,000	$ 561,000
Long-term line of credit			$ 245,705,000	$ 245,705,000	$ 245,705,000	$ 245,705,000
APC | MPP
Debt Instrument [Line Items]
Asset acquisition, percentage of shares acquired			100.00%	100.00%	100.00%	100.00%
APC | AMG Properties
Debt Instrument [Line Items]
Asset acquisition, percentage of shares acquired			100.00%	100.00%	100.00%	100.00%
APC | ZLL
Debt Instrument [Line Items]
Asset acquisition, percentage of shares acquired			100.00%	100.00%	100.00%	100.00%
MPP
Debt Instrument [Line Items]
Face amount of debt			$ 6,400,000	$ 6,400,000	$ 6,400,000	$ 6,400,000
Minimum debt coverage ratio			1.25
MPP | Prime Rate
Debt Instrument [Line Items]
Basis spread on variable rate			0.50%
AMG Properties
Debt Instrument [Line Items]
Face amount of debt			$ 700,000	$ 700,000	700,000	700,000
Minimum debt coverage ratio				1.25
AMG Properties | Prime Rate
Debt Instrument [Line Items]
Basis spread on variable rate				0.30%
ZLL
Debt Instrument [Line Items]
Face amount of debt			700,000	$ 700,000	$ 700,000	700,000
Minimum debt coverage ratio					1.25
ZLL | Prime Rate
Debt Instrument [Line Items]
Basis spread on variable rate					0.50%
AP-AMH | Affiliated Entity
Debt Instrument [Line Items]
Amount of loan		$ 545,000,000								$ 545,000,000
Standby Letters of Credit | APAACO | Preferred Bank
Debt Instrument [Line Items]
Maximum loan availability							$ 14,800,000		$ 14,800,000
Long-term line of credit			0	0	$ 0	0
Term of facility							1 year
Expiration period, period of notification							90 days
Standby Letters of Credit | Alpha Care | Preferred Bank
Debt Instrument [Line Items]
Maximum loan availability			3,800,000	3,800,000	3,800,000	$ 3,800,000
Term of facility						1 year
Standby Letters of Credit | APC
Debt Instrument [Line Items]
Maximum loan availability			$ 300,000	$ 300,000	$ 300,000	$ 300,000
Term of facility						1 year
Credit Agreement
Debt Instrument [Line Items]
Number of key financial ratios | financial_ratio		2
Maximum consolidated leverage ratio		3.75	3.50	3.50	3.50	3.50
Consolidated leverage ratio, annual change		0.25
Consolidated leverage ratio		3
Minimum consolidated interest coverage ratio						3.25
Default amount of debt instrument		$ 10,000,000
Interest rate during period						3.48%	3.39%	4.72%
Interest expense						$ 1,400,000	$ 500,000
Credit Agreement | Minimum
Debt Instrument [Line Items]
Required annual facility fee		0.20%
Basis spread on variable rate		(1.00%)
Credit Agreement | Minimum | LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate		(2.00%)
Credit Agreement | Maximum
Debt Instrument [Line Items]
Required annual facility fee		0.35%
Basis spread on variable rate		(2.00%)
Credit Agreement | Maximum | LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate		(3.00%)
Credit Agreement | Payment Period One
Debt Instrument [Line Items]
Principal payment on credit agreement		$ 2,400,000
Credit Agreement | Payment Period Two
Debt Instrument [Line Items]
Principal payment on credit agreement		3,600,000
Credit Agreement | Payment Period Three
Debt Instrument [Line Items]
Principal payment on credit agreement		$ 4,800,000
Credit Agreement | Revolver Loan
Debt Instrument [Line Items]
Revolving credit facility term		5 years
Maximum loan availability		$ 60,000,000
Deferred financing costs		6,500,000
Credit Agreement | Revolver Loan | Preferred Bank
Debt Instrument [Line Items]
Outstanding letters of credit			$ 0	$ 0	$ 0	$ 0
Credit Agreement | Revolver Loan | Line of Credit
Debt Instrument [Line Items]
Maximum loan availability		100,000,000
Interest rate at end of period			2.27%	2.27%	2.27%	2.27%
Credit Agreement | Letter of Credit | Preferred Bank
Debt Instrument [Line Items]
Available borrowing capacity			$ 25,000,000	$ 25,000,000	$ 25,000,000	$ 25,000,000
Credit Agreement | Letter of Credit | Line of Credit
Debt Instrument [Line Items]
Maximum loan availability		25,000,000
Credit Agreement | Term loan A | Line of Credit
Debt Instrument [Line Items]
Maximum loan availability		$ 190,000,000
Credit Agreement | Standby Letters of Credit | Minimum
Debt Instrument [Line Items]
Required annual facility fee						2.00%
Credit Agreement | Standby Letters of Credit | Maximum
Debt Instrument [Line Items]
Required annual facility fee						3.00%
NMM Line Of Credit Agreement
Debt Instrument [Line Items]
Default amount of debt instrument			50,000,000	50,000,000	50,000,000	$ 50,000,000
Shareholder approval percentage						50.01%
Approved use of funds			$ 125,000,000	$ 125,000,000	$ 125,000,000	$ 125,000,000
NMM Line Of Credit Agreement | Line of Credit | NMM | Preferred Bank
Debt Instrument [Line Items]
Maximum loan availability	$ 20,000,000												$ 2,200,000
Interest rate at end of period			3.375%	3.375%	3.375%	3.375%
Term of converted loan	5 years
Term of facility	5 years
NMM Line Of Credit Agreement | Line of Credit | NMM | Prime Rate | Preferred Bank
Debt Instrument [Line Items]
Basis spread on variable rate						(0.125%)
NMM Business Loan Agreement | Line of Credit | NMM | Preferred Bank
Debt Instrument [Line Items]
Maximum loan availability																$ 27,000,000	$ 20,000,000
Long-term line of credit														$ 5,000,000
APC Business Loan Agreement | Line of Credit | APC | Preferred Bank
Debt Instrument [Line Items]
Maximum loan availability											$ 4,100,000	$ 43,800,000			$ 40,000,000		$ 10,000,000
Interest rate at end of period			3.375%	3.375%	3.375%	3.375%	4.875%
Available borrowing capacity			$ 0	$ 0	$ 0	$ 0	$ 0
APC Business Loan Agreement | Line of Credit | APC | Prime Rate | Preferred Bank
Debt Instrument [Line Items]
Basis spread on variable rate						(0.125%)

Income Taxes - Income Tax Provi

Income Taxes - Income Tax Provision (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Current
Federal	$ 43,572	$ 9,035	$ 21,059
State	19,155	5,925	9,646
Current income tax expense (benefit)	62,727	14,960	30,705
Deferred
Federal	(4,963)	(3,508)	(5,954)
State	(1,657)	(3,285)	(2,391)
Deferred income tax expense (benefit)	(6,620)	(6,793)	(8,345)
Total provision for income taxes	$ 56,107	$ 8,167	$ 22,360

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Operating Loss Carryforwards [Line Items]
Valuation allowance	$ 15,517	$ 8,192
Valuation allowance, increase	$ 7,300
Federal corporate tax rate	21.00%	21.00%	21.00%
Minimum
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards, expiration period	2027
Maximum
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards, expiration period	2040
Federal
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 69,100
Net operating loss carryforwards, not subject to expiration	49,800
California
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 89,400

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets (Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Deferred tax assets
State taxes	$ 3,932	$ 1,111
Stock options	461	1,293
Accrued expenses	3,905	2,334
Allowance for bad debts	351	544
Investment in other entities	702	2,977
Net operating loss carryforward	20,758	13,850
Lease liability	4,979	3,568
Other	665	0
Deferred tax assets before valuation allowance	35,753	25,677
Valuation allowance	(15,517)	(8,192)
Net deferred tax assets	20,236	17,485
Deferred tax liabilities
Property and equipment	(661)	(927)
Acquired intangible assets	(24,661)	(29,195)
Right-of-use assets	(4,888)	(3,544)
481(a) adjustment	(985)	(1,623)
Other	0	(465)
Deferred tax liabilities	(31,195)	(35,754)
Net deferred liabilities	$ (10,959)	$ (18,269)

Income Taxes - Provision for In

Income Taxes - Provision for Income Taxes (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Tax provision at U.S. Federal statutory rates	21.00%	21.00%	21.00%
State income taxes net of federal benefit	7.70%	8.10%	6.70%
Non-deductible permanent items	0.30%	3.30%	1.30%
Non-taxable entities	(0.20%)	(2.70%)	(0.70%)
Stock-based compensation	0.30%	(1.50%)	(1.80%)
Change in valuation allowance	3.20%	3.20%	0.00%
Other	(1.00%)	0.20%	0.60%
Effective income tax rate	31.30%	31.60%	27.10%

Mezzanine and Stockholders' E_3

Mezzanine and Stockholders' Equity - Additional Information (Details) - USD ($)	Sep. 11, 2019	Sep. 10, 2019	Dec. 08, 2017	Mar. 30, 2016	Oct. 14, 2015	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Class of Stock [Line Items]
Stock issued during period new issues							$ 0
Number of shares holdback percentage			10.00%
Share-based compensation arrangement by based payment award outstanding (in shares)						725,864	607,346
Stock issued during period share conversion of notes (in shares)			520,081
Stock issued during period value conversion of notes			$ 5,400,000
Holdback shares not issued to former shareholders (in shares)						276,038
Warrants exercises in period (in shares)						1,247,644	177,405
Warrant issued during period value stock options exercised						$ 10,500,000	$ 1,700,000
Payments of ordinary dividends common stock						$ 51,319,000	$ 61,717,000	$ 17,759,000
Treasury stock, common, shares (in shares)						12,323,164	17,458,810
Allied Pacific of California Brokerage Account
Class of Stock [Line Items]
Treasury stock						$ 7,700,000	$ 7,300,000
Minimum
Class of Stock [Line Items]
Share-based compensation arrangement by share based payment award, warrant exercised, exercise price						$ 9	$ 9
Maximum
Class of Stock [Line Items]
Share-based compensation arrangement by share based payment award, warrant exercised, exercise price						$ 11	$ 11
Tranche one
Class of Stock [Line Items]
Share-based compensation arrangement by based payment award outstanding (in shares)							1,511,380	1,519,805
Warrant 1
Class of Stock [Line Items]
Exercise price per share (in dollars per share)			$ 11
Number of warrants (in shares)			850,000
Warrant 2
Class of Stock [Line Items]
Exercise price per share (in dollars per share)			$ 10
Number of warrants (in shares)			900,000
Private Placement
Class of Stock [Line Items]
Number of shares purchased by related party (in shares)					1,111,111
Stock issued during period new issues					$ 10,000,000
Exercise price per share (in dollars per share)				$ 10	$ 9
Former Shareholders of NMM
Class of Stock [Line Items]
Shares issued (in shares)						25,675,630
Series B Preferred Stock
Class of Stock [Line Items]
Number of shares purchased by related party (in shares)				555,555
Stock issued during period new issues				$ 5,000,000
Exercise price per share (in dollars per share)				$ 10
APC
Class of Stock [Line Items]
Interest costs incurred	$ 900,000
Payments of ordinary dividends common stock						$ 136,600,000	$ 60,000,000	$ 2,000,000
Treasury stock, common, shares (in shares)						12,323,164	17,290,317
AP-AMH | Affiliated Entity | Series A Preferred Stock
Class of Stock [Line Items]
Number of shares purchased by related party (in shares)	1,000,000
Stock issued during period new issues	$ 545,000,000
CDSC
Class of Stock [Line Items]
Payments of ordinary dividends common stock						$ 2,100,000	$ 2,600,000	2,000,000
AMG | APC
Class of Stock [Line Items]
Interest acquired		100.00%
Payments to acquire business		$ 1,200,000
Value of shares transferred in acquisition		$ 400,000
NMM
Class of Stock [Line Items]
Stock repurchased during period (in shares)			30,397,489
Number of shares holdback percentage						10.00%
Number of shares held back (in shares)			3,039,749
NMM | NMM
Class of Stock [Line Items]
Payments of ordinary dividends common stock						$ 0	$ 0	$ 13,800,000

Mezzanine and Stockholders' E_4

Mezzanine and Stockholders' Equity - Summary of Warrant (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Shares
Warrants outstanding (in shares)	3,154,590	3,331,995	3,648,541
Warrants granted (in shares)	0	0
Warrants exercised (in shares)	(1,247,644)	(177,405)	(286,357)
Warrants forfeited (in shares)	(28,820)	0	(30,189)
Warrants outstanding (in shares)	1,878,126	3,154,590	3,331,995	3,648,541
Weighted Average Exercise Price
Warrants outstanding (in dollars per share)	$ 9.96	$ 9.93	$ 9.75
Warrants granted (in dollars per share)	0	0
Warrants exercised (in dollars per share)	9.33	9.32	7.84
Warrants forfeited (in dollars per share)	9		4.50
Warrants outstanding (in dollars per share)	$ 10.39	$ 9.96	$ 9.93	$ 9.75
Weighted Average Remaining Contractual Term (Years)
Warrants outstanding balance	1 year 7 months 17 days	2 years 3 days	2 years 11 months 19 days	3 years 8 months 26 days
Aggregate Intrinsic Value (in millions)
Warrants outstanding, beginning balance	$ 26.7	$ 33.1	$ 52
Warrants granted	0	0
Warrants exercised	9.8	1.6	3
Warrants forfeited	0	0	0
Warrants outstanding, ending balance	$ 14.8	$ 26.7	$ 33.1	$ 52

Mezzanine and Stockholders' E_5

Mezzanine and Stockholders' Equity - Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Class of Warrant or Right [Line Items]
Weighted Average Exercise Price Per Share (in dollars per share)	$ 10.39	$ 9.96	$ 9.93	$ 9.75
Warrant Exercise Price Range One
Class of Warrant or Right [Line Items]
Exercise Price Per Share (in dollars per share)	$ 9
Warrants Outstanding (in shares)	10,810
Weighted Average Remaining Contractual Life	2 months 26 days
Warrants Exercisable (in shares)	10,810
Weighted Average Exercise Price Per Share (in dollars per share)	$ 9
Warrant Exercise Price Range Two
Class of Warrant or Right [Line Items]
Exercise Price Per Share (in dollars per share)	$ 10
Warrants Outstanding (in shares)	1,115,342
Weighted Average Remaining Contractual Life	1 year 5 months 8 days
Warrants Exercisable (in shares)	1,115,342
Weighted Average Exercise Price Per Share (in dollars per share)	$ 10
Warrant Exercise Price Range Three
Class of Warrant or Right [Line Items]
Exercise Price Per Share (in dollars per share)	$ 11
Warrants Outstanding (in shares)	751,974
Weighted Average Remaining Contractual Life	1 year 11 months 4 days
Warrants Exercisable (in shares)	751,974
Weighted Average Exercise Price Per Share (in dollars per share)	$ 11
Warrant Exercise Price Range Four
Class of Warrant or Right [Line Items]
Warrants Outstanding (in shares)	1,878,126
Weighted Average Remaining Contractual Life	1 year 7 months 17 days
Warrants Exercisable (in shares)	1,878,126
Weighted Average Exercise Price Per Share (in dollars per share)	$ 10.39
Warrant Exercise Price Range Four | Minimum
Class of Warrant or Right [Line Items]
Exercise Price Per Share (in dollars per share)	9
Warrant Exercise Price Range Four | Maximum
Class of Warrant or Right [Line Items]
Exercise Price Per Share (in dollars per share)	$ 11

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Jul. 31, 2020	Dec. 31, 2019
Commitments And Contingencies [Line Items]
General amount of guarantee (as a percent)	2.00%
Long-term line of credit	$ 245,705,000
APC | Standby Letters of Credit
Commitments And Contingencies [Line Items]
Long-term line of credit	300,000
Alpha Care | Standby Letters of Credit
Commitments And Contingencies [Line Items]
Long-term line of credit	3,800,000
Standby Letters of Credit | APAACO | Preferred Bank
Commitments And Contingencies [Line Items]
Maximum loan availability		$ 14,800,000	$ 14,800,000
Long-term line of credit	0
Standby Letters of Credit | APC
Commitments And Contingencies [Line Items]
Maximum loan availability	300,000
Standby Letters of Credit | Alpha Care | Preferred Bank
Commitments And Contingencies [Line Items]
Maximum loan availability	$ 3,800,000

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Related Party Transaction [Line Items]
Proceeds from sale of equity method investment	$ 52,743,000	$ 0	$ 0
CQMC
Related Party Transaction [Line Items]
Payments to related party	300,000	500,000	400,000
AHMC
Related Party Transaction [Line Items]
Risk pool revenue recognized under agreement	42,600,000	49,300,000	68,200,000
Remaining outstanding under agreement	$ 45,300,000	40,400,000
NMM | LaSalle Medical Associates – IPA Line of Business
Related Party Transaction [Line Items]
Ownership interest	25.00%
NMM | LaSalle Medical Associates – IPA Line of Business
Related Party Transaction [Line Items]
Revenue from related parties	$ 16,900,000	17,300,000	21,600,000
Due from related parties	2,300,000	2,000,000
NMM | MPP
Related Party Transaction [Line Items]
Payments to related party	1,000,000	1,100,000	1,000,000
NMM | One MSO, Inc.
Related Party Transaction [Line Items]
Payments to related party	1,400,000	200,000
NMM | Board Members | Consulting Services
Related Party Transaction [Line Items]
Expenses from transactions with related party	100,000	200,000
APC | Provider services | PMIOC
Related Party Transaction [Line Items]
Payments to related party	2,200,000	2,700,000	2,500,000
APC | Provider services | DMG
Related Party Transaction [Line Items]
Payments to related party	6,000,000	7,800,000	7,000,000
APC | APC
Related Party Transaction [Line Items]
Payments to related party	$ 33,100,000	30,800,000	35,200,000
APC | APC | Provider services | PMIOC
Related Party Transaction [Line Items]
Ownership interest	40.00%
APC | APC | Provider services | DMG
Related Party Transaction [Line Items]
Ownership interest	40.00%
APC | Advance Diagnostic Surgery Center | Provider services
Related Party Transaction [Line Items]
Payments to related party	$ 500,000	400,000	300,000
APC | Fresenius | Provider services
Related Party Transaction [Line Items]
Payments to related party	100,000	100,000	100,000
APC | Fulgent Genetics, Inc. | Provider services
Related Party Transaction [Line Items]
Payments to related party	300,000	0
APC | Officer | APC
Related Party Transaction [Line Items]
Payments to related party	9,000,000	8,800,000	13,500,000
APAACO | Fresenius | Provider services
Related Party Transaction [Line Items]
Payments to related party	700,000	$ 0
Dr. Sim And Dr. Lam | One MSO, Inc.
Related Party Transaction [Line Items]
Ownership interest		50.00%
Dr. Sim And Dr. Lam | APC | One MSO, Inc.
Related Party Transaction [Line Items]
Proceeds from sale of equity method investment	2,400,000
SCHC | Numen
Related Party Transaction [Line Items]
Payments to related party	$ 400,000	$ 400,000	$ 500,000

Related Party Transactions - Sc

Related Party Transactions - Schedule of Related Party Transactions (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Related Party Transaction [Line Items]
Receipts, net	$ 27,515	$ 38,000
AHMC
Related Party Transaction [Line Items]
AHMC – Risk pool earnings net claims payment	28,767	40,000
HSMSO
Related Party Transaction [Line Items]
Management fees	(949)	(1,700)
Aurion
Related Party Transaction [Line Items]
Management fees	$ (303)	$ (300)

Employee Benefit Plan - Additio

Employee Benefit Plan - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Retirement Benefits [Abstract]
Defined contribution plan, service period	6 months
Employee benefit vested estimated year	6 years
Employer discretionary contribution amount	$ 0.4	$ 0.2

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($)	Oct. 01, 2014	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 08, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense		$ 3,383,000	$ 1,547,000	$ 1,441,000
Shares issued for exercise of options and warrants (in shares)		120,000	241,214
Cashless options, exercises in period (in shares)		0
Options outstanding (term)		3 years 9 months	3 years 5 months 1 day
Weighted average exercise price (in dollars per share)		$ 13.25	$ 9.22
Total share-based compensation expense		$ 3,383,000	$ 1,547,000	1,442,000
Unrecognized compensation expense		$ 7,100,000
APC
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Incentive consideration per provider	$ 25,000
Incentive consideration preferred provider	$ 15,000
Fair value assumptions. exercise price (in dollars per share)	$ 0.17
NMM
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value assumptions. exercise price (in dollars per share)	$ 2.44
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options exercisable weighted average exercise price (in usd per share)		$ 2.10	$ 1.50
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options exercisable weighted average exercise price (in usd per share)		$ 5	$ 10
APC Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price adjustment from Merger		$ 300,000	$ 1,500,000
Board Members
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options, grants in period (in shares)		191,742
Board Members | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price (in dollars per share)		$ 18.20
Board Members | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price (in dollars per share)		$ 18.41
Executives
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options, grants in period (in shares)		59,004
Weighted average exercise price (in dollars per share)		$ 17.78
Restricted stock awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock awards granted (in shares)		97,447
Weighted average grant date fair value (in dollars per share)		$ 17.58
Grant date fair value of restricted stock to be recognized straight-line		$ 1,600,000
Vesting period		3 years
Grant date fair value, forfeited (in dollars per share)		$ 100,000
Forfeited (in shares)		7,394
Restricted stock awards | Executives
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock awards granted (in shares)		130,484
Weighted average grant date fair value (in dollars per share)		$ 17.78
Vesting period		3 years
Grant date fair value, forfeited		$ 2,300,000
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense		$ 1,763,000	$ 688,000	0
Stock options | Board Members and Directors
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		5 years	5 years
Stock Awards and Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense		$ 1,620,000	$ 252,000	$ 632,000
2013 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)					500,000
2015 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)					1,500,000
Number of share available for grant (in shares)		100,000	500,000	900,000

Stock Based Compensation - Shar

Stock Based Compensation - Share-Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	$ 3,383	$ 1,547	$ 1,442
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	1,763	688	0
Stock options | APC
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	0	607	810
Restricted stock awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	$ 1,620	$ 252	$ 632

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Shares
Beginning balance (in shares)	725,864	607,346	725,864	607,346
Options granted (in shares)	250,746
Options exercised (in shares)	(120,000)	(241,214)
Options canceled, forfeited or expired (in shares)	(12,228)
Ending balance (in shares)	725,864	607,346
Options exercisable (in shares)			449,464
Weighted Average Exercise Price
Beginning balance (in dollars per share)	$ 9.22
Options granted (in dollars per share)	18.11
Options exercised (in dollars per share)	2.58
Options forfeited (in dollars per share)	17.57
Ending balance (in dollars per share)	$ 13.25	$ 9.22
Options exercisable (in dollars per share)			$ 6.33
Weighted Average Remaining Contractual Term (Years)
Options outstanding	3 years 9 months	3 years 5 months 1 day
Options exercisable	1 year 11 months 8 days
Aggregate Intrinsic Value (in millions)
Options outstanding			$ 3.4	$ 5.6
Options exercised	$ 1.8
Options exercisable			$ 3.6

Stock-Based Compensation - Opti

Stock-Based Compensation - Options, Assumptions Under Black-Scholes (Details)	12 Months Ended
	Dec. 31, 2020$ / shares
Board Members
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected Term	3 years
Annual dividend yield	0.00%
Forfeiture rate	0.00%
Board Members | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	85.44%
Risk-free interest rate	0.23%
Market value of common stock	$ 18.20
Board Members | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	90.01%
Risk-free interest rate	1.43%
Market value of common stock	$ 18.41
Executives
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected Term	3 years 6 months
Expected volatility	80.95%
Risk-free interest rate	0.23%
Market value of common stock	$ 17.78
Annual dividend yield	0.00%
Forfeiture rate	0.00%

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Details) - shares	Dec. 08, 2017	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Shares held back in merger to secure indemnification (as a percent)	10.00%	10.00%	10.00%	10.00%
Period shares will be held back	24 months
Issued on first anniversary (as a percent)	50.00%
Issued on second anniversary (as a percent)	50.00%
APC
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Antidilutive securities (in shares)		12,323,164	17,290,317	1,682,110

Earnings Per Share - Basic Net

Earnings Per Share - Basic Net Income (loss) Per Share is Calculated Using Weighted Average Number of Shares (Details) - $ / shares	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Earnings Per Share [Abstract]
Earnings per share – basic (in dollars per share)	$ 0.27	$ 0.46	$ 0.20	$ 0.11	$ 0.19	$ 0.11	$ 0.10	$ 0	$ 1.04	$ 0.41	$ 0.33
Earnings per share – diluted (in dollars per share)	$ 0.26	$ 0.45	$ 0.19	$ 0.11	$ 0.18	$ 0.10	$ 0.09	$ 0	$ 1.01	$ 0.39	$ 0.29
Weighted average shares of common stock outstanding – basic (in shares)									36,527,672	34,708,429	32,893,940
Weighted average shares of common stock outstanding - diluted (in shares)									37,448,430	36,403,279	37,914,886

Earnings Per Share - Summary of

Earnings Per Share - Summary of Shares Included in Diluted Earnings Per Share (Details) - shares	Dec. 08, 2017	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Weighted average shares of common stock outstanding – basic (in shares)		36,527,672	34,708,429	32,893,940
Weighted average shares of common stock outstanding – diluted (in shares)		37,448,430	36,403,279	37,914,886
Shares held back in merger to secure indemnification (as a percent)	10.00%	10.00%	10.00%	10.00%
Common Stock
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Adjustments to weighted average shares of common stock (in shares)		0	0	2,935,512
Warrants
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Adjustments to weighted average shares of common stock (in shares)		717,029	1,384,078	1,625,994
Stock options
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Adjustments to weighted average shares of common stock (in shares)		182,999	295,672	459,440
Management restricted stock awards (dilutive) | Management restricted stock awards (dilutive)
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Adjustments to weighted average shares of common stock (in shares)		7,242	15,100	0
Management restricted stock awards (dilutive) | Executive restricted stock awards (dilutive)
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Adjustments to weighted average shares of common stock (in shares)		13,488	0	0

Variable Interest Entities (V_3

Variable Interest Entities (VIEs) - Eliminated Upon Consolidation Included In Accompanying Consolidated Balance Sheets (Details) - USD ($) $ in Thousands		Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents		$ 193,470	$ 103,189	$ 106,892
Restricted cash		0	75
Investment in marketable securities		67,695	116,539
Receivables, net		7,058	11,004
Receivables, net – related party		49,260	48,136
Other receivables		4,297	16,885
Prepaid expenses and other current assets		16,747	10,315
Loans receivable		50	22,925
Total current assets		338,577	329,068
Noncurrent assets
Intangible assets, net		86,985	103,012
Goodwill		239,053	238,505	$ 185,806
Investments in other entities – equity method		43,292	28,427
Restricted cash		500	746
Operating lease right-of-use assets		18,574	14,248
Other assets		18,915	1,681
Total noncurrent assets		478,909	399,645
Total assets	[1]	817,486	728,713
Current liabilities
Accounts payable and accrued expenses		36,143	27,279
Fiduciary accounts payable		9,642	2,027
Medical liabilities		50,330	58,725
Income taxes payable		4,224	4,529
Dividend payable		485	271
Current portion of long-term debt		10,889	9,500
Finance lease liabilities		102	102
Operating lease liabilities		3,177	2,991
Total current liabilities		114,992	105,424
Noncurrent liabilities
Long-term debt, net of current portion		230,211	232,172
Deferred tax liability		10,959	18,269
Finance lease liabilities, net of current portion		311	415
Operating lease liabilities, net of current portion		15,865	11,373
Total noncurrent liabilities		257,346	262,229
Total liabilities	[1]	372,338	367,653
Variable Interest Entity, Primary Beneficiary
Current assets
Cash and cash equivalents		126,158	87,110
Restricted cash		0	75
Investment in marketable securities		67,637	123,948
Receivables, net		5,155	9,300
Receivables, net – related party		46,718	42,976
Other receivables		1,084	744
Prepaid expenses and other current assets		14,813	7,403
Loans receivable		50	6,425
Loans receivable - related parties		0	16,500
Total current assets		261,615	294,481
Noncurrent assets
Land, property and equipment, net		27,599	9,547
Intangible assets, net		69,250	81,439
Goodwill		109,460	108,913
Loans receivable – related parties		4,145	0
Investment in affiliates		225,144	318,315
Investments in other entities – equity method		43,516	28,427
Investment in privately held entities		36,584	1,615
Restricted cash		500	746
Operating lease right-of-use assets		6,298	4,751
Other assets		17,177	1,057
Total noncurrent assets		539,673	554,810
Total assets		801,288	849,291
Current liabilities
Accounts payable and accrued expenses		12,963	11,187
Fiduciary accounts payable		9,642	2,027
Medical liabilities		37,684	49,019
Income taxes payable		4,225	4,530
Dividend payable		485	271
Amount due to affiliate		22,698	28,058
Current portion of long-term debt		201	0
Finance lease liabilities		102	102
Operating lease liabilities		1,242	1,088
Total current liabilities		89,242	96,282
Noncurrent liabilities
Long-term debt, net of current portion		7,379	0
Deferred tax liability		9,144	14,059
Liability for unissued equity shares		0	0
Finance lease liabilities, net of current portion		311	416
Operating lease liabilities, net of current portion		5,242	3,742
Total noncurrent liabilities		22,076	18,217
Total liabilities		$ 111,318	$ 114,499
[1]	The Company's consolidated balance sheets include the assets and liabilities of its consolidated variable interest entities ("VIEs"). The consolidated balance sheets include total assets that can be used only to settle obligations of the Company’s consolidated VIEs totaling $801.3 million and $849.3 million as of December 31, 2020 and December 31, 2019, respectively, and total liabilities of the Company’s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $111.3 million and $114.5 million as of December 31, 2020 and December 31, 2019, respectively. See Note 18 – Variable Interest Entities (VIEs) for further detail.

Leases - Additional information

Leases - Additional information (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Lessee, Lease, Description [Line Items]
Operating lease option to extend (up to)	10 years		10 years
Finance lease option to extend (up to)	10 years		10 years
Operating lease, termination period, if applicable			1 year
Finance lease, termination period, if applicable			1 year
Assets recorded under finance leases	$ 400	$ 500	$ 400	$ 500
Accumulated depreciation associated with finance leases	$ 400	$ 300	$ 105	$ 102
Minimum
Lessee, Lease, Description [Line Items]
Remaining lease terms, operating	1 month		1 month
Remaining lease terms, financing	1 month		1 month
Maximum
Lessee, Lease, Description [Line Items]
Remaining lease terms, operating	5 years		5 years
Remaining lease terms, financing	5 years		5 years

Leases - Components of Lease Ex

Leases - Components of Lease Expense (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Operating lease cost			$ 6,589	$ 5,437
Finance lease cost
Amortization of lease expense	$ 400	$ 300	105	102
Interest on lease liabilities			14	17
Sublease income			(784)	(415)
Total lease cost			$ 5,924	$ 5,141

Leases - Other Information Rela

Leases - Other Information Related to Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 5,804	$ 5,254
Operating cash flows from finance leases	14	17
Financing cash flows from finance leases	105	102
Right-of-use assets obtained in exchange for lease liabilities:
Operating leases	7,652	16,728
Finance leases	$ 0	$ 0
Weighted Average Remaining Lease Term
Operating leases	6 years 9 months 18 days	6 years 5 months 23 days
Finance leases	3 years 8 months 1 day	4 years 8 months 1 day
Weighted Average Discount Rate
Operating leases	6.10%	6.11%
Finance leases	3.00%	3.00%

Leases - Future Minimum Payment

Leases - Future Minimum Payments Under Non-cancelable Leases After Adoption of 842 (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Operating Leases
2021	$ 4,297
2022	3,529
2023	3,303
2024	2,940
2025	2,648
Thereafter	6,818
Total future minimum lease payments	23,535
Less: imputed interest	4,493
Total lease obligations	19,042
Less: current portion	3,177	$ 2,991
Long-term lease obligations	15,865	11,373
Finance Leases
2021	119
2022	119
2023	119
2024	79
2025	0
Thereafter	0
Total future minimum lease payments	436
Less: imputed interest	23
Total lease obligations	413
Less: current portion	102	102
Long-term lease obligations	$ 311	$ 415

Quarterly Financial Informati_3

Quarterly Financial Information (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	Apr. 30, 2020	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Effect of Fourth Quarter Events [Line Items]
Revenue		$ 176,783	$ 180,123	$ 165,169	$ 165,105	$ 178,751	$ 156,060	$ 130,050	$ 95,757	$ 687,180	$ 560,618	$ 519,908
(Loss) income from operations		25,876	37,356	12,906	4,365	10,933	10,066	14,728	(3,307)	80,503	32,420	88,432
Net (loss) income		12,908	25,424	81,001	2,987	(1,280)	10,739	10,664	(2,450)	122,320	17,673	60,267
Net income attributable to ApolloMed		$ 10,057	$ 16,713	$ 7,044	$ 4,052	$ 6,727	$ 3,704	$ 3,545	$ 140	$ 37,866	$ 14,116	$ 10,835
Earnings per share - basic attributable to common stock (in dollars per share)		$ 0.27	$ 0.46	$ 0.20	$ 0.11	$ 0.19	$ 0.11	$ 0.10	$ 0	$ 1.04	$ 0.41	$ 0.33
Earnings per share - diluted attributable to common stock (in dollars per share)		$ 0.26	$ 0.45	$ 0.19	$ 0.11	$ 0.18	$ 0.10	$ 0.09	$ 0	$ 1.01	$ 0.39	$ 0.29
Gain on sale of equity method investment										$ 99,839	$ 0	$ 0
Universal Care, Inc.
Effect of Fourth Quarter Events [Line Items]
Gain on sale of equity method investment	$ 99,647

Subsequent Events - Additional

Subsequent Events - Additional Information (Details)	Jun. 30, 2021
CAIPA MSO | Subsequent Event | Forecast
Subsequent Event [Line Items]
Ownership interest	30.00%

Uncategorized Items - ameh-2020

Label	Element	Value
Restricted Cash Equivalents, Noncurrent	us-gaap_RestrictedCashEquivalentsNoncurrent	$ 500,000
Restricted Cash Equivalents, Noncurrent	us-gaap_RestrictedCashEquivalentsNoncurrent	746,000
Restricted Cash Equivalents, Noncurrent	us-gaap_RestrictedCashEquivalentsNoncurrent	745,000
Restricted Cash Equivalents, Current	us-gaap_RestrictedCashEquivalentsCurrent	0
Restricted Cash Equivalents, Current	us-gaap_RestrictedCashEquivalentsCurrent	75,000
Restricted Cash Equivalents, Current	us-gaap_RestrictedCashEquivalentsCurrent	0
Dividends Payable	us-gaap_DividendsPayableCurrentAndNoncurrent	0
Dividends Payable	us-gaap_DividendsPayableCurrentAndNoncurrent	485,000
Dividends Payable	us-gaap_DividendsPayableCurrentAndNoncurrent	$ 271,000